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ABSTRACT 
 
 
 Lysophosphatidic acid (LPA) and its ether analog alkyl glycerophosphate (AGP) 
elicit arterial wall remodeling when applied intralumenally into the uninjured carotid 
artery. LPA is the ligand of eight GPCRs and the peroxisome proliferator-activated 
receptor ! (PPAR!). We pursued a gene knockout strategy to identify the LPA receptor 
subtypes necessary for the neointimal response in a non-injury model of carotid 
remodeling and also compared the effects of AGP and the PPAR! agonist rosiglitazone 
(ROSI) on balloon injury-elicited neointima development. In the balloon injury model 
AGP significantly increased neointima; however, rosiglitazone application attenuated it. 
AGP and ROSI were also applied intralumenally for 1 hour without injury into the 
carotid arteries of LPA1, LPA2, LPA1&2 double knockout, and Mx1Cre-inducible 
conditional PPAR! knockout mice targeted to vascular smooth muscle cells, 
macrophages, and endothelial cells. The neointima was quantified and also stained for 
CD31, CD68, CD11b, and "-smooth muscle actin markers. In LPA1, LPA2, LPA1&2 
GPCR knockouts, Mx1Cre transgenic, PPAR!fl/-, and uninduced Mx1Cre#PPAR!fl/- mice 
AGP- and ROSI-elicited neointima was indistinguishable in its progression and 
cytological features from that of WT C57BL/6 mice. In PPAR!-/- knockout mice, 
generated by activation of Mx1Cre-mediated recombination, AGP and ROSI failed to 
elicit neointima and vascular wall remodeling. Our findings point to a difference in the 
effects of AGP and ROSI between the balloon-injury- and the non-injury 
chemically-induced neointima. The present data provide genetic evidence for the 
requirement of PPAR! in AGP- and ROSI-elicited neointimal thickening in the 
non-injury model and reveal that the overwhelming majority of the cells in the neointimal 
layer express !-smooth muscle actin. 
 
Cyclic phosphatidic acid (1-acyl-2,3-cyclic-glycerophosphate, CPA), one of 
nature’s simplest phospholipids, is found in cells from slime mold to humans and has 
largely unknown function. We find that CPA is generated in mammalian cells in a 
stimulus coupled-manner by phospholipase D2 (PLD2), and binds to and inhibits the 
nuclear hormone receptor PPAR! with nanomolar affinity and high specificity through 
stabilizing its interaction with the corepressor SMRT. CPA production inhibits the 
PPAR! target-gene transcription that normally drives adipocytic differentiation of 
3T3-L1 cells, lipid accumulation in RAW264.7 cells and primary mouse macrophages, 
and arterial wall remodeling in vivo. Inhibition of PLD2 by shRNA, a dominant negative 
mutant, or a small molecule inhibitor blocks CPA production and relieves PPAR! 
inhibition. We conclude that CPA is a novel second messenger and a physiological 
inhibitor of PPAR!, revealing that PPAR! is regulated by endogenous agonists as well as 
by antagonists. 
 
PPAR" is a nuclear hormone receptor related to many human diseases, including 
obesity, atherosclerosis, diabetes, and cancers. Recent studies have provided evidence 
that LPA and its analog AGP activate PPAR". On the other hand, CPA, similar in 
structure to LPA, can be generated by PLD2 and negatively regulates PPAR" functions. 
PPAR" agonists elicit lipid accumulation in macrophages and arterial wall remodeling 
vi 
 
when topically applied to the carotid artery in the rat non-injury model. Stimulation of 
PLD2 protects the carotid artery from PPAR"-mediated neointima formation. Consistent 
with this, inhibition of PLD2 activity using a PLD inhibitor,  
5-fluoro-2-indolyl des-chlorohalopemide, diminishes the protective effect of insulin. 
Stimulation of PPAR"  by AGP leads to the recruitment of circulating vascular progenitor 
cells into the vessel wall and the cells of the ensuing neointima express the !-smooth 
muscle actin marker. We summarize our current knowledge about the mechanism of 
PPAR" elicits in response to the endogenous lysophosphatidic acid analogs LPA, AGP, 
CPA, and the methodological challenges that one faces when working on the intracellular 
action of LPA. 
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1 
CHAPTER 1.    GENERAL INTRODUCTION 
 
 
1.1    LPA RECEPTORS AND SIGNALING 
 
 
1.1.1 The Lysophosphatidic Acid Family 
 
Lysophosphatidic acid (LPA) is a naturally occurring simple phospholipid that 
functions as a bioactive lipid mediator and a second messenger. It is made up of a 
glycerol backbone with a hydroxyl group, a phosphate group, and a long-chain saturated 
or unsaturated fatty acid (Figure 1-1). Different molecular species of LPA, dominated by 
16-, 18-, and 20-carbon chains, have been detected in biological fluids and elicit a wide 
variety of biological actions including cell proliferation, migration, morphologic changes, 
and survival. 
 
 Alkyl glycerophosphate (AGP; Figure 1-1) is an alkyl-ether analog of LPA. It is 
abundant in brain tissue, found in egg yolk and saliva (Sugiura et al., 1999, Nakane et al., 
2001). AGP is a weak agonist of plasma membrane LPA receptors except the LPA5 
receptor. LPA5 shows a preference for AGP relative to LPA (Williams et al., 2009). 
Interestingly, AGP also shows a higher potency than LPA at the intracellular LPA 
receptor peroxisome proliferator-activated receptor gamma (PPAR!) (Zhang et al., 2004, 
Tsukahara et al., 2010). 
 
Cyclic phosphatidic acid (CPA; Figure 1-1) is a naturally occurring acyl analog of 
LPA present in mammalian blood and brain. CPA is also a weak agonist of many plasma 
membrane LPA receptors (Fujiwara et al., 2005, Williams et al., 2009), whereas CPA is 
an inhibitor of PPAR! (Tsukahara et al., 2010). 
 
 
1.1.2  Plasma Membrane LPA Receptors and Signaling  
 
LPA activates multiple plasma membrane receptors that belong to the G 
protein-coupled receptor (GPCR) superfamily (Choi et al., 2010). LPA GPCRs have been 
identified in two distinct gene families, the endothelial differentiation gene (EDG) family 
and purinergic GPCR cluster. LPA1, LPA2, and LPA3 belong to the EDG family and 
share 45-56% amino acid identity with the most divergence at the C-termini (Anliker and 
Chun, 2004). LPA4 (P2Y9/GPR23), LPA5 (GPR92), LPA6 (P2Y5), GPR87, P2Y10, and 
GPR35 are closely related to the P2Y purinergic receptor gene cluster (Ishii et al., 2009). 
Upon LPA stimulation, LPA GPCRs interact with different G proteins (Gs, Gi/o, Gq and 
G12/13) to activate various downstream pathways, which mediate the diverse cellular 
effects of LPA. 
 
LPA1 couples with three types of heterotrimeric G proteins: Gi/o, Gq, and G12/13 
(Chun et al., 2010). LPA1 induces Ca2+ mobilization, cell proliferation, cell migration, 
activation of mitogen-activated protein kinase (MAPK), and activation of Akt and Rho 
 
 
2 
 
 
 
Figure 1-1 Structure of LPA, AGP, CPA, and ROSI 
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pathways (Anliker and Chun, 2004, Ishii et al., 2004). LPA1 is widely expressed in mice 
and humans (Anliker and Chun, 2004, Choi et al., 2010). LPA1 deficient mice show 
about 50% perinatal lethality within the first 3 weeks of age and the pups is attributed to 
an impaired suckling behavior (Contos et al., 2000). Surviving LPA1 deficient mice have 
a reduced body size and craniofacial dysmorphism with shorter snouts and more widely 
spaced eyes (Contos et al., 2000).  
 
LPA2 also interacts with Gi/o, Gq, and G12/13 (Chun et al., 2010). Hence, some of 
the LPA2 signals are similar to LPA1, such as Ca2+ mobilization, proliferation, Akt 
activation (Choi et al., 2010). LPA2 also signals via a C-terminal macromolecular 
complex that includes proteins recruited to its PDZ-motif and LIM-motif (E et al., 2009). 
LPA2 is highly expressed in the embryonic brain, testis, kidney, lung, and uterus in mice 
(Choi et al., 2010). In humans it is detected in the testis, pancreas, prostate, thymus, 
spleen, and leukocytes (Choi et al., 2010). LPA2 knockout mice are born normally and 
show no obvious phenotypic abnormalities (Contos et al., 2002), whereas our group 
showed these mice have increased sensitivity to radiation (Deng et al., 2007).  
 
LPA3 can couple to Gi/o and Gq, and induces Ca2+ mobilization, phospholipase C 
activation, and MAPK activation (Fukushima et al., 1998, Ishii et al., 2000). LPA3 is 
highly expressed in testis, kidney, lung, small intestine, heart, thymus, brain, and in the 
female reproductive system such as the oviduct, placenta, and uterus in adult mice (Choi 
et al., 2010). It is also found in heart, pancreas, prostate, testis, lung, ovary, and brain in 
humans (Choi et al., 2010). LPA3 deficient female mice show delayed and abnormal 
embryo implantation in the uterus (Ye et al., 2005). LPA3 knockout along with the lack of 
LPA1 and 2 also contribute to male infertility in aging mice (Ye et al., 2008).  
 
LPA4 couples to Gi/o, Gq, and G12/13, as well as Gs, and induces Ca2+ mobilization, 
cAMP accumulation, neurite retraction (Ishii et al., 2009). LPA4 is ubiquitously 
expressed and specifically abundant in ovary, uterus, and placenta (Ishii et al., 2009). 
LPA4 deficient mice display no apparent abnormalities (Lee et al., 2008), whereas an 
independent study reported that LPA4 deletion in a different C57BL/6 background mouse 
showed abnormal embryonic blood and lymphatic vessel formation (Sumida et al., 2010).  
 
LPA5 couples to Gq and G12/13 (Kotarsky et al., 2006, Lee et al., 2006) and induces 
Ca2+ mobilization, neurite retraction, and cAMP accumulation (Ishii et al., 2009, 
Williams et al., 2009). Unlike other LPA receptors LPA5 prefers AGP over LPA 
(Williams et al., 2009) and is broadly expressed in tissues such as brain, small intestine, 
placenta, spleen, lung, embryonic stem cells (Kotarsky et al., 2006, Lee et al., 2006).  
 
LPA6 couples to Gs and G12/13 (Yanagida et al., 2009). It was reported that 
2-acyl-LPA rather than 1-acyl-LPA is more potent ligand of LPA6 (Yanagida et al., 
2009). LPA6 plays an important role in human hair growth (Pasternack et al., 2008, 
Shinkuma et al., 2010).  
 
GPR87 is highly expressed in squamous cell carcinomas and lung carcinomas 
(Gugger et al., 2008). GPR87 was reported to increase Ca2+ mobilization using G16 fusion 
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protein system (Tabata et al., 2007). P2Y10 fused with G16 can induce Ca2+ transients by 
sphingosine-1-phosphate (S1P) as well as LPA (Murakami et al., 2008). The transcripts 
of P2Y10 were detected in uterus, prostate, brain, lung, placenta, and skeletal muscle 
(Murakami et al., 2008).  
 
 
1.1.3  Intracellular LPA Receptor – PPAR!  
 
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear 
hormone receptor superfamily, many of which function as lipid-activated transcription 
factors (Tontonoz and Spiegelman, 2008). There are three PPAR isoforms that include 
PPAR", $/%, and !. PPAR!, the most extensively studied among the three PPAR 
subtypes, plays an important role in regulating lipid metabolism, glucose homeostasis, 
cell differentiation, and motility (Duval et al., 2002, Evans, 2005, Kiec-Wilk et al., 2005). 
PPAR! has two isoforms, PPAR!1 and !2. PPAR!2 differs from PPAR!1 only by 30 
additional amino acids at the N-terminus, caused by differential promoter usage and 
alternative splicing (Fajas et al., 1997). PPAR!1 is expressed in almost all tissues, 
whereas PPAR!2 is highly expressed in only in the adipose tissue (Lehrke and Lazar, 
2005). Genetic deletion of PPAR!1 causes embryonic mortality (Asami-Miyagishi et al., 
2004). In contrast, deletion of PPAR!2 causes minimal alterations in lipid metabolism 
(Medina-Gomez et al., 2005). PPAR! heterodimerizes with the retinoid X receptor ! 
(RXR!), and it is the ligand binding domain (LBD) of PPAR! that interacts with its 
agonists, including LPA (Weatherman et al., 1999). The PPAR"-RXR! heterodimer 
binds the peroxisome proliferator response element (PPRE) in the promoter region of the 
target genes. In the absence of ligands, the corepressors nuclear receptor corepressor 
(NCoR) and silencing mediator of retinoid and thyroid hormone (SMRT) bind to the 
heterodimer to suppress the target gene activation (Chen and Evans, 1995, Dowell et al., 
1999, Yu et al., 2005). Upon ligand binding, PPAR! undergoes a conformational change 
that facilitates the dissociation of the corepressors and recruits coactivators such as p300 
and PGC-1" (Nolte et al., 1998, Yu and Reddy, 2007), resulting in target gene 
transcription (Lala et al., 1996). 
 
A number of putative physiological agonists of PPAR! have been identified, 
including 15d-prostaglandin J2 (15d-PGJ2) (Forman et al., 1995), oxidatively modified 
fatty acids (Nagy et al., 1998, Baker et al., 2005, Li et al., 2008), select species of LPA 
and AGP (McIntyre et al., 2003, Zhang et al., 2004, Tsukahara et al., 2006), oxidized 
phospholipids (Davies et al., 2001), and nitrated fatty acids (Li et al., 2008). Among these 
ligands, AGP stands out with an equilibrium binding constant of 60 nM (Tsukahara et al., 
2006) that is similar to that of the thiazolidinedione (TZD) class of synthetic agonists. 
Interestingly, some of the residues required for PPAR! activation by AGP are different 
from those required by ROSI. Histidine 323 and 449 within the ligand-binding domain of 
PPAR! are required for the binding and activation by rosiglitazone (ROSI; Figure 1-1) 
but are not required by AGP. Arginine 288 is an important residue for binding of AGP 
but not ROSI. Tyrosine 273 is required for activation by both agonists (Tsukahara et al., 
2006). 
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The TZD class of antidiabetics, ROSI, pioglitazone, and troglitazone, are full 
agonists of PPAR! and have been clinically used to improve insulin sensitivity and lipid 
metabolism in type 2 diabetics (Froberg and Andersen, 2005, Lautamaki et al., 2005, 
Negro et al., 2005, Sarafidis et al., 2005). However, despite the beneficial effects of 
PPAR! on glucose and lipid homeostasis, excessive PPAR! activity can be deleterious. 
PPAR! agonists promote adipocytic differentiation of 3T3-L1 cells and also stimulate the 
uptake of low density lipoprotein (LDL) by macrophages, leading to foam cell formation 
in the arterial wall (Moore et al., 2001).  
 
The cells of the vascular wall expresses LPA1-5 receptors as well as PPAR! 
(Cheng et al., 2009). Topical application of unsaturated LPA species into the non-injured 
carotid artery of rodents induces arterial wall remodeling (Yoshida et al., 2003), and this 
response requires PPAR! but not LPA1 or LPA2 (Yoshida et al., 2003, Zhang et al., 2004, 
Cheng et al., 2009) suggesting that LPA-mediated activation of PPAR! can also 
contribute to vascular wall pathologies. 
 
 
1.2    LPA IN VASCULAR BIOLOGY 
 
Accumulating evidence has shown that LPA plays an important role in the 
vascular system including proliferation, migration differentiation of vascular smooth 
muscle cells (VSMCs) and vascular endothelial cells and the recruitment and trafficking 
of macrophages and histiocytes (Figure 1-2). 
 
LPA has been identified as a bioactive lipid and is produced in serum after the 
activation of multiple biochemical pathways linked to platelet activation (Sano et al., 
2002, Spector, 2003, Tigyi and Parrill, 2003, Bolen et al., 2011). The concentration of 
LPA in plasma is in the nanomolar range, whereas it can reach concentrations as high as 
10 #M in serum during blood clotting (Baker et al., 2001, Aoki et al., 2002, Baker et al., 
2002). LPA production in blood requires autotaxin (ATX), which is a secreted 
lysophospholipase D that generates LPA from lysophosphatidylcholine (LPC) (Tokumura 
et al., 2002, Umezu-Goto et al., 2002).  
 
Tokumura et al. reported that crude soybean lecithin contains a vasopressor lipid 
identified as LPA (Tokumura et al., 1978a, Tokumura et al., 1978b). They demonstrated 
LPA had hypertensive effects in rats and guinea pigs and hypotensive effects in cats and 
rabbits (Tokumura et al., 1978b).  
 
LPA increases endothelial permeability via RhoA activation (Schulze et al., 1997, 
Alexander et al., 1998, van Nieuw Amerongen et al., 2000). LPA activates the 
endothelial isoform of nitric oxide synthase (eNOS) through the activation of the 
PI3-K/Akt pathway (Kou et al., 2002). LPA also induces E-selectin, vascular cell 
adhesion molecule-1 (VCAM-1), and vascular endothelial growth factor-C (VEGF-C) 
expression in human endothelial cells (Rizza et al., 1999, Lin et al., 2008). Moreover, 
LPA regulates the expression of pro-atherogenic connective tissue growth factor (CTGF)  
in human endothelial cells (Muehlich et al., 2004). CTGF is known to mediate migration 
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Figure 1-2 The effects of LPA in the vasculature 
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of monocytes, VSMCs, and activated platelets.  
 
LPA promotes proliferation and migration of VSMCs (Hayashi et al., 2001, Siess, 
2002, Kim et al., 2006). Hayashi et al. showed that LPA promotes VSMC 
dedifferentiation from the contractile phenotype to a secretory phenotype and stimulates 
VSMC signaling pathways in vitro (Hayashi et al., 2001). LPA induces early growth 
response gene 1(Egr-1), an important transcription factor that activates expression of a set 
of genes involved in vascular diseases (Cui et al., 2006). Myocyte contractility is 
regulated by LPA via Gi-mediated mechanism (Cremers et al., 2003). The authors 
showed that LPA suppressed isoprenaline-induced cell shortening through the activation 
of LPA1 and/or LPA3 in a pertussis toxin sensitive manner. 
 
LPA activates monocytes with low nanomolar concentration (Fueller et al., 2003) 
and recruits them via inducing monocyte chemoattractant protein-1 (MCP-1) secretion 
through p38 and JNK pathways in endothelial cells (Lin et al., 2006, Shimada and 
Rajagopalan, 2010) suggesting the important role in inflammation processes. LPA 
inhibits conversion of monocytes into migratory cells and keep them in the 
subendothelium (Llodra et al., 2004). LPA via LPA1 and LPA3 induces CXCL-1, which 
promotes monocyte adhesion to the murine vascular endothelium (Zhou et al., 2011).  
 
Many of the cellular responses elicited by LPA, including platelet activation 
(Siess et al., 1999, Rother et al., 2003, Haseruck et al., 2004), endothelial cell activation 
(Siess et al., 1999), proliferation, migration, and phenotypic modulation of VSMCs 
(Hayashi et al., 2001, Siess, 2002, Kim et al., 2006), can be involved in neointima 
formation. Oxidative modification of LDL is considered to be an early event in arterial 
wall remodeling leading to atherosclerosis (Stocker and Keaney, 2004, Asmis et al., 
2005); and uptake and oxidation of LDL in the arterial wall is an important mechanism in 
the pathogenesis of atherosclerosis (Meydani, 2001). It has been shown that LPA is 
formed during mild oxidation of LDL (mox-LDL) (Siess et al., 1999, Law et al., 2000). 
In addition, the lipid-rich core of human atherosclerotic plaques, which accumulates 
oxidized lipids including mox-LDL, contains several species of LPA and AGP (Siess et 
al., 1999). LPA and AGP accumulated in human atherosclerotic plaques are likely to 
activate platelets and initiate thrombus formation upon plaque rupture (Rother et al., 
2003, Spector, 2003). Following plaque rupture, LPA becomes available to circulating 
platelets, initiating activation, which in turn may contribute to the induction of 
thrombosis, leading to myocardial infarction and stroke. Furthermore, a recent report 
revealed that ATX can bind to platelet integrin receptors through its N-terminal 
somatomedin B-kike domains (Hausmann et al., 2011) suggesting the possibility that 
ATX could be localized to the surface of activated platelets, which might concentrate the 
production of LPA at the sites of vascular injury. 
 
Some clinical studies have shown the correlation between plasma LPA and 
vascular diseases. Chen et al showed that the serum LPA level was significantly elevated 
in patients with acute myocardial infarction (Chen et al., 2003).  
 
 
 
 
8 
LPA also plays an important role in vascular development (van Meeteren et al., 
2006). ATX-deficient mice die at approximately embryonic day 9.5 with severe vascular  
formation defects in the yolk sac and enlarged embryonic blood vessels (Tanaka et al., 
2006, van Meeteren et al., 2006). Mice that overexpress ATX have elevated plasma LPA 
levels and show bleeding diathesis, whereas ATX+/- heterozygous mice have almost half 
the plasma LPA levels and are prone to thrombosis (Pamuklar et al., 2009).  
 
 
1.3    VASCULAR WALL REMODELING  
 
 
1.3.1 Neointima Formation Induced by LPA 
 
Neointimal lesions are characterized by accumulation of cells within the arterial 
wall and are an early step in the pathogenesis of atherosclerosis (Ross, 1999, Baim et al., 
2002). Atherosclerosis is the leading cause of death and serious morbidity in the United 
States (Xu et al., 2010). 
 
Yoshida et al. reported that LPA species containing unsaturated fatty acyl groups 
16:1, 18:1, and 18:2 induced neointima formation when injected intralumenally into the 
rat carotid artery, whereas saturated 16:0 and 18:0 LPA species were inactive (Yoshida et 
al., 2003). This model comes close to the pathophysiological response seen in humans 
because mechanical injury is not the cause of the arterial wall remodeling leading to 
neointimal lesions. In Yoshida's model, LPA was injected through the external carotid 
artery into a ligated section of the common carotid artery (CCA) that was rinsed free of 
blood and maintained close to the mean arterial perfusion pressure. There was no 
mechanical injury or removal of endothelial cells in the CCA. A brief one-hour exposure 
to unsaturated but not to saturated species of LPA caused neointima development.  
 
Our group found that the LPA-elicited neointima was not mediated by the LPA 
GPCRs LPA1 and LPA2, which are the major LPA receptor subtypes expressed in the 
vessel wall (Cheng et al., 2009). PPAR"-specific inhibitor, GW9662, abolished the 
LPA-induced neointima formation, suggesting that arterial wall remodeling elicited by 
LPA is a PPAR"-mediated response (Zhang et al., 2004). Conversely, the 
PPAR"-specific agonist ROSI also elicited neointima formation in the same model. 
Genetic evidence also supports the role of PPAR" in arterial wall remodeling. When 
conditional knockout PPAR!-/- mice with this receptor knocked out in the endothelial 
cells, VSMCs, and cells of the macrophage/monocyte lineage were exposed to AGP, 
LPA, or ROSI no neointima formation or vascular wall remodeling was observed (Cheng 
et al., 2009).  
 
It is important to note that in a carotid injury model, ROSI diminished the size of 
the neointima. The opposite effect of ROSI and LPA in these two different models 
indicates differences in the mechanism underlying vascular wall remodeling in these 
models (Cheng et al., 2009). These results, combined with the observation that GW9662 
abolished neointima in response to ROSI or AGP (Zhang et al., 2004), suggest that 
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PPAR! is required for LPA-induced neointima formation in the absence of vascular wall 
injury. 
 
Panchatcharam et al. reported that LPA1 and LPA2 receptors play an important 
role in injury-induced neointima formation (Panchatcharam et al., 2008). They 
demonstrated that neointima formation induced by mechanical injury was attenuated in 
LPA1-/-LPA2-/- mice compared to wild type mice. In contrast, in our non-injury model, 
LPA1-/-LPA2-/- mice developed neointima in response to LPA treatment (Cheng et al., 
2009), suggesting that the mechanism underlying these two models in neointima is 
fundamentally different.  
 
Moreover, Subramanian et al. reported that LPA1 and LPA3 GPCRs play an 
important role in injury-induced neointima formation (Subramanian et al., 2010). Using a 
wire-injury model, these authors showed that neointima formation was inhibited by the 
LPA1 and LPA3 inhibitor Ki16425 and that vascular wall remodeling induced by LPA 
was inhibited by short-term knockdown of either LPA1 or LPA3 with small interfering 
RNA (siRNA) (Subramanian et al., 2010). In sharp contrast with the findings of 
Subramanian et al., LPA1-/- mice in our non-injury model develop neointima in response 
to AGP stimulation. Moreover, although LPA1 and LPA3 GPCRs are respectively 12 and 
100 times less sensitive to AGP than LPA (Fujiwara et al., 2005), AGP is more potent 
than LPA in inducing neointima formation (Zhang et al., 2004). Subramanian and 
colleagues also observed that Mac-2 positive cells accumulated in the neointimal area 
after vascular injury (Subramanian et al., 2010); in contrast, our non-injury model 
showed few macrophages in the neointimal region induced by AGP or ROSI (Cheng et 
al., 2009), suggesting that the cellular elements leading to neointima formation are 
different between the two models. 
 
Although some clinical studies in diabetic patients have shown a reduction in 
carotid artery wall thickness after treatment with TZDs (Minamikawa et al., 1998, 
Haffner et al., 2002), other studies suggested that ROSI increases the risk of myocardial 
infarction and death from cardiovascular causes (Goldberg et al., 2005, Nissen and 
Wolski, 2007, 2010), indicating that TZD therapy may actually increase the risk of 
cardiovascular events. Moreover, in 2010, the U.S. Food and Drug Administration 
restricted use of ROSI to patients with type 2 diabetes due to the potential for 
cardiovascular ischemic risks, including heart attack. 
 
 
1.3.2 The Structure-Activity Relationship (SAR) of Neointima Induction  
 
The different molecular species of LPA contain either saturated or unsaturated 
fatty acids. Only unsaturated LPA species including oleoyl (18:1), linolenoyl (18:2), and 
arachidonoyl (20:4) LPA induce neointima (Yoshida et al., 2003, Zhang et al., 2004). In 
contrast, saturated LPA species including palmitoyl (16:0) and stearoyl (18:0) LPA are 
inactive in non-injury carotid wall remodeling assay (Yoshida et al., 2003, Zhang et al., 
2004). The SAR of neointima induction does not match that of the known LPA GPCRs 
because saturated LPA activate LPA GPCRs (Zhang et al., 2004). On the other hand, 
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experiments conducted to determine the SAR for PPAR! activation in vitro and the SAR 
of the neointimal response in vivo are closely matched (Zhang et al., 2004). In vitro, 
ROSI, unsaturated LPA and AGP species all activate the peroxisome activator response 
element-containing acyl-coenzyme A oxidase-luciferase (PPRE-Acox-Luc) reporter 
construct, whereas all saturated LPA species, CPA, and the related lipid mediator S1P are 
inactive (Zhang et al., 2004). The similarity of the SAR of neointimal lesions and PPAR! 
activation support the hypothesis that LPA receptor required for neointima formation is 
PPAR! (Zhang et al., 2004, Tsukahara et al., 2006). 
 
 
1.4    THE ROLE OF PPAR!  
 
 
1.4.1 PPAR!  in Vascular Biology 
 
PPAR! plays an important role in the cardiovascular system. PPAR! is expressed 
in all cell types of the vessel wall (Marx et al., 1998, Delerive et al., 1999, Rangwala and 
Lazar, 2004), as well as in monocytes and macrophages (Tontonoz et al., 1998). PPAR! 
expression is upregulated in VSMCs (Law et al., 2000), endothelial cells (Delerive et al., 
1999), and macrophages (Tontonoz et al., 1998) in human atherosclerotic plaques and 
neointimal lesions.  
 
PPAR! expression is also elevated in neointimal lesions after mechanical injury to 
the endothelium (Law et al., 2000). There are some reports that ROSI suppresses 
neointima formation after endothelial injury in rodent (Lim et al., 2006, Meredith et al., 
2009). Our group found that when AGP was infused to an injured carotid artery, 
neointima was augmented, although ROSI attenuated neointima induced by mechanical 
injury (Cheng et al., 2009). Furthermore, in our non-injury model, ROSI induces 
neointima when applied intralumenally into the carotid artery (Zhang et al., 2004, Cheng 
et al., 2009). Thus, the mechanisms underlying neointima formation in the 
chemically-induced neointima model are likely to be different from those in the 
injury-induced neointima models. It is important to note that circulating LPA makes a 
complex with serum albumin (Tigyi and Miledi, 1992) and LPA-albumin complex cannot 
activate PPAR! because the LPAcomplex can not be internalized (Zhang et al., 2004). 
Therefore, the source of LPA is likely to originate from either the uptake lipid particles 
such as oxidized LDL (oxLDL) or generated intracellularly.  
 
 
1.4.2 PPAR!  in Macrophages/Monocytes 
 
 Macrophages play essential roles in immunity and lipid homeostasis. It has been 
reported that PPAR! is induced during the differentiation of monocytes into macrophages 
and is highly expressed in activated macrophages including the foam cells in 
atherosclerotic lesions (Ricote et al., 1998, Tontonoz et al., 1998). PPAR! is also induced 
during the differentiation of monocytes into dendritic cells (Figure 1-3) (Gosset et al., 
2001, Szatmari et al., 2004).  
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Figure 1-3 Mechanism of PPAR!-mediated effects 
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CD36 is a scavenger receptor and one of the PPAR! response genes. PPAR! 
activation upregulates CD36 expression, which results in increased lipid uptake in  
macrophages (Figure 1-3) (Tontonoz et al., 1998). In macrophages, oxLDL uptake 
through CD36 results in the development of foam cells. Accumulation of foam cells in 
the arterial wall is a hallmark of the early atherosclerotic lesion. There is evidence that 
oxLDL uptake is decreased in PPAR! deficient macrophages due to the loss of CD36 
(Moore et al., 2001) suggesting that the activation of PPAR! in macrophages plays an 
important role atherosclerosis. 
 
 Interestingly, it has been shown that macrophages are accumulated in the 
injury-induced neointima lesions (Subramanian et al., 2010). On the other hand, very few 
macrophages are detected in neointima lesions induced in non-injury model (Cheng et al., 
2009) implying that the roles of macrophages in the two models are different. 
 
 Dendritic cells are antigen-presenting cells, which play an important role in 
stimulating T and B cells. It has been shown that PPAR! promotes antigen-presenting 
molecule CD1d expression in DCs, and LPA is capable of modulating CD1d expression 
(Szatmari et al., 2004, Leslie et al., 2008). This line of evidence suggests that LPA may 
have a critical role in dendritic function through the activation of PPAR!.  
 
 
1.4.3 PPAR!  in Lipid Metabolism 
 
Excess fat is stored as triglycerides in the adipose tissue, and fatty acids are 
released into the circulation in response to increased energy requirement. If lipid storage 
capacity of adipocytes is exceeded, adipocytes can no longer regulate the level of free 
fatty acids (FFAs) in the circulation, which results in the inappropriate deposition of 
lipids in tissues, including the liver and skeletal muscle (Camp et al., 2002). 
Accumulation of triglycerides in the liver and the muscle is thought to lead to metabolic 
dysregulation, especially,to increased levels of triglycerides and FFAs (Camp et al., 
2002).  
 
It has been shown that PPAR! plays an important role in regulating glucose 
metabolism and fatty acid storage (Evans, 2005). Activation of PPAR! in adipose tissue 
leads to target gene expression including aP2, CD36, PEPCK, which are involved in FFA 
uptake and triglyceride storage (Rosen and MacDougald, 2006). Consistent with their 
ability to promote lipid uptake and storage in cultured cells, PPAR! agonists increase 
adipose tissue mass in vivo (Tai et al., 1996).  
 
LPA can be generated intracellularly through multiple pathways and is also an 
intermediate of fatty acid metabolism. Fatty acids taken up by cells are activated to form 
fatty acyl-coenzyme A (fatty acyl-CoA). The next biochemical step is the generation of 
LPA from fatty acyl-CoA and glycerol-3-phosphate by the different forms of 
glycerophosphate acyltransferase (GPAT; Figure1-3) (Vancura et al., 1991). The LPA 
generated by GPAT might activate PPAR! leading to upregulation of PPAR! target genes 
involved in lipogenesis, lipid storage, and adipocyte differentiation (Stapleton et al., 
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2011). In addition, CPA, an acyl analog of LPA, is also generated intracellularly by 
phospholipase D 2 (PLD2) upon the stimulation of insulin, and negatively regulates  
PPAR! functions (Tsukahara et al., 2010) suggesting that PPAR! functions  are regulated 
by agonists as well as by antagonists. 
 
 
1.5    CYCLIC PHOSPHATIDIC ACID 
 
 
1.5.1 CPA Production 
 
CPA (Figure 1-1), an analog of LPA with a five-atom ring linking the phosphate 
to two of the glycerol carbons, is found in diverse organisms from slime mold to humans 
(Murakami-Murofushi et al., 2000); its functions are largely unknown. The concentration 
of CPA in human serum is estimated to be ~0.01 #M, 10-fold lower than that of LPA 
(Eichholtz et al., 1993, Kobayashi et al., 1999). 
 
Friedman et al. demonstrated that CPA can be formed by a intermediate product 
through transphosphatidylation reaction with lysophosphatidylcholine (LPC) mediated by 
a bacterial PLD (Friedman et al., 1996). LPC is a second most abundant phospholipid in 
serum and a substrate of PLD (Tokumura et al., 1983). Tsuda et al. found that fetal 
bovine serum has activity to produce CPA, and they identified ATX, a serum 
lysophospholipase D (lysoPLD), that can produce CPA ex vivo in an ether/water two 
phase buffer system (Tsuda et al., 2006). ATX may not be the only source responsible of 
CPA in serum. In addition, our group showed that CPA is generated intracellularly from 
LPC through the activation of PLD2 (Tsukahara et al., 2010). 
 
 
1.5.2 CPA Receptors  
 
 It has been reported that CPA activates LPA1-5 and GPR87 receptors (Fujiwara et 
al., 2005, Baker et al., 2006, Williams et al., 2009, Tigyi, 2010). CPA activates LPA1-4 
receptors with a lower potency than that of LPA (Fujiwara et al., 2005, Baker et al., 
2006), whereas CPA activates LPA5 with a slightly higher EC50 concentration than LPA 
(Williams et al., 2009). GPR87 and P2Y10 are also activated by CPA with lower 
efficiency than LPA (Tigyi, 2010). In contrast to LPA, CPA does not activate 
intracellular LPA receptor PPAR! (Zhang et al., 2004, Tsukahara et al., 2010). 
 
 
1.5.3 Functions of CPA 
 
The concentration of CPA in human serum is estimated to be ~0.01 #M, 10-fold 
lower than that of LPA (Eichholtz et al., 1993, Kobayashi et al., 1999). Although CPA is 
structurally similar to LPA and activates LPA GPCRs (Fujiwara et al., 2003, Fujiwara et 
al., 2005, Williams et al., 2009), CPA shows several unique actions compared to LPA. 
CPA inhibits cell proliferation in human fibroblast cells whereas LPA stimulates it 
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(Fischer et al., 1998). CPA directly inhibits Cdc25, leading to dephosphorylation 
of cyclin-dependent kinase 2 that results in cell cycle arrest (Murakami-Murofushi et al., 
2002). Nanomolar concentrations of CPA promote neuron outgrowth and enhance 
differentiation and survival in cultured embryonic hippocampal neurons (Fujiwara et al., 
2003). CPA with an acyl chain inhibits LPA-induced platelet aggregation, whereas CPA 
with an alkyl chain shows weak platelet aggregation (Gueguen et al., 1999). Although 
LPA induces transcellular migration, CPA shows inhibitory effect on transcellular 
migration in rat hepatoma, human lung cancer, and mouse melanoma cells (Mukai et al., 
1999). It has been reported that CPA attenuates cancer cell invasion in vivo (Ishihara et 
al., 2004, Uchiyama et al., 2007). Moreover, metabolically stabilized derivatives of CPA 
suppressed pulmonary metastasis when mouse melanoma cells were injected into 
C57BL6 mice (Baker et al., 2006).  
 
 
1.6    PHOSPHOLIPASE D 
 
 
1.6.1 Functions of PLD 
  
PLD catalyzes the hydrolysis of phosphatidylcholine (PC) and LPC to generate 
the lipid second messenger phosphatidic acid (PA) or CPA and choline (Frohman et al., 
1999). PLD can also catalyze the hydrolysis of LPC to generate LPA, which could be the 
source of ligand for intracellular LPA receptors. PLD is conserved in cells from bacteria 
to mammals (Exton, 2002). Mammalian PLD is regulated by many factors, including 
phosphatidylinositol-4,5-bisphosphate (PIP2), protein kinase C (PKC), and small 
G-proteins of the Rho, Ral, and ARF families (Liscovitch et al., 2000, Exton, 2002). PLD 
plays an important role in a wide variety of cellular responses such as vesicular 
trafficking (Cockcroft, 1996, Liscovitch, 1996), Golgi function (Yang et al., 2008, 
Riebeling et al., 2009), cell proliferation, migration, and survival (Plevin et al., 1991, 
Banno et al., 2001, Zheng et al., 2006, Carrigan et al., 2007). 
 
 
1.6.2 Mammalian PLD Isoforms 
 
There are two mammalian PLD isoforms, PLD1 and PLD2 (Liscovitch et al., 
2000). These isoforms share about 50% amino acid similarity and have a highly 
conserved HKD domain necessary for catalysis. They also require PIP2 as a cofactor for 
activation, however, they exhibit quite distinct regulatory properties (Liscovitch et al., 
2000). PLD1 has a low basal activity and responds to members of small G proteins Rho 
and ARF, whereas PLD2 shows a high basal activity and a little or no response to PLD1 
activators (Colley et al., 1997, Exton, 2002). Their distribution is also different. PLD1 is 
predominantly expressed in Golgi, lysosome, and perinuclear endosome, whereas PLD2 
is exclusively expressed at the plasma membrane (Brown et al., 1998, Du et al., 2004). 
Our recent study showed that PLD2, but not PLD1, can generate CPA from LPC 
intracellularly in mammalian cells (Tsukahara et al., 2010). Furthermore, we showed that 
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inhibition of PLD2 by knockdown or dominant negative constructs blocked the protective 
effect of insulin or other stimulators of this enzyme (Tsukahara et al., 2010).  
 
 
1.6.3 PLD Inhibitors 
 
Primary alcohols are often used to quench PLD activity in vitro studies to confirm 
PLD effects. PLD catalyses a transphosphatidylation reaction in the presence of primary 
alcohols like primary butanol, leading to the formation of phosphatidylethanol instead of 
PA (Munnik et al., 1995). Therefore, primary alcohols inhibit cellular responses elicited 
by PLD1- and PLD2-produced PA. Secondary and tertiary alcohols cannot be substrates 
of the transphosphatidylation reaction. 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) is 
an analog of halopemide, a dopamine receptor antagonist, and identified as an inhibitor of 
both PLD1 and PLD2 (Monovich et al., 2007, Su et al., 2009). FIPI inhibits 
PLD-mediated PA production, leading to the inhibition of F-actin cytoskeleton 
reorganization, cell spreading, and chemotaxis (Su et al., 2009). Recently, we 
demonstrated that FIPI inhibits PLD2-mediated CPA production in human peripheral 
mononuclear cells (Tsukahara et al., 2010). 
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CHAPTER 2.    LYSOPHOSPHATIDIC ACID-INDUCED ARTERIAL WALL 
REMODELING: REQUIREMENT OF PPAR! BUT NOT LPA1 OR LPA2 GPCR* 
 
 
2.1    INTRODUCTION 
 
Lysophosphatidic acid (LPA, 1-acyl-2-hydroxy-sn-glycero-3-phophate) and its 
ether-linked analog alkyl glycerophosphate (AGP, 
1-alkyl-2-hydroxy-sn-glycero-3-phophate) are naturally occurring lipid mediators with 
growth factor-like effects in almost every mammalian cell type (Siess and Tigyi, 2004). 
AGP and LPA elicit their biological responses through eight plasma membrane receptors 
that belong to the GPCR superfamily and intracellularly through the peroxisome 
proliferator-activated receptor ! (PPAR!) (McIntyre et al., 2003, Tsukahara et al., 2006). 
AGP and LPA are present in blood plasma (Xiao et al., 2001) and become enriched after 
minimal oxidative modification of LDL (Rother et al., 2003, Zhang et al., 2004). The 
lipid rich core in human carotid endarterectomy specimens contains high concentrations 
of AGP and LPA (Siess et al., 1999) and upon plaque rupture could activate platelet 
aggregation  and lead to atherothrombosis (Rother et al., 2003). 
 
All major cell types of the arterial wall respond to LPA. In endothelial cells, LPA 
has been shown to regulate the expression of adhesion molecules, proliferation, 
apoptosis, permeability, motility and cell-to-cell contacts responsible for transendothelial 
permeability (Rizza et al., 1999, Lin et al., 2006). LPA induces vascular smooth muscle 
cell (VSMC) contraction, proliferation (Tokumura et al., 1994) and phenotypic 
transdifferentiation in vitro (Hayashi et al., 2001, Zhang et al., 2004). LPA and oxidized 
LDL inhibit macrophage/dendritic cell egress across endothelial cell monolayers (Angeli 
et al., 2004, Llodra et al., 2004). LPA also stimulates the formation of platelet-monocyte 
aggregates, which are considered as an early marker of acute myocardial infarction 
(Fueller et al., 2003, Siess, 2006). 
 
Yoshida and colleagues were the first to test lumenally applied LPA on the 
non-injured arterial wall in vivo (Yoshida et al., 2003). These authors infused LPA 
through the external carotid artery of rats into a ligated section of the common/internal 
carotid artery that was rinsed free of blood and maintained close to the mean arterial 
perfusion pressure. In this model, which involves no mechanical injury or the removal of 
endothelial cells in the common carotid artery, after 1-hour exposure to unsatured but not 
to saturated species of low micromolar LPA leads to neointima development. These 
authors interpreted their observation as if a yet unknown LPA GPCR activated only by 
unsaturated species of LPA. However, the structure-activity relationship of neointima 
induction does not match that of the known LPA GPCRs but matches the 
structure-activity relationship of PPAR! activation by LPA. 
 
* Adapted with permission. Cheng Y, Makarova N, Tsukahara R, Guo H, Shuyu E,  
Farrar P, Balazs L, Zhang C, Tigyi G (2009) Lysophosphatidic acid-induced arterial  
wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. Cell Signal  
21:1874-1884. 
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LPA is an agonist of the nuclear transcription factor PPAR! (McIntyre et al., 
2003). PPAR! has long been implicated in atherogenesis (Diep and Schiffrin, 2001, Li 
and Glass, 2002). Many compounds activate PPAR, including the synthetic drug 
Rosiglitazone (ROSI) of the thiazolidinedione family, oxidized phospholipids, fatty acids, 
eicosanoids, and oxidized LDL. PPAR! is expressed in macrophages/monocytes, 
vascular smooth muscle cells, endothelial cells, and is highly expressed in atherosclerotic 
lesions and hypertensive vascular wall (Diep and Schiffrin, 2001). GW9662, a specific 
irreversible antagonist of PPAR! (Leesnitzer et al., 2002) completely abolished AGP, 
LPA and ROSI-induced neointima formation in the rat model (Zhang et al., 2004). 
Although, these lines of evidence support the role of PPAR! as the receptor responsible 
for the neointimal thickening elicited by AGP and LPA, the pharmacological evidence 
does not exclude the possibility that LPA GPCR mediate this response alone or through 
the indirect activation of PPAR!. Several investigators reported that systemic and chronic 
administration of ROSI attenuates neointima in models with mechanical injury of the 
arterial wall which is different from findings reported using the non-injury model (Lim et 
al., 2006, Lee et al., 2009). 
 
Here we compared the effects of AGP and ROSI on arterial wall remodeling in a 
balloon injury model with that in the non-injury model and found that these agents elicit 
model-dependent different responses. We pursued a gene knockout (KO)-based strategy 
to seek the identification of the LPA receptor subtype(s) necessary for the neointimal 
response in the non-injury model. We tested AGP and ROSI in LPA1, LPA2, LPA1 and 
LPA2 double knockout (DKO), and in inducible conditional PPAR!  knockout mice 
targeted to VSMCs, macrophages and endothelial cells by the Mx1Cre promoter. We also 
sought to characterize the phenotypic properties of cells involved in LPA-elicited 
neointimal thickening and found that the overwhelming majority of the cells in the 
neointimal layer express !SMA characteristic of the VSMC lineage. Our findings showed 
that LPA1&2 GPCR KO mice behave like wild type (WT) mice whereas, PPAR! KO fail 
to develop AGP- and ROSI-induced neointimal thickening. 
 
 
2.2    EXPERIMENTAL PROCEDURES 
 
 
2.2.1 Reagents 
 
 1-O-octadecenyl glycerophosphate (AGP 18:1) was purchased from Avanti Polar 
Lipids (Alabaster, AL). Rosiglitazone (ROSI) was from ALEXIS Biochemicals, Inc. 
(Plymouth Meeting, PA). TRIzol Reagent, DNase I, and the ThermoScript RT-PCR 
System for First-Strand cDNA Synthesis were from Invitrogen (Carlsbad, CA). The RT2 
Real-Time SYBR Green/ROX kit was purchased from SuperArray (Frederick, MD). 
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2.2.2 Quantitative RT-PCR 
 
 Total RNA was prepared using TRIzol reagent from mouse common carotid 
artery from which the adventitia had been peeled off. One #g of total RNA was digested 
with DNase I and used for the subsequent synthesis of cDNA using the First Strand 
Synthesis kit as recommended by the manufacturer. The following primer pairs were 
used:  LPA1, (forward) GTCTTCTGGGCCATTTTCAA and (reverse) TCATAGTCCTC 
TGGCGAACA; LPA2, (forward) GGGCCAGTGCTACTACAACG and (reverse) ACC 
AGCAGATTGGTCAGCA; LPA3, (forward) GAATTGCCTCTGCAACATCTC and 
(reverse) ATGAAGAAGGCCAGGAGGTT; LPA4, (forward) TCTGGATCCTAGTCCT 
CAGTGG and (reverse) CCAGACACGTTTGGAGAAGC; LPA5, (forward) CGCCATC 
TTCCAGATGAAC and (reverse) TAGCGGTCCACGTTGATG; and GAPDH, 
(forward) CTGCACCACCAACTGCTTAG and (reverse) GGGCCATCCACAGTCTTC 
T. The primer sets were designed with a melting temperature of 59–61°C. Amplicon size 
was 50–200 bases. Amplification was performed for 40 cycles at 94ºC/15 sec and 60ºC 
/60 sec. Quantitative values were obtained from the threshold cycle value (Ct) as 
previously described (Guo et al., 2008). 
 
 
2.2.3 Immunofluorescence Staining 
 
 Cryosections dipped in 4% buffered paraformaldehyde were blocked in 10% goat 
serum and incubated with rat anti-mouse CD31 (anti-PECAM-1 rat monoclonal antibody, 
1:400 dilution; RDI Inc.; Concord, MA), or anti-mouse CD11b (anti-Mac-1 rat 
monoclonal antibody, 1:100 dilution; BD Pharmingen; San Diego, CA), or anti-mouse 
CD68 (anti-macrosialin rat monoclonal antibody, 1:400 dilution; ABD SeroTec; Oxford, 
UK) antibodies. Anti-rat fluorescein-conjugated secondary antibody was used at a 1:200 
dilution (Vector Laboratories; Burlingame, CA). Cell nuclei were stained with DAPI. The 
MOM kit (Vector Laboratories) was used for !-smooth muscle actin (!SMA) staining. 
Briefly, after fixation and permeabilization, tissue sections were incubated with mouse 
IgG blocking reagent for 1 h, followed by 1:200 diluted anti-!SMA antibody (1:400 
dilution; DAKO; Carpinteria, CA) and then 1:200 diluted Texas Red conjugated 
anti-mouse antibody (1:200 dilution; Vector Laboratories). For the double staining of 
mouse carotid artery sections, !SMA staining was carried out using the MOM kit on 
anti-CD11b- or anti-CD68-stained sections. The fluorescence was observed by Nikon 
Eclipse 80i fluorescence microscope. Merged images for double-stained sections were 
generated by the NIS-Elements (V2.1, Nikon Instruments) image analysis software. 
 
 
2.2.4 Rat Carotid Artery Balloon Injury Model 
 
 The animal procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Tennessee and were consistent with the Guide for the 
Care and Use of Laboratory Animals (National Institutes of Health publication 85-23, 
revised 1985). Carotid artery balloon injury was induced in male Sprague-Dawley rats 
(230 to 300 g) anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg). Under a 
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dissecting microscope, the right common carotid artery was exposed through a midline 
cervical incision. A 2F Fogarty catheter (Baxter-Edwards) was introduced via an 
arteriotomy via the external carotid artery, and then the catheter was advanced to the 
proximal edge of the omohyoid muscle. The balloon was inflated with saline and 
withdrawn three times from under the proximal edge of the omohyoid muscle to the 
carotid bifurcation. The common and internal carotid arteries were clamped and a 100 #l 
aliquot of AGP (10 µM), ROSI (10 µM), or vehicle was instilled into the injured segment 
via a PE-10 catheter and was incubated for 60 min. Subsequently, the catheter was 
withdrawn and the external carotid artery was ligated with 6-0 silk suture. The clips at the 
common and internal carotid arteries were released, and blood flow in the common 
carotid artery was restored. Three weeks after injury the carotids were dissected and 
processed for histology as described for the mouse specimens above. Each group 
consisted of six rats. 
 
 
2.2.5 Transgenic and Knockout Animals 
 
 LPA1 and LPA2 knockout breeders on C57BL/6 background were generously 
provided by Jerold Chun (Scripps Institute, CA) and have been characterized previously 
(Contos et al., 2000, Contos et al., 2002, Yang et al., 2002). LPA1&2 double knockout 
(DKO) mice were obtained by crossing homozygous LPA1 males with LPA2 females. 
Genotyping of the DKO mice was done as described by Contos et al. coworkers (Contos 
et al., 2002). The C57BL/6-Mx1Cre mouse line was made available by Dr. Matthew 
Breyer (Vanderbilt University) that allows the differential, interferon (IFN)-inducible 
targeting of the Cre recombinase to vascular and renal endothelium, vascular smooth 
muscle cells and macrophages (Akiyama et al., 2002, Schneider et al., 2003). The 
Mx1Cre is induced intraperitoneal injection of the IFN-inducer synthetic double-stranded 
RNA polyinosinic-polycitidylic acid (pIpC, Sigma-Aldrich, St. Louis, MO). Dr. Mark 
Magnuson (Vanderbilt University) generously provided us a mouse line with exon 2 of 
PPAR! has been flanked by LoxP sites on the C57BL/6 background (Jones et al., 2002). 
PPAR!fl/- mice were bred with homozygous Mx1Cre mice to generate mice that are 
PPAR!fl/-#Mx1Cre. Upon Mx1 induction with pIpC in PPAR!fl/-#Mx1Cre mice, Cre 
recombines the single PPAR! allele creating a conditional knockout (Jones et al., 2002, 
Guan et al., 2005, Jones et al., 2005). These induced conditional KO mice will be referred 
to as &PPAR!. Thus, &PPAR! mice allowed the targeted disruption of PPAR! in the 
three most important cell types – vascular endothelium, VSMC and macrophages 
(Akiyama et al., 2002, Guan et al., 2005) – involved in vascular remodeling whereas, 
littermates not induced with pIpC injections served as controls. In addition, Mx1Cre 
transgenic mice and pIpC-induced PPAR!fl/- mice were also used to examine AGP- and 
ROSI-induced vascular wall remodeling. 
 
 
2.2.6 Monitoring PPAR!  Recombination 
 
 Genotyping of Mx1/Cre#PPAR!fl/- and PPAR!fl/- mice was done as described by 
Jones et al.(Jones et al., 2002). The position of the genotyping primers and their 
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respective PCR products is shown in Figure 2-1A and B. Examples of the wild-type 
(WT) Mx1/Cre#PPAR!fl/- genotype (mouse #23) and PPAR!fl/- genotype (mouse #24) are 
shown in Figure 2-1C. The following genotyping primers were used: A1, (forward) 5’- 
TACTTAATGTCATGATGATCTGT-3’; A2, (reverse) 5’-GATAAGACAGCACAA 
CAATGTTC-3’; B1, (reverse) 5’-GCTCCTGAGTGCTAATATTAAAG-3’; and B2, 
(forward) 5’-CCATGGACTAATGCTGTAATATTA-3’ Cre-specific primers – (forward) 
5’-ACCTGAAGATGTTCGCGATTATCT-3’ and (reverse) 5’-ACCGTCAGTACGTGA 
GATATCTT-3’ – were used, yielding a 370-bp fragment (Figure 2-1D). Amplification 
was done using a 200-ng template for 40 cycles (Tag DNA Polymerase; New England 
Biolabs; Ipswich, MA). Two weeks after pIpC induction of young animals RT-PCR for 
PPAR! mRNA expression was done using peritoneal macrophages, carotid arteries, or 
abdominal aorta samples (Figure 2-1D). For PPAR! the 5’-GGAAAGACAACAGACAA 
ATCACC-3’ (forward) and 5’-ATTCAGCTTGAGCTGCAGTTC-3’ (reverse) primers 
were used the amplicon yielding a 558 bp fragment. For quantitative monitoring of 
pIpC-induced Mx1Cre-mediated recombination of PPAR!, 18 mice were randomly 
divided into two equal groups. One group was injected i.p. with 250 µl of pIpC (2 mg/ml) 
on days 1, 3, 5, and 7; the others received vehicle. Two weeks after the last injection, the 
mice were anesthetized with ketamine and xylazine and injected i.p. with 5 µl of sterile 
PBS. About 5 # 105-106 macrophages per mouse were collected from the peritoneal wash 
by centrifugation and the common carotid artery and the aorta were dissected. RNA 
purified using TRIzol was pooled from three mice, yielding three samples (treated 
separately) from the nine mice. One µg of RNA was digested with DNase I and used for 
the subsequent synthesis of cDNA, using the First Strand Synthesis kit. The following 
primer pairs were used: PPAR!, (forward) 5’-CATGCTTGTGAAGGATGCAA-3’ and 
(reverse) 5’-CCCAAACCTGATGGCATT-3’; and GAPDH, (forward) 5’-CTGCACCAC 
CAACTGCTTAG-3’ and (reverse) 5’-GGGCCATCCACAGTCTTCT-3’. Amplification 
was performed for 40 cycles at 94ºC/15 sec and 60ºC/60 sec. Quantitative values were 
obtained from the Ct. &Ct was defined by subtracting the average Ct value of PPAR! 
from the corresponding Ct value of the GAPDH gene in a given sample. Results were 
expressed as fold difference (N) in gene expression relative to GAPDH, where N = 2(&Ct 
pIpC - &Ct vehicle). In peritoneal macrophages, the PPAR! transcript number decreased 
by 95% after pIpC induction, whereas in the carotid tissue the decrease was 87% (Figure 
2-1E). 
 
 
2.2.7 Mouse Model of Neointima Induction 
 
 The surgical procedure for exposing and cannulating the external carotid artery 
originally developed by Yoshida et al. (Yoshida et al., 2003) rats was adopted to mice. 
Briefly, the right carotid arteries of anesthetized adult (8-12 week) and sex-matched mice 
(20 – 30 g) was surgically exposed. The caudal origin of the common carotid artery was 
ligated using a vessel clip, followed by exposure and ligation of the internal carotid artery 
above the bifurcation. The external carotid artery was then exposed and a polyethylene 
catheter was inserted into the external carotid such that it never reached the common 
carotid artery, thereby avoiding mechanical injury to this segment of the vessel. The clip 
occluding the common carotid artery was temporarily released, and the vessel was rinsed 
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Figure 2-1 Genotyping of PPAR! fl/- and Mx1Cre#PPAR! fl/- mice 
 
(A) Scheme of PPAR! gene arrangement upon Cre-mediated recombination. Note the 
position and sizes of the different allele-specific primers. (B) Sizes and expected product 
sizes of allele-specific primers. (C) Genotyping of WT, Mx1Cre#PPAR!fl/- mouse #23, 
and  PPAR!fl/- mouse #24. (D) RT-PCR for PPAR! using carotid and aortic tissues from 
pIpC-induced &PPAR!fl/- (mouse #23) and PPAR!fl/- (mouse #24) mice. Note the 
diminished 558 bp PPAR! band intensity in mouse #23 compared to mouse #24. (E) 
Q-PCR using mRNA isolated from peritoneal macrophages and carotid arteries of 
uninduced vehicle-injected and pIpC-induced &PPAR!fl/- mice. Note the substantial but 
incomplete reduction in PPAR! transcripts in macrophages and carotids. 
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with a retrograde injection of 100#l physiological saline to remove residual blood. The 
vessel was again clipped, and 50 #l of treatment solution containing 5#M AGP or ROSI 
dissolved in 3% DMSO PBS (vehicle) was injected under pressure. After 60 min of 
incubation, the cannula was withdrawn, the external carotid artery was ligated, and blood 
flow was restored by removing the clips. Three weeks post surgery the animals were 
euthanized, and the common carotid artery from the jugular arch to the bifurcation was 
dissected on both sides, snap frozen in liquid N2-cooled isopentane and processed for 
histological analysis. Cryostat sections (~5 µm) were cut and stained with hematoxylin 
and eosin, Masson's trichrome stain (Richard-Allan Scientific Inc.) or processed for 
immunohistological staining. Intima-to-media ratios were measured using the NIH Image 
(version 1.62) software. Groups consisted of four-to-ten animals per treatment or control 
group. Intima-to-media ratios (mean ± SEM) were compared between the appropriate 
groups using student’s t-test and p < 0.05 was considered statistically significant. 
 
 
2.3    RESULT 
 
 
2.3.1 Differential Effects of AGP and ROSI on Injury-Induced Neointima 
 
Several literature reports describe the inhibitory effect of the PPAR! agonist 
ROSI on injury-induced neointima (Lim et al., 2006, Lee et al., 2009). In contrast, in the 
non-injury model using topical application of ROSI or LPA we and others (Yoshida et 
al., 2003, Zhang et al., 2004) have found that these PPAR! agonists elicited arterial wall 
remodeling that includes neointimal growth. To resolve this apparent contradiction, we 
hypothesized that the mechanisms causing neointima differ between the injury and the 
non-injury models. Consequently, these agents might exert different effects in these two 
models. To examine this possibility, we applied a balloon injury model of the rat carotid 
followed by ROSI or AGP treatments. The injury-induced neointima increased 
significantly by AGP application following injury (p < 0.02, Figure 2-2). However, in 
agreement with previous reports, ROSI application following balloon injury attenuated 
neointima formation; although, this attenuation was not statistically significant (p=0.24). 
These observations suggest different mechanisms for AGP and ROSI in this balloon 
injury model and warn against a direct comparison between this and the non-injury 
model. 
 
 
2.3.2 Expression of LPA GPCR Subtypes in the Mouse Carotid  
 
QPCR was used to assess the expression of LPA1-5 GPCR. Transcripts were 
detected with a rank order of LPA1 > LPA4 >> LPA2 = LPA3 > LPA5 (Figure 2-3A) in 
both the carotid and aortic tissue (not shown). LPA1, LPA2, LPA3, and LPA4 GPCR are 
12-, 30-, 100-, and 1.5-times less sensitive to AGP than LPA (Fujiwara et al., 2005, 
Williams et al., 2009), respectively. In contrast, AGP is more potent than LPA inducing 
arterial wall remodeling (Zhang et al., 2004). LPA4 KO mice only became available after 
the conclusion of the experiments presented herein and were not included in the present 
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Figure 2-2 Effects of 10 !M AGP or ROSI on neointima induced by balloon 
injury of the rat carotid artery.
 
(A) Intima-to-media ratios three weeks after balloon injury followed by a one-hour 
treatment with vehicle, 10 #M AGP or ROSI. (B, C, and D) Representative cross sections 
of vehicle-, AGP-, and ROSI-treated carotid arteries. The calibration bar is 200 #m. 
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Figure 2-3 AGP and ROSI elicit arterial wall remodeling in C57/BL6 mouse 
carotids 
 
(A) Quantitative RT-PCR of LPA GPCR expression in the mouse carotid artery. (B) 
Trichrome-stained cross section of a C57/BL6 mouse carotid treated with vehicle. (C and 
D) Cross section of a trichrome-stained mouse common carotid artery three weeks after 
intralumenal application of 2.5 µM AGP. (E and F) Cross section of a mouse common 
carotid artery three weeks after intralumenal application of 2.5 µM ROSI. Trichrome 
staining, the bars are 100 µm. Note the multi-layered neointima and changes in the media 
indicated by the blue stain. 
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study. Although LPA3 was reported to prefer unsaturated LPA species over saturated 
ones (Bandoh et al., 2000), this is not unique to LPA3 but also found at LPA1 and LPA2 
(Fujiwara et al., 2005). Due to the 100-fold lesser potency of AGP over LPA at the LPA3 
GPCR combined with the low abundance of its transcripts in the carotid LPA3 KOs were 
not included in the study. The ligand selectivity of the LPA GPCR tend to discount but 
do not exclude the role of these receptors in AGP-induced arterial wall remodeling. 
 
 
2.3.3 Lumenally Applied AGP and ROSI Elicit Vascular Remodeling in the 
Uninjured Mouse Carotid Artery 
 
In an effort to examine the contribution of the different cell surface and 
intracellular LPA receptors to AGP-elicited vascular remodeling we adopted the carotid 
infusion model to mice. Similarly to our findings in rats (Zhang et al., 2004), infusion of 
vehicle to the mouse carotid failed to induce remodeling (Figure 2-3B, Figure 2-4A). In 
contrast, a brief 60 min application of 2.5 #M AGP elicited multilayered neointima 
(Figure 2-3C). The PPAR! agonist ROSI (2.5 #M) also elicited arterial wall remodeling 
(Figure 2-3E). No apparent morphologically distinguishable features were found between 
intimal thickening elicited by AGP or ROSI. Neointima development was accompanied 
by changes in the media as indicated by the blue staining in the trichrome-stained slides 
(Figure 2-3D and E) in segments of the common carotid artery not subjected to 
mechanical injury either by cannulation or clipping. The arteries taken from the 
contralateral side showed no visible alteration upon microscopic observation (data not 
shown). The beginning of intimal thickening was clearly observed by the second week 
and progressed up to the fourth week, the latest time point examined. The neointimal 
layer developed in response to AGP was not stained with anti-CD31 (Figure 2-4C) but 
strongly reacted with anti-"SMA antibody (Figure 2-4D). Using double staining, only a 
few cells in the neointima expressed the CD68 marker (Figure 2-4E) and CD11b positive 
cells were scarce (Figure 2-4D). Similar immunocytological findings were noted in the 
ROSI treated mice (Figure 2-5A-F). 
 
 
2.3.4 Neointimal Responses in LPA GPCR KO Mice 
 
LPA1, LPA2, and DKO mice were subjected to intralumenal application of 2.5 
#M AGP or ROSI and the carotids were isolated 3 weeks later and neointima formation 
was quantified. Intima-to-media ratio measurements in LPA1, LPA2, and DKO mice 
showed that AGP (Figure 2-6A, Figure 2-7A) and ROSI (Figure 2-6B) elicited neointima 
development that was indistinguishable from that seen in WT mice. The cells comprising 
the neointima were not stained with anti-CD31 (Figure 2-7B) but showed strong 
immunoreactivity with the anti-"SMA antibody (Figure 2-7C). The neointima contained 
scattered CD68 positive cells (Figure 2-7D), whereas CD11b positive cells were scarce 
(Figure 2-7E). Double staining with anti-"SMA and CD68 (not shown) or CD11b 
(Figure 2-7F) antibodies showed distinct populations of cells expressing the two markers 
that was similar to the staining patterns seen in WT animals (Figure 2-4E and F, Figure 
2-5D-F). The immunohistological staining of the single KO mice showed features (not  
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Figure 2-4 Histological and immunohistological staining of neointima in C57/BL6 
mouse carotids three weeks after intralumenal application of 2.5 !M AGP 
 
(A) Vehicle injected control carotid artery shows no neointima. (B) AGP-treatment 
causes concentric neointima with capillary formation within the neointima. (C) 
Anti-CD31 staining shows single layer of staining and lack of staining in the neointimal 
layers. (D) Anti-"SMA staining shows intensive immunoreactivity in the neointimal 
layers. (E) Merged image of anti-CD68 (green) and anti-"SMA (red) staining shows 
scattered cells bearing this marker in the neointima and no double stained cells in this 
merged image. (F) Anti-CD11b stained cells are few and anti-"SMA double positive 
cells are not visible. Calibration bar is 100 #m. 
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Figure 2-5 Histological and immunohistological staining of neointima three 
weeks after intralumenal application of 2.5 !M ROSI into the carotid of WT 
C57BL/6 mice 
 
(A) Masson’s trichrome stain shows multi-layered neointima. (B) Anti-CD31 staining 
shows lack of staining in the neointimal layers. (C) Anti-"SMA staining shows intensive 
positivity of the neointimal layers. (D) Anti-CD68 stains cells bearing this marker in the 
neointima and at the media-adventitia boundary. (E) No anti-CD11b stained cells are 
detected in the neointima. (F) Merged image of double staining with anti-CD11b (green) 
and anti-"SMA (red) shows distinct populations of cells bearing only one but not both 
markers. Calibration bar is 100 #m. 
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Figure 2-6 Intima-to-media ratios measured in WT and LPA1, LPA2, and DKO 
mice 
 
Effect of 2.5 #M intralumenal application of either AGP (A) or ROSI (B) three weeks 
after treatment. Note the similar intima-to-media ratios elicited by the treatments 
regardless of the genotype of the mice. No statistically significant differences were found 
between the different KOs. 
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Figure 2-7 Immunohistological phenotyping of neointima three weeks after 
intralumenal application of 5 !M AGP in DKO mice 
 
(A) Masson trichrome-stained carotid shows multi-layered neointima. (B) Anti-CD31 
staining shows lack of staining in the neointimal layers. (C) Anti-"SMA staining shows 
intensive immunoreactivity in the neointimal layers. (D) Anti-CD68 staining shows 
positive cells in the neointima. (E) Anti-CD11b stained cells are few and localized at the 
media-to-adventitia border. (F) Merged double staining for CD11b (green) and 
anti-"SMA staining shows no double positive cell. Calibration bar is 100 #m. 
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shown) that were similar to those seen in DKO or WT mice. These observations did not 
support the requirement for LPA1 and LPA2 GPCR in AGP- and ROSI-elicited arterial 
wall remodeling; thus we focused our investigation to PPAR!. 
 
 
2.3.5 Neointimal Responses in Conditional PPAR!  KO Mice 
 
Knocking out PPAR! causes embryonic lethality, hence we were limited to the 
availability of conditional KOs that reach adulthood. We chose the Mx1Cre#PPAR!fl/- 
mouse because in this strain we could experimentally activate Cre-mediated 
recombination through the Mx1 promoter in the endothelium, VSMC, and macrophages 
(Akiyama et al., 2002, Schneider et al., 2003). The added benefit of inducible 
Cre-mediated recombination was that we could compare induced and uninduced 
littermates. In addition, we examined mice from the parental strains Mx1Cre and 
PPAR!fl/- for their responses to intracarotid application of AGP and ROSI. In these 
experiments Mx1Cre mice showed neointima similar to WT mice (Figure 2-8A, Figure 
2-9A and B). PPAR!fl/- littermate mice were randomly assigned to two groups, one of 
which received vehicle, the other was induced with pIpC three weeks prior to carotid 
surgeries. The uninduced (vehicle injected) group was included to determine whether 
deletion of one PPAR! allele has any effect on arterial wall remodeling elicited by the 
two compounds. The pIpC induced control group was designed to assess the effect of 
pIpC pretreatment on AGP- and ROSI-elicited arterial wall remodeling. Three weeks 
after these pretreatments the animals were exposed to either vehicle, 2.5 #M AGP, or 
ROSI for 1 h. After 21 days post carotid surgery the arteries were processed for histology 
and immunohistology to examine the arterial wall. Determination of the intima-to-media 
ratio regardless of pretreatment by vehicle or pIpC in the AGP-treated animals showed 
increases that were identical to those seen in WT animals (Figure 2-8B and G). Similarly, 
when ROSI was infused into the carotids of pretreated animals the intima-to-media ratio 
increased (Figure 2-8H, Figure 2-9C and D). These results indicate that neither presence 
of only a single PPAR! allele nor pretreatment with pIpC abolished arterial remodeling 
elicited by AGP or ROSI.  
 
Littermates of Mx1Cre#PPAR!fl/- animals were randomly assigned to two  
pretreatment groups to receive either pIpC induction or vehicle. After a 3-week period the 
carotids of these animals were exposed to either 2.5 #M AGP, 2.5 #M ROSI, or vehicle. 
Carotid arteries of vehicle pretreated Mx1Cre#PPAR!fl/- animals three weeks after AGP 
or ROSI treatment showed significant increases in intima-to-media ratio (Figure 2-8C, G, 
and H, Figure 2-9E and F). The neointima-to-media ratios were similar to that seen in 
WT animals or PPAR!fl/- animals, establishing that the Mx1Cre#PPAR!fl/- genetic 
background without pIpC induced Mx1Cre recombination develops arterial wall 
remodeling in response to AGP or ROSI. In sharp contrast, in the pIpC-induced &PPAR! 
animals AGP or ROSI treatment failed to alter the intima-to-media ratio (Figure 2-8D 
and F-H, Figure 2-9G and H). These results indicate that conditional KO of PPAR! 
completely abolished the arterial wall remodeling elicited by AGP or ROSI. Carotid 
arteries obtained from every group of animals were also stained with anti-CD31, anti-
"SMA, anti-CD68, and anti-CD11b antibodies. In those groups of animals that showed  
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Figure 2-8 Effect of Mx1Cre-mediated conditional knock out of PPAR!  on 
AGP-induced neointima 
 
(A) Trichrome staining of a representative Mx1Cre transgenic mouse carotid three weeks 
after exposure to 2.5 #M AGP. (B) Representative trichrome-stained carotid of a 
pIpC-induced PPAR!fl/- mouse three weeks after AGP treatment. (C) Trichrome-stained 
mouse carotid from a Mx1Cre#PPAR!fl/- mouse without pIpC induction three weeks after 
exposure to 2.5 #M AGP. (D) Trichrome-stained carotid from a pIpC-induced &PPAR! 
mouse three weeks after AGP treatment. Note the complete lack of neointima 
development. (E) Anti-"SMA staining of an uninduced Mx1Cre#PPAR!fl/- mouse three 
weeks after AGP treatment. Note the "SMA positive neointimal cells inside the internal 
elastic lamina (IEL) that shows red autofluorescence. EEL- external elastic lamina. (F) 
Anti-"SMA staining of a pIpC-induced &PPAR! mouse three weeks after AGP 
treatment. Note the complete lack of "SMA staining inside the IEL. Calibartion bars are 
100 #m. Intima to media ratios in mice with or without pIpC induction three weeks after 
exposure to 2.5 #m AGP (G) or ROSI (H). Asterisks denote significant differences to 
uninduced vehicle-treated Mx1Cre#PPAR!fl/- mice (p< 0.05, n= 5-10 mouse per group). 
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Figure 2-9 Effect of Mx1Cre-mediated conditional knock out of PPAR!  on 
ROSI-induced neointima 
 
Trichrome (A) and anti-"SMA (B) staining of a pIpC-treated Mx1Cre mouse carotid 
three weeks after treatment with 2.5 #M ROSI. Trichorme (C) and anti-"SMA (D) 
staining of a carotid from a pIpC-induced PPAR!fl/- mouse. Trichorme (E) and 
anti-"SMA (F) staining of a carotid from a non-pIpC-induced Mx1Cre#PPAR!fl/- mouse 
carotid. Note the anti-"SMA positive neointimal cells inside the IEL. Trichorme (G) and 
anti-"SMA (H) staining of an pIpC-induced &PPAR! mouse three weeks after ROSI 
treatment. Note the complete lack of "SMA staining inside the IEL. Calibartion bars are 
100 #m.  
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increased intima-to-media ratios the immunohistological profile was qualitatively 
indistinguishable form that of the WT treated with AGP or ROSI. In &PPAR! animals 
that showed no alterations in the intima-to-media ratio we did not observed an increase in 
SMA positive cells (Figure 2-8F, Figure 2-9H) or alterations in the CD68 or CD11b (not 
shown) marker-bearing cell populations. 
 
 
2.4    DISCUSSION 
 
Arterial wall remodeling is considered a prelude to atherosclerotic disease and its 
pharmacological modulation is of significance in the prevention of several associated 
pathologies. Injury-induced and post-angioplasty arterial wall remodeling also represent 
human pathologies that would benefit from pharmacological intervention. The growth 
factor-like phospholipid mediator LPA has been shown to induce arterial wall remodeling 
in the absence of injury following only a brief 1-h-long topical application into the lumen 
of the carotid artery (Yoshida et al., 2003, Zhang et al., 2004). In the present study we 
sought genetic evidence for the role of LPA1 and LPA2 GPCRs and the intracellular LPA 
receptor PPAR! in this chemically-induced model of arterial wall remodeling.  
  
First, we attempted to resolve the apparent contradiction between chronic 
ROSI-induced attenuation of injury-elicited neointima (Lim et al., 2006, Lee et al., 2009) 
and the ROSI-induced neointimal response in the non-injury model by comparing AGP 
and ROSI effects in the two models. We hypothesized that the mechanisms underlying 
neointima formation in the chemically-induced and injury-induced models differ leading 
to the opposite outcome in the response to ROSI application. In the balloon injury model 
AGP significantly augmented the intima-to-media ratio over that elicited by the injury 
(Figure 2-2A-C). In contrast, ROSI treatment did not cause either a significant 
attenuation or augmentation in the intima-to-media ratio relative to the injury control, 
although the neointima in this treatment group was lesser than in the injury control group 
(Figure 2-2A and D). This set of experiments clearly indicates that ROSI and AGP 
application to an injured vessel with disrupted epithelium elicit different outcomes. 
Future experiments will be conducted using the KO mouse models to evaluate the role of 
LPA GPCR and PPAR! after vessel wall injury. 
  
Our second objective was to establish and validate a chemically-induced arterial 
remodeling model in the mouse. We scaled down the treatment from the previously 
reported rat model (Yoshida et al., 2003, Zhang et al., 2004) and found that in C57BL/6 
mice, which represent the genetic background of our knockouts, lumenal application of 
AGP elicited carotid remodeling at low micromolar concentrations (Figure 2-3C and D). 
No such changes were found in vehicle treated (Figure 2-3B) or sham operated animals 
or in the contralateral carotid of AGP-treated mice. Just as in the rat, in mice luminal 
intracarotid application of ROSI (Figure 2-3E and F) mimicked the effects of AGP when 
applied at the same concentration and over the same time course. This observation 
extended the utility of this model from the rat to the mouse, creating the opportunity for 
inclusion of transgenic and knockout mice in our experiments. 
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The cellular markers of the treated carotids were examined using antibodies 
specific to Von Willebrand factor (CD31), "SMA, the pan macrophage marker CD68, 
and the CD11b marker, which is expressed by tissue macrophages including dendritic 
cells. Carotid arteries collected from AGP- or ROSI-treated WT mice showed a single 
layer of CD31 positive cell layer (Figure 2-4C, Figure 2-5B) indicating that the cells in 
the neointima lack this endothelial cell marker. The neointimal layer showed very strong 
staining with the "SMA marker (Figure 2-4D, Figure 2-5C) suggesting that the AGP- or 
ROSI-induced neointima involves the expansion of a cell lineage expressing this smooth 
muscle cells and myofibroblast marker. Infiltration by cells of the macrophage lineage 
has been noted in atherosclerotic lesions as well as in the injury-induced neointima (Levy 
et al., 2007, Papaspyridonos et al., 2008, Seimon et al., 2009). We applied double 
immunostaining for "SMA cells and CD68 markers in search for double positive cells 
but failed to detect double positive cells (Figure 2-4E). Immunostaining for the CD11b 
marker showed few cells localized to the media-adventitia boundary. We did not detect 
double CD11b and "SMA immunoreactive cells (Figure 2-4F, Figure 2-5F). These 
observations provide important insight into the mechanism of AGP-induced arterial wall 
remodeling. It has been reported that LPA blocks the egress of macrophage/dendritic 
cells from the subendothelium leading to their accumulation (Llodra et al., 2004) and our 
experiments showed few CD68 and CD11b positive monocytoid cells within multiple 
layers of "SMA positive cells. Thus in this model the overwhelming majority of 
neointimal cells expresses "SMA marker which tends to favor a hypothesis that the 
vascular smooth muscle lineage dominates the cell type responsive to AGP or ROSI 
stimulation. Whether macrophages are retained initially and cytokines derived from them 
lead to a secondary immigration and/or proliferation of "SMA positive cells remains to 
be subject in future studies. Even if this hypothesis will turn out to be correct, the 
initiating signal that attracts macrophages into the subendothelium would have to 
originate from the AGP-activation of cells resident to the normal carotid wall. LPA 
through the LPA1 and LPA2 GPCRs has been shown to induce the expression of 
proinflammatory chemokines including MIP-1beta, IL-8, and MCP-1(Lin and Boyce, 
2005, Lin et al., 2006, Kaneyuki et al., 2007). Thus if LPA1 and/or LPA2 receptors were 
required for the accumulation of macrophages leading to neointima, we should have 
found no macrophage accumulation and neointima in the DKO mice but this was not 
supported by the experimental findings. Because in rats we found that the effects of LPA 
or AGP on carotid artery remodeling were indistinguishable from that of ROSI, we tested 
this compound also. The cellular composition of the ROSI-elicited neointima resembled 
those in AGP treated carotids (Figure 2-5). These similarities provide added 
circumstantial support to the hypothesis that these compounds activate a similar 
mechanism leading to arterial wall remodeling. 
 
LPA1, LPA2, and DKO mice have been generated and show no spontaneous 
vascular pathology (Contos et al., 2002). Because LPA1 and LPA2 both are activated by 
AGP (Fujiwara et al., 2005), we focused initially on their role in LPA-induced arterial 
wall remodeling. Because of the availability of these single KOs, we also crossed them 
and established DKO animals. Both AGP and ROSI elicited neointima in the three KO 
strains that were statistically and immunohistologically indistinguishable from that seen 
in the WT mice (Figure 2-6, Figure 2-7). LPA GPCR are activated by both saturated and 
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unsaturated acyl-LPA with a rank order of potency of acyl-LPA > alkyl-GP (Fujiwara et 
al., 2005, Williams et al., 2009). Only LPA5 prefers AGP over LPA (Panchatcharam et 
al., 2008, Williams et al., 2009) but transcripts of this receptor subtype were the least 
abundant in the mouse carotid (Figure 2-3A). Moreover, LPA GPCRs do not show 
stereoselectivity to AGP (Yokoyama et al., 2002). The structure-activity relationship for 
LPA-induced neointima formation is markedly different from that described for LPA 
GPCR (Zhang et al., 2004): it shows a rank order of alkyl-GP > acyl-LPA, only 
unsaturated but not saturated fatty acyl species stimulate lesion formation, and the effect 
shows stereoselectivity for 1-O-AGP over 3-O-AGP. Whereas, LPA-induced cell VSMC 
proliferation and migration is blocked by pertussis toxin (Tokumura et al., 1994), 
pretreatment by this toxin only slightly attenuated, but did not abolish neointima 
formation (Zhang et al., 2004). Diacylglycerol pyrophosphate, a competitive antagonist 
of the LPA3 and LPA1 receptors (Fischer et al., 2001), produced only a partial inhibition 
of neointima formation. Based on the present results from the LPA GPCR KOs we now 
expand our previous indirect pharmacological observations and conclude that neither 
LPA1 nor LPA2 receptors are required for AGP- and ROSI-induced arterial wall 
remodeling. 
 
Because the specific PPAR! antagonist GW9662 fully abolished arterial wall 
remodeling in rat carotids exposed to AGP, or ROSI, we examined the effect of these 
agents in conditional PPAR! KO mice. Knocking out PPAR! leads to embryonic lethality 
and the inducible conditional KO of PPAR! activated by the IFN-regulated Mx1Cre 
transgene offers an ideal model system in our case because the Mx1Cre is predominantly 
expressed in endothelial cells, vascular smooth muscle cells and in also in macrophages 
(Akiyama et al., 2002, Schneider et al., 2003), which represent the three cell types 
implicated in the literature in neointima formation. The inducible Mx1Cre-regulated 
recombination of the single floxed PPAR! allele also provided littermate controls that 
were not exposed to pIpC induction. We also evaluated the effect of pIpC induction in 
PPAR!fl/- animals three weeks prior to AGP or ROSI treatment of the carotid artery to 
determine whether it would alter the responsiveness of the arterial wall. Quantitative 
RT-PCR for PPAR! showed that three weeks was sufficient to induce the recombination 
of the floxed PPAR! allele with high penetration although recombination was not 
complete (Figure 2-1). Topical intracarotid application of AGP or ROSI in pIpC-induced 
PPAR!fl/- animals elicited arterial wall remodeling with intima-to-media ratio 
indistinguishable from that seen in WT animals (Figure 2-8G and H). These findings 
indicate that pIpC induction does not affect the arterial wall remodeling elicited by AGP 
and ROSI. Furthermore, these results also establish that deletion of one PPAR! allele 
does not attenuate AGP- or ROSI-induced neontima. Uninduced Mx1Cre#PPAR!fl/- 
developed neointima in response to the treatments indicating that spontaneous 
recombination and the ensuing deletion of this nuclear hormone receptor, if present, is 
not sufficient to abolish arterial wall remodeling. The immunohistological observations 
of the arterial wall of these AGP or ROSI treated mice showed qualitative features that 
resembled those seen in WT animals (Figure 2-8, Figure 2-9). In sharp contrast, in 
&PPAR! mice AGP or ROSI failed to cause a significant change in intima-to-media ratio 
(Figure 2-8G and H).  
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Immunohistological examination of carotid arteries taken from these mice showed 
no "SMA positive cells between the endothelium and the internal elastic lamina (Figure 
2-8F, Figure 2-9H). These observations taken together provide genetic evidence for the 
requirement of PPAR! in the arterial remodeling elicited by AGP and ROSI. The present 
findings combined with our previous report showing that the PPAR! antagonist GW9662 
fully blocked AGP- and ROSI-induced arterial wall remodeling in rats, now provide two 
independent lines of evidence for the requirement of PPAR! in neointima development in 
the non-injury model. 
 
LPA and AGP activate platelets, stimulate the formation of platelet-monocyte 
aggregates (Fueller et al., 2003), and accumulate in the lipid rich core of human 
atherosclerotic plaques. LPA production in blood is linked to platelet activation (Sano et 
al., 2002). LPA activates the expression of V-CAM and E-selectin adhesion molecules in 
endothelial cells which promote cell adherence and invasion of the vessel wall by blood 
cells (Rizza et al., 1999). LPA also stimulates proinflammatory cytokine production 
(Kaneyuki et al., 2007, Lin et al., 2007) and inhibits the egress of macrophages from the 
subendothelium (Llodra et al., 2004). This abundance of evidence combined with our 
present observations support the role of LPA in vascular wall remodeling and the present 
study underlines the importance of PPAR! as an important molecular target in this 
pathology. 
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CHAPTER 3.    PHOSPHOLIPASE D2-DEPENDENT INHIBITION OF THE 
NUCLEAR HORMONE RECEPTOR PPAR!  BY CYCLIC PHOSPHATIDIC 
ACID* 
 
 
3.1    INTRODUCTION 
 
 PPAR! plays an essential role in regulating lipid and glucose homeostasis, cell 
proliferation, apoptosis, and inflammation (Ricote and Glass, 2007, Tontonoz and 
Spiegelman, 2008). These pathways have a direct impact on human diseases, in particular 
in diabetes(Lehmann et al., 1995), atherosclerosis(Li et al., 2000), and cancer (Sarraf et 
al., 1998). Synthetic agonists of PPAR! include the thiazolidinedione (TZD) class of 
drugs, which are widely used to improve insulin sensitivity in type 2 diabetes. 
Physiological agonists of PPAR! include 15d-PGJ2 (Forman et al., 1995), modified fatty 
acids (Nagy et al., 1998, Li et al., 2008), select species of lysophosphatidic acid 
(1-acyl-2-hydroxy-sn-glycero-3-phosphate, LPA; Figure 3-1A) (McIntyre et al., 2003), 
and oxidized phospholipids (Tontonoz et al., 1998). Another phospholipid, 
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine has recently been recognized as a 
physiologically relevant agonist of PPAR" (Chakravarthy et al., 2009). Despite the 
beneficial effects of PPAR! on glucose and lipid homeostasis, excess PPAR! activity can 
be deleterious. PPAR! agonists promote adipocytic differentiation of 3T3-L1 cells and 
also stimulate the uptake of low-density lipoprotein (LDL) by macrophages, leading to 
foam cell formation in the arterial wall (Tontonoz et al., 1998, Moore et al., 2001). When 
applied topically to the carotid arterial wall in rodents, select molecular species of LPA 
and the TZD drug rosiglitazone (ROSI) induce PPAR!-mediated intimal thickening 
(Zhang et al., 2004, Cheng et al., 2009). Alkyl-ether analogs of LPA accumulate in the 
atherogenic oxidized-LDL (Zhang et al., 2004) and human atherosclerotic plaques 
(Rother et al., 2003), and are potent agonists of PPAR! (Tsukahara et al., 2006). This led 
us to hypothesize that select LPA analogs could be endogenous regulators of PPAR!; 
hence, we investigated the structure-activity relationship of activation by naturally 
occurring lysophospholipids (Figure 3-1A). 
 
 
* Adapted with permission. Tsukahara T, Tsukahara R, Fujiwara Y, Yue J, Cheng Y,  
Guo H, Bolen A, Zhang C, Balazs L, Re F, Du G, Frohman MA, Baker DL, Parrill AL,  
Uchiyama A, Kobayashi T, Murakami-Murofushi K, Tigyi G (2010) Phospholipase D2 
dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic 
phosphatidic acid. Mol Cell 39:421-432.  
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Figure 3-1 CPA is an antagonist of PPAR" 
 
(A) Structures of the lysophospholipids and ROSI. (B) CPA does not activate 
PPAR"-dependent PPRE-ACox-Luc expression. CV-1 cells were transfected with 
ACox-luc plus pcDNA3.1-PPAR" and treated for 20 h with 5 mM each of ROSI, LPA 
18:1, AGP 18:1, CPA 18:1, MG, AG, or OA. Luciferase activities are presented as 
relative light units (RLU, mean ± SEM, n = 4, *p < 0.05, **p < 0.01). (C) Different 
molecular species of CPA and CGP dose-dependently suppress ROSI-induced 
PPAR"-dependent PPRE-TK-Luc reporter gene activation in B103 cells. B103 cells 
(3.0$104) were transfected with pMH100-PPRE-TK-Luc, pCMX-PPAR"-Gal4, and 
pSV-$-gal. After transfection, the cells were exposed to CPA or CGP (0.1, 1 and 10 #M) 
with or without ROSI (10 #M) for 20h, and reporter gene expression measured (mean ± 
SEM, n=4). (D and E) Competitive displacement of 5 nM [3H]-ROSI or [32P]-AGP from 
PPAR"-LBD was determined using 2.5 mM cold ROSI, AGP, or CPA. (F) CPA 18:1 and 
CGP 18:1 displace [3H]-ROSI from purified LBD of PPAR". Competition binding was 
performed using 5 nM [3H]-ROSI and increasing concentrations of CPA or CGP. (G) 
BODIPY-CPA competitively displaces [3H]-ROSI from PPAR" LBD. Competition 
biding assay was performed using purified 3 µg PPAR"-LBD with 5 nM [3H]-ROSI and 
increasing concentrations of either ROSI or BODIPY-CPA competitor. (H and I) Uptake 
of BODIPY-CPA (3 nmoles) into RAW264.7 macrophages. The rate of accumulation 
and the metabolic fate of labeled CPA were monitored in the medium (M or circles) and 
macrophages (C or squares) using TLC. The major fluorescent metabolite observed 
co-migrated with a standard for BODIPY-FA (fatty acid), indicating phospholipase/acyl 
transferase action. BODIPY-LPA was not detected. (J) BODIPY-CPA rapidly 
accumulated in the cell-associated pool and was present in the cytoplasm. Representative 
fluorescent microscopy image of 3 nmole BODIPY-CPA-treated RAW264.7 
macrophages after 0.5 min and 30 min exposure (bar, 50 mm). 
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3.2    EXPERIMENTAL PROCEDURES 
 
 
3.2.1 Cells 
 
All cell lines were from ATCC unless stated otherwise. MDA-MB-231 cells were 
grown in Leibovitz’s L-15 medium (Gibco) containing 10% (v/v) FBS, 100 U/ml 
penicillin, and 10 µg/ml streptomycin. CV-1, B103 (rat neuroblastoma cells, from Dr. 
Jerold Chun, Scripps Institute, La Jolla, CA), RAW 264.7 mouse macrophage cells and 
3T3-L1 mouse fibroblast cells were grown in Dulbecco’s modified Eagle’s medium 
containing 10% FBS, penicillin, streptomycin, and 1 mM sodium pyruvate. Tetracycline 
operator-regulated PLD1 and PLD2 transfected CHO have been characterized elsewhere 
(Du et al., 2004) and were grown in Ham’s F12 medium with 5% FBS. Induction of PLD 
expression was done by 1.5 µg/ml doxycycline (Sigma) for 24 h. Sf-9 insect cells 
(Invitrogen) were grown in serum-free medium Sf-900 II (Life Sciences).  
 
 
3.2.2 Ligand-Binding Assays 
 
Ligand binding assays were preformed as described in detail previously 
(Tsukahara et al., 2006). 
 
 
3.2.3 PPAR Reporter Gene Assays  
 
 Determination of PPAR!, !/", and " activation was done in CV-1 cells 
(endogenously express LPA1/2/3) or B103 cells (lack endogenous LPA1/2/3 receptors and 
PPAR") transfected with 125 ng of the appropriate reporter gene 
(pGL3-PPRE-acyl-CoA oxidase luciferase or in some experiments with 
MH100-PPRE-TK-luciferase) and 62.5 ng of pcDNA3.1-PPAR" or pCMX-PPAR"-Gal4 
and 12.5 ng of pSV–!-galactosidase (Promega) construct as previously reported 
(Tsukahara et al., 2006). To monitor activation of PPAR#, 62.5 ng of 
pG4M-PPAR#-ligand binding domain and 12.5 ng of pSV-!-galactosidase or 125 ng of 
17 m5$-!GLOB-luc plasmids were transfected into B103 cells using Lipofectamine 
2000. For PPAR !/", we used 62.5 ng of pG4M-PPAR!/"-LBD plasmid DNA and 12.5 
ng of pSV-!-galactosidase or 125 ng of 17m5$-!GLOB-luc plasmids. Twenty-four hours 
after transfection, cells were treated with Opti-MEM containing 10 µM test compound 
dissolved in DMSO and cultured for an additional 20 h. Luciferase activity was measured 
with the Steady-Glo Luciferase Assay System (Promega) using a Fusion Alpha plate 
reader (Perkin-Elmer).  
 
 
3.2.4 Co-Repressor Two-Hybrid Assays  
 
The effect of CPA on SMRT co-repressor binding to PPAR" was done as 
described by Yu et al. (Yu et al., 2005). Briefly, CV-1 cells were plated onto 96-well 
 
 
43 
plate at the density of 1.0$104 cells per well in DMEM containing 10% FBS. The next 
day, the cells were transiently transfected with 71 ng of UAS-Luc, 14.3 ng of 
Gal4-SMRT, 14.3 ng of pVP16-PPAR"2, and 10 ng of pSV–!-galactosidase (Promega) 
using Lipofectamine LTX (Invitrogen). Twenty hours after transfection, the cells were 
pretreated with various concentrations of CPA or CGP 18:1 in Opti-MEM (Invitrogen) 
for 30 min, followed by treated with Opti-MEM containing 1nM ROSI for 6 h. 
Luciferase and #-galactosidase activities were measured as above. Samples were run in 
quintuples, and the mean ± SEM were calculated. Data are representative of at least three 
independent transfections. Student’s t test was used to test for statistical analysis and 
p<0.05 was considered significant. 
 
 
3.2.5 Biosynthetic Labeling of Cells and Measurement of CPA Synthesis 
 
MDA-MB-231 cells (3.5$106) or CV-1 cells (1.0$106) were serum-starved for 12 
h and washed with phosphate-free medium and incubated in balanced salt solution (135 
mM NaCl, 4.5 mM KCl, 1.5 mM CaCl2, 0.5 mM MgCl2, 5.6 mM glucose, 10 mM 
HEPES-NaOH, pH7.2) containing 1 mCi/ml [32P]-orthophosphoric acid. After 3 h, the 
labeling medium was removed, and the cells were washed 3$with Ca2+/Mg2+ free 
phosphate-buffered saline (PBS) and preincubated at 37 oC in serum-free medium for 15 
min. After treatment with 100 nM PMA (Fluka) for 30 min, the cells were washed once 
with ice-cold PBS and collected by centrifugation. The phospholipids were extracted 
(Bligh and Dyer, 1959), spotted on indicator-free high-performance silica gel TLC plates 
(Whatman) and separated by two-dimensional TLC using 
chloroform-methanol-acetic acid-1% sodium disulfite (100:40:12:5) solvent in the first 
dimension and chloroform-methanol-ammonium hydroxide (3:6:1) in the second 
dimension. Unlabeled LPA and CPA standards were mixed into the samples and 
visualized by 0.01% primulin (Sigma) staining, whereas radioactivity was detected by a 
Cyclone phosphorimager (Perkin-Elmer).  
 
 
3.2.6 Statistical Methods 
 
Significant differences were based on student’s t-test relative to the appropriate 
control. Equilibrium binding constants (KD) were calculated from the binding data using 
the Kaleida-Graph Software version 4.0 (Synergy Software). 
 
 
3.3    RESULT 
 
 
3.3.1 CPA Is a Specific and a High-Affinity Antagonist of PPAR$   
 
When testing lysophospholipids using a PPAR$ reporter gene assay, we observed 
that CPA at concentrations as high as 5 %M failed to activate transcription (Figure 3-1B). 
In contrast, lower concentrations of LPA 18:1 and its ether analog alkyl glycerophosphate 
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(AGP 18:1) strongly activated PPAR$. Smaller chemical components of CPA namely 
oleoyl glycerol (OG), alkyl glycerol (AG), and oleic acid (OA) showed weak activation. 
To establish a direct interaction between CPA and the PPAR$ ligand-binding domain 
(LBD), recombinant LBD was purified to examine the displacement of agonists 
[3H]-ROSI (Figure 3-1C) and [32P]-AGP (Figure 3-1D) by CPA. CPA and its ether 
analog 1-O-octadecyl-2,3-cyclic-glycerophosphate (CGP 18:1, Figure 3-1A) displaced 
both labeled agonists, and Scatchard analysis revealed single high-affinity binding 
constants at 124 ± 19 nM and 172 ± 27 nM, respectively (Figure 3-1E), which was 
comparable to that of ROSI (84 ± 6 nM).  
 
To monitor the metabolic fate and distribution of exogenously applied CPA, we 
synthesized a fluorescent analog BODIPY-CPA (Figure 3-1A), which also displaced 
[3H]-ROSI from the PPAR$-LBD (Figure 3-1F). BODIPY-CPA was applied to RAW 
267.4 macrophages and uptake of the fluorescent lipid was determined as a function of 
time (Figure 3-1G and H). BODIPY-CPA uptake peaked at 15 min before beginning to 
undergo metabolism by deacylation into BODIPY-fatty acid, whereas no BODIPY-LPA 
or any other metabolic product was detectable, indicating the stability of the 
cyclic-phosphate ring. The cellular half-life of BODIPY-CPA in this experiment was 
approximately 60 min and the label was present in both the cytoplasm and nuclei of the 
cells after 30 min (Figure 3-1I). Exogenously applied CPA species inhibited 
PPAR$-dependent gene expression elicited by TZDs ROSI (Figure 3-1J), pioglitazone 
and troglitazone (Figure A-1A and B) in a cell-based PPAR$ reporter gene assay. The 
highly homologous PPAR! and PPAR#/" receptors were neither inhibited nor activated 
by CPA (Figure A-1C-F). 
 
 
3.3.2 Differential Interactions between Agonists and the Antagonist CPA with the 
PPAR$-LBD 
 
The crystal structures of the PPAR$-LBD and the ROSI-bound complex have 
previously been solved (Nolte et al., 1998). Currently no reported studies on 
antagonist-bound structures of the PPAR$-LBD are currently available in the public 
domain. Using a crystal structure of the highly homologous PPAR! bound to antagonist 
GW6471, we generated a homology model of the inactive PPAR$-LBD complex. The 
active-LBD and inactive-LBD served as targets in computational docking studies with 
ROSI, AGP 18:1, and CPA 18:1 (Figure 3-2A and B). CPA 18:1 forms ion-pairing 
interactions with residue R288 was previously shown for the interaction of AGP 18:1 
with PPAR$-LBD (Tsukahara et al., 2006). This interaction is required for binding of the 
phosphate-containing agonists. However, only the alkyl chain of AGP 18:1 showed 
favorable interactions with a hydrophobic residue of the AF-12 helix, L469, in the 
active-LBD (Figure 3-2B). In contrast, CPA 18:1 bound with higher affinity to the 
inactive-LBD, failing to stabilize the active conformation of the AF-12 helix (Figure 
3-2A). The docked positions of ROSI and AGP overlap and differ from the docked 
position of CPA. This is consistent with the agonist activity of ROSI and AGP, and 
corresponding lack of such activity for CPA. Although CPA does not overlap with the 
docked position of AGP and ROSI, interactions with common residues occur from a  
 
 
45 
 
Figure 3-2 CPA inhibits PPAR! activation and is generated by PLD  
 
(A) Comparison of ROSI crystallized in PPAR" (1FM6) and CPA 18:1 docked into the 
inactive homology model of PPAR". Blue ribbons show the backbone structure of the 
inactive PPAR" homology model. The inactive homology model differs from the active 
crystallographic structures only in the position of the AF-12 segment, which is shown as 
a green and a red ribbon in the inactive homology model and the crystallographic 
structure, respectively. Ligands are shown as ball and stick models. (B) Comparison of 
AGP 18:1 docked into the activated crystallographic structure of PPAR" (1FM9) and 
overlay of CPA 18:1 docked into the inactive homology model of PPAR". Note that 
agonists ROSI and AGP occupy the same location and interact with residue R288, while 
CPA prevents the AF-12 domain from acquiring its activated conformation (red) by 
stabilizing the inactivated conformation (green). (C and D) Arginine 288 is required for 
inhibition of PPAR" by CPA. Purified WT and R288A mutant PPAR" (1 %g) were 
incubated with 5 nM [3H]-ROSI or [32P]-AGP 18:1 under equilibrium binding conditions 
with 2.5 %M cold ROSI, AGP, and CPA, and the bound ligand quantified using a 
filtration assay (mean ± SEM, n = 4). (E) ROSI-induced SMRT release from PPAR" is 
dose-dependently inhibited by both CPA 18:1 and CGP 18:1. CV-1 cells were transfected 
with UAS-Luc, pECE-Gal4-SMRT (containing full length SMRT), pVP16-PPAR"2, and 
pSV-!-gal. After transfection, the cells were treated with CPA 18:1 or CGP 18:1 for 30 
min, followed by 1nM ROSI for 6 h. Luciferase activities are presented as fold increase 
(mean ± SEM, n=4, representative of 3 transfections). (F) Stimulation of biosynthetically 
[32P]-orthophosphate-labeled MDA-MB-231 cells with PMA (100 nM, 30 min) leads to 
CPA generation. PMA stimulation (100 nM) was also performed in the presence of either 
1.5% 1-BuOH or t-BuOH. Phospholipids were separated using 2D-TLC and visualized 
using phosphorimaging. Arrows point to the position of the authentic CPA standard and 
asterisks indicate the position of the LPA standard. (G) CPA production in 
PMA-stimulated cells is inhibited by 1-BuOH but not by t-BuOH. 
Phosphorimaging-based quantification of labeled CPA after stimulation of 
MDA-MB-231 cells by 100 nM PMA in the presence or not of 1.5% v/v 1-BuOH and 
t-BuOH (mean cpm ± SEM, n = 4). 
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different pocket. These common interactions preclude binding of CPA at the same time 
as either ROSI or AGP, which explains the competitive antagonistic effect of CPA. 
 
The phosphate group common to LPA and AGP has been previously validated to 
form a salt bridge with R288 in the LBD (Tsukahara et al., 2006). The R288A mutant 
loses AGP binding and activation; nevertheless, binding to and activation by ROSI 
remains unchanged (Tsukahara et al., 2006). To evaluate the computationally predicted 
role of R288 in CPA binding, we expressed its alanine mutant LBD recombinant protein, 
and examined it for binding to [3H]-ROSI and to [32P]-AGP 18:1 (Figure 3-2C and D). 
The R288A mutant bound [3H]-ROSI but did not bind [32P]-AGP 18:1. Although an 
excess of unlabeled ROSI, AGP 18:1, or CPA 18:1 competed with [3H]-ROSI binding at 
the WT PPAR$ LBD, only ROSI displaced the labeled ligand in the R288A mutant. 
These results confirm the critical role of the predicted salt bridge between residue R288 
and CPA 18:1 and support the hypothesis that CPA functions as a high-affinity antagonist 
of PPAR$.  
 
The inactive conformation of PPAR$ promotes binding of corepressor proteins. 
Antagonists should prevent the agonist-induced dissociation of this complex. Using a 
two-hybrid assay (Yu et al., 2005) in CV-1 cells that allows detection of the complex 
formed between PPAR$ and its corepressor SMRT, we tested the effect of CPA on 
ROSI-induced dissociation of this molecular complex. CPA and CGP dose-dependently 
stabilized the SMRT-PPAR$ and antagonized ROSI-induced dissociation of the complex 
(Figure 3-2E).  
 
 
3.3.3 Activation of PLD2 Generates CPA  
 
CPA has been detected in mammalian tissues (Murakami-Murofushi et al., 2000). 
To establish a physiological role for CPA in the regulation of PPAR$, we determined 
whether cellular activation of phospholipase D (PLD) can generate it because prior work 
showed that the catalytic mechanism of PLD from Streptomyces chromofuscus includes 
CPA as a reaction intermediate (Friedman et al., 1996). MDA-MB-231 breast cancer 
cells, which express both PLD PLD1 and PLD2 isoenzymes (Eisen and Brown, 2002), 
were biosynthetically labeled with [32P]-orthophosphate and stimulated with 100 nM 
phorbol myristate acetate (PMA), a strong nonselective activator of both PLD isoforms. 
After 30 min of stimulation the phospholipids were extracted, separated and compared to 
phospholipids from vehicle-stimulated cells using two-dimensional thin layer 
chromatography (2DTLC). No label was detected at the position of an authentic CPA 
standard spiked into the sample in the vehicle-treated cells (Figure 3-2F). In contrast, a 
spot co-migrating with the CPA standard became detectable in PMA-stimulated cells. 
The hydrolysis of lysophosphatidyl choline (LPC) by PLD includes a 
transphosphatidylation step that can be inhibited by the primary alcohol 1-butanol 
(1-BuOH), but not by secondary alcohol 2-methyl-2-propanol (t-BuOH). When the 
PMA-stimulated cells were treated with 1-BuOH, the intensity of the [32P]-CPA spot on 
2DTLC was significantly reduced, whereas t-BuOH had no effect (Figure 3-2F and G).  
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To determine which of the two PLD isozymes was responsible for CPA 
production, we used CHO cell lines stably expressing tetracycline-inducible alleles of 
wild-type (WT) or catalytically-inactive (CI) forms of PLD1 or PLD2 (Du et al., 2004). 
PMA stimulation of cells with doxycycline (DOX)-induced expression of PLD1 caused a 
two-fold increase in CPA production, which was similar to that observed for WT cells. In 
contrast, PMA-stimulation of cells with DOX-induced PLD2 expression caused a 
ten-fold increase in CPA production compared to unstimulated WT cells (Figure 3-3A) 
and elevated the basal levels of CPA. However, expression of the catalytically-inactive 
PLD2 (CI-PLD2) failed to amplify the PMA-induced CPA production. In the absence of 
DOX induction, all four cell lines contained very low amounts of CPA, and PMA 
stimulation yielded similar increases in CPA (Figure A-2A). These findings suggest that 
PLD2 activation underlies the stimulus-coupled CPA production.  
 
To obtain direct proof that PLD2 generates CPA, recombinant WT and CI-PLD2 
were purified and reacted with [14C]-LPC in vitro, and the reaction products were 
separated by TLC (Figure 3-3B). WT-PLD2, but not the CI-PLD2, generated [14C]-CPA 
(Vmax = 190 pmol/min/mg; Km = 8 µM; Figure A-2B). Addition of 1-BuOH to this 
reaction generated lysophosphatidylbutanol, whereas inclusion of t-BuOH yielded no 
such product (Figure 3-3C and D). These data indicate that mammalian PLD2 is capable 
of producing CPA from LPC in vitro and in vivo. 
 
 
3.3.4 Physiological Stimulation of PLD2 Generates CPA  
 
CPA levels were then quantified in unstimulated control and PMA-stimulated 
MDA-MB-231 cells by liquid chromatography mass spectrometry (LC-MS). CPA was 
below the detection limit in control cell extracts (Figure A-2C). Treatment with 100nM 
PMA for 30 min resulted in the generation of CPA 16:0 and 18:1 (595 ± 1.5 pmol and 
293 ± 25.6 pmol / 3$107 cells, respectively; Figure A-2D). Insulin is a physiological 
activator of PLD2 (Slaaby et al., 2000). LC-MS quantification of CPA in 
insulin-stimulated cells showed peak production with 967 ± 111.2 pmol CPA 16:0 and 
573 ± 33.5 pmol CPA 18:1 per 3$107 cells, respectively (Figure A-2E). Insulin generated 
higher levels of CPA compared to PMA (Figure 3-3E) that peaked at 30 min (Figure 
3-3F). Insulin stimulation of CV-1 cells did not increase the biosynthetically labeled pool 
of LPA (Figure 3-4A, Figure A-3A-C), indicating that the major lysophospholipid 
product of PLD2 is CPA.  
 
We extended our studies to human peripheral blood monocytes and found that 
insulin, lipopolysaccharide, H2O2, or PMA stimulation of PLD2 of within 30 minutes 
caused production of CPA 18:1 and 16:0 (Figure 3-4B, Figure A-2F-I). In resting 
monocytes the level of CPA 16:0 and 18:0 was 0.14 and 1.5 pmole/107 cells, 
respectively. After stimulation with 100 nM PMA CPA 16:0 rose ~ 1,300-fold and CPA 
18:1 rose ~ 390-fold (Figure 3-4B). After stimulation with 100 nM insulin CPA 16:0 rose 
8.5-fold and CPA 18:1 rose 67-fold. Addition of the PLD2 inhibitor 
5-fluoro-2-indolyl des-chlorohalopemide (FIPI 750nM) inhibited production of both CPA 
species (Figure 3-4B, Figure A-2G and H). Thus, physiological stimuli of PLD2 in 
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Figure 3-3 In vitro and in vivo generation of CPA by PLD2 
 
(A) PLD2 is the major source of CPA in vivo. CHO cells expressing tet-regulated WT or 
CI-PLD1 or PLD2 constructs were induced by DOX and subsequently stimulated with 
100 nM PMA for 30 min. Cellular phospholipids were biosynthetically labeled with 0.1 
mCi [32P]-Pi for 12 h, and CPA generation quantified using phosphorimaging after 
2D-TLC separation (mean ± SEM, n = 3). (B) PLD2 generates CPA in vitro. 
Affinity-purified WT or CI-PLD2 (10 mg/reaction) was incubated with [14C]-LPC 16:0 at 
40 ºC for 1 h. The reaction mixtures were spotted on a TLC plate and separated. 
Authentic cold CPA and LPA standards were used to determine the product Rfs. (C) 
1-BuOH but not t-BuOH diverts recombinant PLD2 formation of CPA to 
lysophosphatidyl butanol (lyso-PtBuOH). TLC analysis of [14C]-phospholipids generated 
by purified PLD2 from Sf-9 insect cells after treatment with 0.5% 1-BuOH or t-BuOH. 
(D) Quantification of CPA and [14C]-lyso-PtBuOH formation by PLD2 in the presence of 
0.5% 1-BuOH and t-BuOH (n = 3). N.D., not detectable. (E) LC-MS quantification of 
CPA 16:0 and 18:0 after stimulation of MDA-MB-231 cells by 100 nM insulin or PMA 
for 30 min (pmol mean ± SEM, n = 3). (F) Time course of insulin-stimulated CPA 
production in MDA-MB-231 cells. Cells (3$106) biosynthetically labeled with 
[32P]-orthophosphate were exposed to 100 nM insulin for different times and the CPA 
purified using 2DTLC and quantified using liquid scintillation counting (n=3).  
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Figure 3-4 PLD2 activation inhibits PPAR!  
 
(A) Insulin stimulation elevates CPA but not LPA levels. CV-1 cells (3$106) were labeled 
with [32P]-orthophosphate for 6 h and stimulated with 100 nM insulin or the DMSO 
solvent for 30 min at 37 oC. Lipids were extracted, separated by 2DTLC and quantified 
by phosphorimaging (n = 3). (B) CPA is generated in human peripheral blood 
mononuclear cells in response to PLD2 stimulation. The cells were pretreated with the 
PLD2 inhibitor FIPI (750 nM) or solvent control for 30 min prior to stimulation by 100 
nM insulin, PMA 100 nM, 1 %g/ml LPS, or 1 mM H2O2. Data are representative of three 
other experiments with different donors. (C) Stimulation of PLD2 with insulin or 
mastoparan inhibits ROSI-induced PPAR"-reporter gene expression in a PLD-dependent 
manner. CV-1 cells were transfected with ACox–luc together with pcDNA3.1-PPAR$ 
plasmid and treated for 20 h with 10 %M ROSI, 100 nM insulin, 20 µM mastoparan, 
and/or 1.5% 1-BuOH. Luciferase activities are presented as RLU (mean ± SEM, n = 4). 
(D) Insulin attenuates PPAR" activation. The ACox-luc reporter alone or in combination 
with the PPAR$ plasmid was transfected into B103 cells and exposed to ROSI (5 mM) 
alone or with insulin. Reporter gene expression was measured 20h later (n = 5). (E) 
CI-PLD2 inhibits insulin-induced CPA production in CV-1 cells. Cells were either 
transduced with a CI-PLD2 or an empty adenovirus at MOI of 10. Phospholipids were 
biosynthetically labeled using [32P]-orthophosphate for 24 h post-transduction, and the 
cells stimulated with 100 nM insulin for 30 min. Phospholipids were separated using 
2DTLC and visualized by phosphorimaging. Radioactivity incorporated into the CPA 
spot was scraped off and quantified by liquid scintillation counting (cpm mean ± SEM, n 
= 3, **p < 0.01). (F) CI-PLD2 acts as a dominant negative and abolishes insulin-induced 
inhibition of ROSI-induced PPAR" activation. CV-1 cells were either transduced with an 
adCI-PLD2 or an empty adenovirus. Subsequently, the transduced cells were transfected 
with the ACox-luc reporter gene and PPAR" plasmids for an additional 24 h. Cells were 
stimulated with 10 mM ROSI with or without 100 nM insulin for 20 h, and luciferase 
reporter expression determined (mean ± SEM , n=3, **p < 0.01).  
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primary human monocytic cells and also in cultured bone marrow-derived mouse and 
human peripheral blood mononuclear cells (data not shown) elicited a rapid and 
substantial rise CPA level. These results are consistent with the second messenger 
properties of CPA; low levels in unstimulated cells, a substantial rise rapidly following 
PLD2 stimulation, and deacylation-mediated breakdown (Figure 3-1G). 
 
Another stimulator of PLD2 is mastoparan. Stimulation of PLD2 with mastoparan 
or insulin increases CPA production, which in turn should inhibit the transcriptional 
activity of PPAR$. To test this hypothesis, CV-1 cells were transfected with PPAR$ 
reporter plasmids, and exposed to ROSI with and without stimulation with 20 µM 
mastoparan or 100 nM insulin (Figure 3-4C). Neither PLD-stimulating agent alone 
caused a significant activation in acetyl CoA-oxidase-luciferase (ACox-luc) reporter gene 
expression. Rather, mastoparan and insulin both attenuated the ROSI-induced 
transcriptional activity of PPAR$. When 1-BuOH was added to the cells to quench 
PLD2-mediated CPA production, the inhibitory effect was attenuated, most strongly for 
mastoparan (Figure 3-4C). Attenuation of ROSI-induced ACox-luc reporter expression 
positively correlated with the concentration of insulin applied (Figure 3-4D).  
 
Insulin stimulates a complex signaling network of which PLD2 activation 
represents only one component. To obtain evidence that the PLD2 branch of insulin 
signaling is necessary for CPA production, we treated cells with adenoviral (ad) 
CI-PLD2, which should abrogate CPA production and the attenuate of PPAR$ activation. 
Insulin elicited an increase in the biosynthetically-labeled pool of [32P]-CPA in CV-1 
cells; and adCI-PLD2 reduced the insulin-induced generation of [32P]-CPA (Figure 
3-4E). We also probed the requirement of PLD2 for insulin-induced inhibition of PPAR$ 
by using ad CI-PLD2 to attenuate of CPA production in the reporter gene assay. 
adCI-PLD2 completely abrogated the inhibitory effect of insulin on PPAR$ (Figure 
3-4F). In addition, we knocked down PLD2 expression using a lentivirally-delivered 
shRNA against PLD2 in RAW264.7 and NIH3T3-L1 cells (Figure A-3D-F). PLD2 
knockdown caused a more than 75% reduction in PMA- and insulin-stimulated CPA 18:1 
production in RAW264.7 and 3T3L1 cells (Figure 3-5A and B).  
 
CPA and LPA share similar structure. One concern when treating cells with CPA 
is that CPA may activate LPA GPCR receptors directly before it enters cells. B103 
neuroblastoma cells, which express barely detectable levels of PPAR$1&2 (Figure 3-5C 
inset) and also lack the LPA1/2/3 GPCR (Tsukahara et al., 2006). Hence, B103 cells 
represent an ideal cell model for add-back expression of the PPAR$ and PPRE-Acox-luc 
reporter. In wild type B103 cells transfected only with the PPRE-Acox-luc reporter ROSI 
caused a marginal activation. However, in B103 cells transfected with PPAR" and the 
reporter, ROSI- or AGP-induced ACox-luc expression that was inhibited by CPA (5 µM) 
and insulin (1 nM) (Figure 3-5C). These observations are consistent with the hypothesis 
that CPA is a physiological product of PLD2 and that PLD2-dependent inhibition of 
PPAR$ activity is mediated by CPA independently of the LPA1/2/3 GPCR. 
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Figure 3-5 CPA production by PLD2 inhibits PPAR$-mediated cellular 
responses 
 
(A and B) PLD2 knockdown inhibits insulin- and PMA-induced CPA production in 
RAW264.7 and 3T3-L1 cells. 3$106 RAW264.7 or NIH3T3 cells expressing scrambled 
shRNA or PLD2 shRNA were stimulated with 30 nM insulin or 100 nM PMA for 30 min 
prior to extraction of phospholipids for MS analysis (n=3). (C) B103 cells were 
transfected with the ACox-luc reporter gene alone or together with the PPAR$ plasmid 
and exposed to ROSI (5 mM) with or without CPA (5 mM), AGP (5 mM) and insulin (1 
nM) for 20 h, and reporter gene expression measured (mean ± SEM, n = 3). The inset 
shows PPAR$ expression in WT B103 cells or cells transfected with the 
pcDNA3.1-PPAR$ construct as determined by western blotting. (D) CPA inhibits foam 
cell formation and AC-LDL accumulation in the RAW264.7 mouse macrophage cell line. 
Cells were stimulated with combinations of 5 mM CPA and ROSI in the presence of 25 
mg/ml AC-LDL for 24 h. Lipid accumulation was determined by ORO staining (bar = 50 
mm). (E) CPA and the PPAR$ antagonist GW9662 (5 mM each) inhibited ROSI- and 
AGP-induced (5 mM each) lipid accumulation in RAW264.7 macrophages. ORO 
accumulation was quantifed spectrophotometrically (mean ± SEM, n = 3). The inset 
shows PPAR$ expression as assessed by western blotting and the lower panel shows 
#-actin as a loading control. (F) CPA inhibition of PPAR$ target gene cd36 activation 
requires a PPRE element. CV-1 cells were transfected with PPAR$ together with a cd36 
reporter gene containing PPRE at position -273 in the promoter, or a truncated version at 
position -261 lacking the PPRE, and were treated for 20 h with 10 mM ROSI, AGP, or 
CPA. Luciferase activity was determined, and data are presented as RLU (mean ± SEM, 
n = 4).  
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3.3.5 CPA Inhibits PPAR$-Dependent Physiological Responses 
 
We also examined the effect of CPA on PPAR$-regulated lipid accumulation in 
RAW 264.7 macrophages after exposure to acetylated low-density lipoprotein 
(AC-LDL). Uptake of AC-LDL by unstimulated RAW 264.7 cells was below the 
detection limit of the Oil Red O (ORO)-staining (Figure 3-5D). When the AC-LDL was 
coapplied with 5 µM ROSI, many ORO-positive macrophages were visible. CPA (5M) 
addition to ROSI-stimulated macrophages completely abolished ORO-stained cells, 
supporting the hypothesis that CPA inhibits PPAR$-regulated AC-LDL uptake. The 
inhibitory effect of CPA on AC-LDL uptake was compared with that of the synthetic 
PPAR$ antagonist GW9662 (Figure 3-5E). Both CPA and GW9662 at 5 %M completely 
abolished ORO accumulation elicited by either ROSI or AGP in these cells, while 
causing no change in the expression of PPAR$ (Figure 3-5E inset). The scavenger 
receptor CD36, under direct transcriptional regulation of PPAR$, plays an important role 
in the uptake of oxidized phospholipids into macrophages (Boullier et al., 2000). In CV-1 
cells, CPA inhibited ROSI- or AGP-activated cd36 reporter gene activation only when 
the reporter construct contained an intact PPAR$ response element (PPRE) between 
nucleotides -273 to -261 in the promoter (Figure 3-5F). When the cd36 promoter was a 
truncated at position -261, neither ligand showed significant modulation of the 
expression, which is consistent with the hypothesis that CPA exerts its inhibitory effect 
on lipid accumulation via the inhibition of PPAR$ transcriptional targets. PPAR$ is 
required for adipocytic differentiation of 3T3-L1 cells (Tzameli et al., 2004). In 3T3-L1 
cells, 100 nM ROSI treatment elicits the expression of the adipocytic marker FABP4, 
which is a direct target of PPAR$ (Figure 3-6A). CPA treatment caused an 
anti-adipogenic effect evident by the reduced expression of FABP4 mRNA, protein, and 
by reduced lipid accumulation using ORO staining (Figure 3-6B). 
 
Stimulation with low nanomolar insulin leads to PLD2-dependent CPA formation 
that inhibited PPAR$-dependent reporter gene expression (Figure 3-4A-F). To examine 
the effects of low-dose insulin on adipocytic differentiation, at concentrations similar to 
that found in plasma under fasting conditions (~ 1 nM), 3T3-L1 cells were induced to 
differentiate with ROSI for 14 days in the absence or presence of insulin and lipid 
accumulation quantified using ORO staining (Figure 3-6C). Continuous low-dose insulin 
treatment resulted in the inhibition of adipogenesis as indicated by reduced lipid 
accumulation, consistent with the dose-response relationship of insulin-induced inhibition 
of PPAR$-reporter gene activation we found in B103 cells (Figure 3-4D). We reasoned 
that because PLD2 knockdown in 3T3-L1 cells attenuated insulin-activated CPA 
production (Figure 3-5B), it should also reverse the inhibition of PPAR$ target genes 
fabp4 and cd36. PLD2 knockdown reversed insulin or mastoparan inhibition of fabp4 and 
cd36 expression compared to 3T3-L1 cells transduced with scrambled shRNA (Figure 
3-6D and E).  
 
Stimulation of macrophages with ROSI elicits direct activation of 
PPAR$-regulated genes (Hodgkinson and Ye, 2003). We selected five PPAR$ target 
genes and monitored their transcriptional regulation in mouse peritoneal macrophages 
treated with ROSI in combination with CPA or GW9662 for 12h. ROSI stimulation 
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Figure 3-6 CPA inhibits PPAR$-dependent transcriptional responses 
 
(A) 3T3-L1 cells, which express both PPAR$1 and PPAR$2 protein (western blotting 
inset), were pretreated with 1 mM CPA, AGP or vehicle for 24 h and exposed to 100 nM 
ROSI. Quantitative RT-PCR (QT-PCR) for the adipocyte marker fabp4 was performed 5 
days later. (B) CPA inhibited ROSI-induced lipid accumulation. 3T3-L1 cells pretreated 
with 1 mM CPA or vehicle for 24 h were induced to differentiate with ROSI (100 nM 
every other day) and stained with ORO after 10 days. Quantification of lipid 
accumulation was done spectrophotometrically (n=3). (C) Insulin or CPA inhibited lipid 
accumulation in 3T3-L1 cells. Cells were pretreated with 1 mM CPA or vehicle for 24 h 
and induced with 100 nM ROSI with or without 1 mM CPA or insulin and stained with 
ORO after 2 weeks. Quantification of lipid accumulation was done 
spectrophotometrically (n=3, **p=0.0002 for DMSO vs. ROSI, *p=0.0126 for ROSI vs. 
ROSI+0.03 nM insulin, **p=0.0010 for ROSI vs. ROSI + 0.3 nM insulin, *p=0.0494 for 
ROSI vs. ROSI+1 nM Insulin, and **p=0.0041 for ROSI vs. ROSI+CPA). (D and E) 
ROSI-induced gene expression of PPAR$ target genes fabp4 and cd36 is inhibited by 
PLD2 in 3T3-L1 cells. 3T3-L1 cells expressing scrambled shRNA or PLD2 shRNA were 
pretreated with 30nM insulin or 10mM mastoparan for 30 min and cultured in ROSI (10 
%M) or vehicle for 24 h. Total RNA was isolated and mRNA levels determined by 
QT-PCR (n=4). (F) Inhibition of ROSI-induced expression of PPAR$ regulated genes by 
CPA in mouse peritoneal macrophages. Macrophages isolated from C57BL/6 mice were 
exposed to a 5 %M ROSI with or without 5 %M CPA or 1 %M GW9662 (positive control) 
for 12 h, and RNA was isolated. mRNA levels for the PPAR$ upregulated (cd36, 
cyp27a1, hadh, capn3) and downregulated (csf1) gene targets were determined by 
QT-PCR) (n=3, representative experiment shown). 
 
 
58 
 
 
 
!"
#
$%%"&??
$%%"&??
??????????????
???????
???????
??????
$'"!%(
)
*
+
&
,
,-
./
01
-
2
"%
#3
)
*
+
&
???????
??????
$'"!%(
????????
$&45$6
&+*)
2-10/.-,,,,,,,,,,
#%",,,
"7%
3
3
?
?
? ?
3
?
?
?
? 3
?
3 3
3 ?
3
?
&4$%#&
? ?? ??
,,
8
898:
???
????
???
????
&+*)
#%"
3
? 3 3 ?
33??
!!
2-10/.- ?? ?
?
??
???
??
??
??
?
,,,
,,
/;<= ??????? ???? ????? ????
2-10/.-,81
??????????
#%"
&+*)
&+*)3#%"
??????
???????????
?
??
???
?
?
?
??
??
??
??
??
??
??
?
?
8
?
?
<
(
:
>
>
>
>
>
>
>
>
>
>
>
>
>
>
? ?
'
&+*)
#%"
3
????????????
?
?
?
2-10/.-
8
898:
???
????
???
????
89<
?
??
???
??
??
??
?
? ?? ? ?
? ?? ?
3 3 3 3 3
3
?
????
???
??? ?
!!
! !
!!
!!
89:
?
???
?
???
<
<9:
(
?????
3
@
@
@
@
@
3
@
@
@
@
3
@
3
3
@
@
3
@
3
@
3
@
@
>>
?????????
???????????
?????????
???????????
89:
?
???
?
???
<
<9:
(
(9:
/;<=
?
??
??
??
??
?
?
?
"
??
??
??
??
??
??
?
?
?
?
??
??
??
??
?
?
?
"
??
??
??
??
??
??
?
?
?
>>
2-10/.-
&+*)
???????
??????????
2-10/.-
&+*)
???????
??????????
3
@
@
@
@
@
3
@
@
@
@
3
@
3
3
@
@
3
@
3
@
3
@
@
 
 
59 
activated the expression of cd36, cyp27a1, hadh and capn3 by 3- to 4-fold, whereas 
inhibited the expression of csf1. CPA as well as GW9662 completely abolished the 
transcriptional regulation of these genes by ROSI  (Figure 3-6F). 
 
To examine the regulatory role of CPA on a PPAR$-dependent 
pathophysiological response we utilized a rodent model of vascular remodeling. ROSI 
and AGP induce neointima when applied topically within the carotid artery (Zhang et al., 
2004). Neointima formation requires PPAR$ because it is abolished by the antagonist 
GW9662 and is absent in mice with conditional knockout of PPAR$ targeted to cells of 
the vessel wall (Cheng et al., 2009). We hypothesized that co-application of CPA with 
the PPAR$ agonists AGP or ROSI should mitigate neointimal thickening. AGP or ROSI 
with or without CPA was injected lumenally into the common carotid artery of rats, 
which had been transiently ligated proximally and distally from the carotid glomus. After 
a 1 h treatment, the cannula was withdrawn and blood flow through the common carotid 
artery restored. Histological evaluation of the dissected common carotid arteries 3 weeks 
later revealed multilayered neointimal thickening in the rats treated with 5 %M AGP 
(Figure 3-7A) or ROSI (Figure A-4B) whereas, no neointima was found in the 
solvent-treated carotids (Figure A-4A). The neointimal thickening was abolished in those 
animals that received 5 %M CPA in addition to AGP or ROSI (Figure 3-7B and C, Figure 
A-4C and D). Our experiments identified insulin as a physiologically relevant stimulator 
of CPA production. Therefore, endogenous production of CPA activated by low 
concentrations of insulin should prevent neointima formation in this model. To test this 
possibility, we co-applied 3 nM insulin with 10 µM AGP or ROSI lumenally for 1 h 
using the same experimental paradigm described for the application of CPA. Examination 
of the intima-to-media ratio three weeks later showed that low-dose insulin treatment 
alone induced no vascular remodeling, but insulin co-treatment significantly reduced the 
neointima formation elicited by AGP or ROSI (Figure 3-4E-G, Figure 3-7D-F). These 
results are consistent with the hypothesis that exogenously applied or endogenously 
generated CPA is effective in negatively modulating PPAR$-dependent vascular wall 
responses in vivo. 
 
 
3.4    DISCUSSION 
 
The present findings provide evidence that CPA is a bona fide second messenger 
and a negative physiological regulator of PPAR$. CPA is a high-affinity ligand of PPAR$ 
with an apparent Kd in the hundred-nanomolar range, comparable to that of TZDs. CPA 
binds to a site within the LBD that prevents activation by three different TZD compounds 
and the endogenous phospholipid agonist AGP, and it stabilizes binding of the  
corepressor SMRT. CPA lacks the ability to activate PPAR$ due to its cyclic phosphate 
moiety. In contrast, AGP and LPA both possess a free phosphate and are agonists of 
PPAR$ (Tsukahara et al., 2006). CPA is barely detectable in resting cells but is generated 
intracellularly in a stimulus-coupled manner by PLD2 and is then degraded by 
phospholipase(s) or acyltransferase(s) via deacylation. PLD2 is the target and 
convergence point of several receptor-coupled signal transduction pathways (Huang and 
Frohman, 2007) suggesting that PPAR$ is modulated by stimuli of this enzyme. The 
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Figure 3-7 CPA and insulin prevent carotid wall remodeling 
 
(A-C) Carotid arteries of anesthetized adult rats (5 per group) were exposed to 5 %M 
AGP alone (A) or with 5 %M CPA (B) for 1 h. (Masson trichrome staining, bar 200 µm).  
(C) CPA treatment blocks increase in intima-to-media ratios AGP-induced rat carotid 
arteries (n=5 per group). (D-F) Insulin (3 nM) was applied alone (D) or with 5 %M AGP 
(E) intralumenally for 1 h and neointima formation assessed three weeks alters. Bar 
represents 200 %m. (F) Quantification of intima/media ratios (n=5).  
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
AGP
+CPA
CPAAGPVehicle
**p < 0.01
**
AGP Insulin AGP
+Insulin
*p < 0.05
*
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0
a
 
oit
a
R
 
aid
e
M/
a
mit
nI
DS
 
±
 
oit
a
R
 
aid
e
M/
a
mit
nI
DS
 
±
 AGP 5 µM 
C
B
 3 nM Insulin
EAGP & CPA 5 µM 5 µM AGP & 3 nM Insulin
F
A D
 
 
61 
present findings establish that PLD2 can produce at least two second messengers, PA 
from the hydrolysis of phosphatidylcholine and CPA from LPC, depending on substrate 
availability. The availability of LPC is likely to be regulated by activation of 
phospholipases A2, which are concomitantly activated by the same stimuli that activate 
PLD2 (Kim et al., 1999). Physiological stimuli of PLD2 can generate CPA in biologically 
effective concentrations, as indicated by our findings using the foam-cell formation and 
adipocyte differentiation models in cultured cell lines and also using primary 
monocytes/macrophages, and PPAR$-dependent vascular remodeling in vivo. In addition, 
the present data reinforce the long-standing observation that low concentrations of insulin 
protect against neointimal growth (Breen et al., 2009). 
 
 Current paradigms for PPAR$ signaling do not take into consideration the 
possibility of endogenous negative regulators fine-tuning, and under certain conditions 
even abrogating the cellular responses mediated through this nuclear hormone receptor. 
Our findings challenge this view by identifying CPA as an endogenous negative regulator 
of PPAR$. Individual variations in patients in the activation of the PLD2-CPA axis are 
likely to modulate therapeutic responses to the widely used class of TZD drugs targeting 
PPAR$. Hence, the present results provide new grounds for rethinking our current 
concepts governing the regulation of this nuclear hormone receptor and raise the 
possibility of utilizing this phospholipid scaffold as a lead for the synthesis of novel 
medicines acting on PPAR$. 
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CHAPTER 4.    REGULATION OF NUCLEAR HORMONE RECEPTOR PPAR$ 
BY ENDOGENOUS LYSOPHOSPHATIDIC ACIDS* 
 
 
4.1    INTRODUCTION 
 
 
4.1.1 Lysophosphatidic Acid (LPA) in the Vasculature 
 
LPA has been identified as a bioactive lipid and is produced in serum after the 
activation of multiple biochemical pathways linked to platelet activation (Sano et al., 
2002, Spector, 2003, Tigyi and Parrill, 2003, Bolen et al., 2011). The concentration of 
LPA in plasma is in the nanomolar range, whereas it can reach concentrations as high as 
10 %M in serum during blood clotting (Baker et al., 2001, Aoki et al., 2002, Baker et al., 
2002). LPA production in blood requires autotaxin (ATX), which is a secreted 
lysophospholipase D that generates LPA from lysophosphatidylcholine (LPC) (Tokumura 
et al., 2002, Umezu-Goto et al., 2002). 
 
LPA plays an important role in vascular development (van Meeteren et al., 2006). 
ATX-deficient mice die at approximately embryonic day 9.5 with severe vascular 
formation defects in the yolk sac and enlarged embryonic blood vessels (Tanaka et al., 
2006, van Meeteren et al., 2006). Mice that overexpress ATX have elevated plasma LPA 
levels and show bleeding diathesis, whereas ATX+/- heterozygous mice have almost half 
the plasma LPA levels and are prone to thrombosis (Pamuklar et al., 2009). 
 
LPA promotes proliferation and migration of vascular smooth muscle cells 
(VSMCs) (Hayashi et al., 2001, Siess, 2002, Kim et al., 2006). LPA increases endothelial 
permeability (Schulze et al., 1997, Alexander et al., 1998, van Nieuw Amerongen et al., 
2000) and induces E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and vascular 
endothelial growth factor-C (VEGF-C) expression in human endothelial cells (Rizza et 
al., 1999, Lin et al., 2008). Hayashi et al. reported that LPA promotes VSMC 
dedifferentiation from the contractile phenotype to a secretory phenotype and stimulates 
VSMC signaling pathways in vitro (Hayashi et al., 2001). 
 
Many of the cellular responses elicited by LPA, including platelet activation 
(Siess et al., 1999, Rother et al., 2003, Haseruck et al., 2004), endothelial cell activation 
(Siess et al., 1999), proliferation, migration, and phenotypic modulation of VSMCs 
(Hayashi et al., 2001, Siess, 2002, Kim et al., 2006), are all involved in neointima 
formation. Oxidative modification of low-density lipoprotein (LDL) is considered to be 
an early event in arterial wall remodeling leading to atherosclerosis (Stocker and Keaney, 
2004, Asmis et al., 2005); and uptake and oxidation of LDL in the arterial wall is an 
important mechanism in the pathogenesis of atherosclerosis (Meydani, 2001). It has been 
 
* Adapted with permission. Tsukahara R, Tsukahahara T, Tigyi G (2011) Regulation of 
the nuclear hormone receptor PPARgamma by endogenous lysophosphatidic acids. In: 
Lysophospholipid receptors: Signaling and biochemistry, in press. NJ: Wiley. 
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shown that LPA is formed during mild oxidation of LDL (mox-LDL)(Siess et al., 1999, 
Law et al., 2000). In addition, the lipid-rich core of human atherosclerotic plaques, which 
accumulates oxidized lipids including mox-LDL, contains several species of acyl-LPA 
and AGP (Siess et al., 1999). Acyl-LPA and AGP accumulated in human atherosclerotic 
plaques are likely to activate platelets and initiate thrombus formation upon plaque 
rupture (Rother et al., 2003, Spector, 2003). Following plaque rupture, LPA becomes 
available to circulating platelets, initiating activation, which in turn may contribute to the 
induction of thrombosis, leading to myocardial infarction and stroke. A clinical study has 
shown that the serum LPA level is significantly elevated in patients with acute 
myocardial infarction (Chen et al., 2003). 
 
 
4.1.2 Neointima Formation Induced by LPA 
 
Atherosclerosis is the leading cause of death and serious morbidity in developed 
countries. Neointimal lesions are characterized by accumulation of cells within the 
arterial wall and are an initial step in the pathogenesis of atherosclerosis, which leads to 
the ischemic syndromes of heart and stroke (Ross, 1999, Baim et al., 2002). 
 
Yoshida et al. first reported that LPA species containing unsaturated fatty acyl 
groups 16:1, 18:1, and 18:2 induced neointima formation when injected intralumenally 
into the rat carotid artery, whereas saturated acyl-LPA species such as 16:0 and 18:0 were 
inactive (Yoshida et al., 2003). This model comes close to the pathophysiological 
response seen in humans when mechanical injury is not the cause of the arterial wall 
remodeling leading to neointimal lesions. In Yoshida's model, LPA was injected through 
the external carotid artery into a ligated section of the common carotid artery (CCA) that 
was rinsed free of blood and maintained close to the mean arterial perfusion pressure. 
There was no mechanical injury or removal of endothelial cells in the CCA. A brief 
one-hour exposure to unsaturated but not to saturated species of LPA caused neointima 
development. Our group found that the LPA-elicited neointima was not mediated by the 
LPA G protein-coupled receptors (GPCRs) LPA1 and LPA2, which are the major LPA 
receptor subtypes expressed in the vessel wall (Cheng et al., 2009). A peroxisome 
proliferator-activating receptor " (PPAR")-specific inhibitor, GW9662, abolished the 
LPA-induced neointima formation, suggesting that arterial wall remodeling elicited by 
LPA is a PPAR"-mediated response (Zhang et al., 2004). Conversely, the 
PPAR"-specific agonist rosiglitazone (ROSI; Figure 4-1) also elicited neointima 
formation in the same model. Genetic evidence also supports the role of PPAR" in 
arterial wall remodeling. When conditional knockout PPAR$-/- mice with this receptor 
knocked out in the endothelial cells, VSMCs, and cells of the macrophage/monocyte 
lineage were exposed to AGP (Figure 4-1) or ROSI, neither agent elicited neointima 
formation or vascular wall remodeling (Cheng et al., 2009). It is important to note that in 
a carotid injury model, ROSI diminished the size of the neointima. The opposite effect of 
ROSI and LPA in these two different models indicates differences in the mechanism 
underlying vascular wall remodeling in the two models (Cheng et al., 2009). These 
results, combined with the observation that GW9662 abolished neointima in response to 
ROSI or AGP (Zhang et al., 2004), suggest that PPAR$ is required for LPA-induced 
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Figure 4-1 Structures of the lysophosphatidic acids, ROSI, and PIO 
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neointima formation in the absence of vascular wall injury. 
 
Subramanian et al. reported that LPA1 and LPA3 GPCRs play an important role in 
neointima formation (Subramanian et al., 2010). Using a wire-injury model, these authors 
showed that neointima formation was inhibited by the LPA1 and LPA3 inhibitor Ki16425 
and that vascular wall remodeling induced by LPA was inhibited by short-term 
knockdown of either LPA1 or LPA3 with siRNA (Subramanian et al., 2010). In sharp 
contrast with the findings of Subramanian et al., LPA1-/- mice in our non-injury model 
develop neointimal in response to AGP stimulation. Moreover, although LPA1 and LPA3 
GPCRs are respectively 12 and 100 times less sensitive to AGP than LPA (Fujiwara et 
al., 2005), AGP is more potent than LPA in inducing neointima formation (Zhang et al., 
2004). They also observed that Mac-2 positive cells were accumulated in the neointimal 
area after vascular injury (Subramanian et al., 2010); in contrast, our non-injury model 
showed few macrophages in the neointimal region induced by AGP or ROSI (Cheng et 
al., 2009), suggesting that the cellular elements leading to neointima formation are 
different between the two models. 
 
Although some clinical studies in diabetic patients have shown a reduction in 
carotid artery wall thickness after treatment with thiazolidinediones (TZDs) 
(Minamikawa et al., 1998, Haffner et al., 2002), other studies suggested that ROSI 
increases the risk of myocardial infarction and death from cardiovascular causes 
(Goldberg et al., 2005, Nissen and Wolski, 2007, 2010), indicating that TZD therapy may 
actually increase the risk of cardiovascular events. Moreover, in 2010, the U.S. Food and 
Drug Administration restricted use of ROSI to patients with type 2 diabetes due to the 
potential for cardiovascular ischemic risks, including heart attack. 
 
 
4.1.3 PPAR$  – an Intracellular LPA Receptor 
 
Only unsaturated acyl-LPA species induce neointima formation; saturated 
acyl-LPA species are inactive (Yoshida et al., 2003, Zhang et al., 2004) indicating the 
need for an unsaturated fatty acid in the activation of the mechanism that underlies the 
formation of neointima. The structure-activity relationship of neointima induction by 
LPA does not match that of the known LPA GPCRs because saturated LPA species 
activate the LPA GPCRs (Zhang et al., 2004, Fujiwara et al., 2005). However, the 
structure-activity relationship of PPAR" activation by LPA species matches that of the 
neointima response in vivo (Zhang et al., 2004). ROSI and the unsaturated acyl-LPA 
species all activate the peroxisome activator response element-contianing 
acyl-coenzyme A oxidase-luciferase (PPRE-Acox-Luc) reporter construct, whereas all 
saturated species, 2,3-cyclic phosphatidic acid (CPA) (Figure 4-1), and the related lipid 
mediator sphingosine-1-phosphate were inactive (Tsukahara et al., 2006). 
 
PPARs are members of the nuclear hormone receptor superfamily, many of which 
function as lipid-activated transcription factors (Tontonoz and Spiegelman, 2008). There 
are three types of PPAR; PPAR!, #/", and $. PPAR$, the most extensively studied among 
the three PPAR subtypes, plays an important role in regulating lipid metabolism, glucose 
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homeostasis, cell differentiation, and motility (Duval et al., 2002, Evans, 2005, 
Kiec-Wilk et al., 2005). PPAR$ has two isoforms, PPAR$1 and $2. PPAR$2 differs from 
PPAR$1 only by 30 additional amino acids at the N-terminus, caused by differential 
promoter usage and alternative splicing (Fajas et al., 1997). PPAR$1 is expressed 
ubiquitously in almost all tissues, whereas PPAR$2 is highly expressed in only in the 
adipose tissue (Lehrke and Lazar, 2005). Genetic deletion of PPAR$1 causes embryonic 
mortality (Asami-Miyagishi et al., 2004). In contrast, deletion of PPAR$2 causes minimal 
alterations in lipid metabolism (Medina-Gomez et al., 2005). PPAR$ heterodimerizes 
with the retinoid X receptor # (RXR#), and it is the ligand binding domain (LBD) of 
PPAR$ that interacts with its agonists, including LPA (Weatherman et al., 1999). The 
PPAR"-RXR# heterodimer binds the peroxisome proliferator response element (PPRE) 
in the promoter region of the target genes. In the absence of ligands, the corepressors 
NCoR and SMRT (Chen and Evans, 1995, Dowell et al., 1999, Yu et al., 2005) bind to 
the heterodimer to suppress the target gene activation. Upon ligand binding, PPAR$ 
undergoes a conformational change that facilitates the dissociation of the corepressors 
and recruits the p300 coactivator and the PGC-1! coactivator (Nolte et al., 1998, Yu and 
Reddy, 2007), resulting in target gene transcription (Lala et al., 1996). 
 
A number of putative physiological agonists of PPAR$ have been identified, 
including 15d-PGJ2 (Forman et al., 1995), oxidatively modified fatty acids (Nagy et al., 
1998, Baker et al., 2005, Li et al., 2008), select species of LPA and AGP (McIntyre et al., 
2003, Zhang et al., 2004, Tsukahara et al., 2006), oxidized phospholipids (Davies et al., 
2001), and nitrated fatty acids (Li et al., 2008). Among these ligands, AGP stands out 
with an equilibrium binding constant of 60 nM (Tsukahara et al., 2006) that is similar to 
that of the TZD class of synthetic agonists. The TZD class of antidiabetics, including 
ROSI, pioglitazone, and troglitazone, are full agonists of PPAR$ and have been clinically 
used to improve insulin sensitivity and lipid metabolism in type 2 diabetics (Froberg and 
Andersen, 2005, Lautamaki et al., 2005, Negro et al., 2005, Sarafidis et al., 2005). 
 
However, despite the beneficial effects of PPAR$ on glucose and lipid 
homeostasis, excessive PPAR$ activity can be deleterious. PPAR$ agonists promote 
adipocytic differentiation of 3T3-L1 cells and also stimulate the uptake of LDL by 
macrophages, leading to foam cell formation in the arterial wall (Moore et al., 2001). Our 
results suggest that LPA-mediated activation of PPAR$ can also contribute to vascular 
wall pathologies. 
 
PPAR$ plays an important role in the cardiovascular system. PPAR$ is expressed 
in all cell types of the vessel wall (Marx et al., 1998, Delerive et al., 1999, Rangwala and 
Lazar, 2004), as well as in monocytes and macrophages (Tontonoz et al., 1998). PPAR$ 
expression is upregulated in VSMCs (Law et al., 2000), endothelial cells (Delerive et al., 
1999), and macrophages (Tontonoz et al., 1998) in human atherosclerotic plaques and 
neointimal lesions. PPAR$ expression is also elevated in neointimal lesions after 
mechanical injury to the endothelium (Law et al., 2000). ROSI suppresses neointima 
formation after endothelial injury in rats (Lim et al., 2006). On the other hand, in our 
non-injury model, ROSI induces neointima formation when intraluminally applied into 
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carotid arteries (Zhang et al., 2004, Cheng et al., 2009). Thus, the mechanisms underlying 
neointima formation in the chemically induced neointima model are likely to be different 
from those in the non-injury induced neointima models. 
 
 
4.1.4 2,3-Cyclic Phosphatidic Acid (CPA) – an Endogenous Antagonist of PPAR$  
 
CPA, an analog of LPA with a five-atom ring linking the phosphate to two of the 
glycerol carbons (Figure 4-1), is found in diverse organisms from slime mold to humans 
(Murakami-Murofushi et al., 2000); its functions are largely unknown. The concentration 
of CPA in human serum is estimated to be ~0.01 %M, 10-fold lower than that of LPA 
(Eichholtz et al., 1993, Kobayashi et al., 1999). Although CPA is structurally similar to 
LPA, CPA shows several unique actions compared to LPA. CPA inhibits cell 
proliferation (Fischer et al., 1998), induces actin stress fiber formation (Fischer et al., 
1998), promotes differentiation and survival of cultured embryonic hippocampal neurons 
(Fujiwara et al., 2003), inhibits LPA-induced platelet aggregation (Gueguen et al., 1999), 
and suppresses cancer cell invasion and metastasis in vitro and in vivo (Mukai et al., 
1999, Ishihara et al., 2004, Uchiyama et al., 2007). Our group showed that CPA 
negatively regulates PPAR$ functions by stabilizing the SMRT-PPAR$ complex 
(Tsukahara et al., 2010). Furthermore, we showed that CPA is generated intracellularly 
by phospholipase D2 (PLD2) (Tsukahara et al., 2010). 
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI) is an inhibitor of both PLD1 and PLD2 
isozymes (Su et al., 2009). FIPI inhibits PLD2-mediated CPA production in human 
peripheral mononuclear cells stimulated with LPS (Tsukahara et al., 2010). We also 
demonstrated that activation of PLD2-mediated CPA production or topical application of 
CPA together with PPAR$ agonists prevents neointima formation, adipocytic 
differentiation, lipid accumulation, and the upregulation of PPAR$ target gene 
transcription in mouse macrophages (Tsukahara et al., 2010). These findings support our 
hypothesis that CPA is an endogenous antagonist of PPAR$. 
 
In the following material, we describe some of the fundamental methodologies 
that we and others have used in probing the actions of LPA and CPA on PPAR$ in vitro 
and in vivo. 
 
 
4.2    METHODS PROBING PPAR$  FUNCTION WITH LPA 
 
 
4.2.1 Reporter Gene Assay for Ligand Activation of PPAR! 
 
The reporter gene assay is a sensitive method of monitoring ligand-induced gene 
expression. The determination of PPAR" activation in cells transiently transfected with 
the PPRE-ACox-Luc or TK-MH100-Luc reporter gene construct has been reported 
previously (Tsukahara et al., 2006, Tsukahara et al., 2010) (Figure 4-2A and B). We used 
the B103 rat neuroblastoma cell line because this cell line lacks LPA GPCRs LPA1, LPA2 
and LPA3 and expresses very low levels of endogenous PPAR$, making it an ideal 
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Figure 4-2 CPA inhibits PPAR!-dependent gene expression 
 
(A and B) Schematic diagram of reporter gene assay using PPAR" and its reporter 
plasmid. PPAR" agonists induce luciferase transcription, whereas PPAR" antagonist 
inhibits PPAR" agonist-induced reporter gene transcription. (C) CPA suppresses 
ROSI-induced PPAR"-dependent reporter gene activation in B103 cells. B103 cells 
(3$104) were transfected with reporter plasmid (PPRE-ACox-Luc or TK-MH100-Luc), 
pcDNA3.1-PPAR" or pCMX-Gal4-PPAR", and SV40-!-galactosidase. After 
transfection, the cells were exposed to 10%M CPA with or without ROSI (10 %M) for 20 
h, and luciferase activities were measured. Data represent mean ± SEM; n = 4. 
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low-background cell type for transfection studies. B103 cells, 3.0$104 per well, were 
plated to 96-well plates the day before transfection. Using LipofectAMINE 2000, the 
cells were transfected with 125 ng of the reporter plasmid (PPRE-ACox-Luc or 
TK-MH100-Luc), 62.5 ng of pcDNA3.1-PPAR" or pCMX-Gal4-PPAR", and 12.5 ng of 
SV40-!-galactosidase (Promega), the latter to monitor transfection efficiency. Twenty 
hours posttransfection, 10 µM ROSI (Figure 4-1) (ALEXIS Biochemicals), 10 µM AGP 
18:1, or 10 µM CPA 18:1 (Avanti Polar Lipids) dissolved in 1% Me2SO and mixed with 
Opti-MEM I (Invitrogen) and 1% fetal bovine serum (HyClone) were applied for 20 h at 
37°C in the presence of 5% CO2. Luciferase and !-galactosidase activities were measured 
with the Steady-Glo luciferase assay system (Promega) and the Galacto-Light Plus 
system (Applied Biosystems), respectively. Samples were run in quadruplicate, and the 
means ± S.E. were calculated. Representative data are shown in Figure 4-2C. 
 
 
4.2.2 Competition Ligand Binding of PPAR! Using ROSI/AGP against 
LPA/AGP/CPA  
 
PPAR" consists of a ligand binding domain (LBD) and a DNA binding domain 
(DBD) (Figure 4-3). To test whether LPA/AGP/CPA interacts with the PPAR" LBD, 
competition ligand binding assays were performed (Figure 4-4A). Hexahistidine (His6) 
epitope-tagged PPAR" LBD fusion proteins or empty vector controls containing the His6 
and thrombin recognition site can be expressed in BL-21 (DE3) E. coli cells (Invitrogen). 
Transformed BL-21 cells were induced using 0.3 mM isopropyl 1-!-D-galactopyranoside 
(Fisher Scientific) for 12 h at 25°C and collected by centrifugation. The PPAR" LBD was 
extracted with lysis buffer (50 mM HEPES-KOH, pH 6.8, 200 mM NaCl, 5 mM DTT, 1 
mM phenylmethanesulfonyl fluoride, 0.5% Triton X-100, and 15% glycerol) and 
centrifuged at 12,000 $ g for 20 min. Supernatant (1 ml) was incubated with 50 µl of 
TALON metal affinity resin (BD Biosciences) at 4°C for 1 h in the lysis buffer. The resin 
was washed five times with wash buffer (50 mM HEPES-KOH, pH 6.8, 200 mM NaCl, 5 
mM DTT, 15% glycerol, and 5 mM imidazole) and eluted with 150 mM imidazole in 
wash buffer. The purity of the PPAR" LBD was determined using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis followed by Coomassie Blue staining and 
western blot analysis using a PPAR" antibody (sc-7196; Santa Cruz Biotechnology). For 
the equilibrium binding assay, 1 µg of His6-PPAR" LBD fusion protein (Figure 4-4A) 
was incubated in binding buffer (50 mM HEPES, pH 6.8, 100 mM NaCl, 5 mM EDTA, 
and 5 mM DTT) in the presence of 5 nM [3H]ROSI (American Radiolabeled Chemicals) 
or [32P]AGP at 18°C for 1 h. [32P]AGP 18:1 was synthesized from 
1-O-octadecenyl-sn-glycerol 18:1 using recombinant 1,2-diacylglycerol kinase 
(Calbiochem). 1-O-octadecenyl-sn-glycerol 18:1 was solubilized in 20 µl of an 
octyl-!-glucoside/cardiolipin solution (7.5% octyl-!-glucoside and 5 mM cardiolipin in 
0.5% Triton X-100) by sonication in a bath sonicator (Branson) for 30 s. To the 
solubilized 1-O-octadecenyl-sn-glycerol 18:1/octyl-!-glucoside/cardiolipin solution was 
added 50 µl of reaction buffer (100 mM imidazole HCl, pH 6.6, 100 mM NaCl, 25 mM 
MgCl2, and 2 mM EGTA), 2 µl of 100 mM DTT (freshly prepared), 10 µl of diluted 1,2-
diacylglycerol kinase, and water to a total volume of 90 µl. The reaction was started by 
the addition of 10 µl of ["-32P]ATP (PerkinElmer; 10 mCi/ml; specific activity,  
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Figure 4-3 The structures of PPAR!1 and PPAR !2 
 
Human PPAR"1 and PPAR "2 proteins are 53 and 57 kDa, respectively. The two PPAR" 
isoforms differ only 30 amino acids at the N-terminal end. Domain C and E represent 
DNA binding domain (DBD) and ligand binding domain (LBD), respectively. 
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Figure 4-4 CPA is a high affinity ligand of PPAR! 
 
(A) Schematic diagram of competitive ligand binding assay using LPA, AGP, ROSI, and 
CPA. (B) Competitive displacement of 5 nM [3H]-ROSI from PPAR"-LBD was 
determined using 2.5 %M cold ROSI, LPA18:1, or CPA. Data are mean ± SEM; **p < 
0.01. 
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111TBq/nmol) and incubated at 25°C for 1 h. 
 
Lipids were extracted by a modification of the method of Bligh and Dyer (Bligh 
and Dyer, 1959). NaCl (1 M) was added to bring the aqueous volume to 0.8 ml. Total 
lipid was extracted with 3 ml of chloroform/methanol (1:2, v/v). Then, 1 ml of 
chloroform and 1 ml of 1 M NaCl were added and phase separated by centrifugation 
(3,000 $ g, 5 min). The lower phase was collected and dried under nitrogen. This was 
dissolved in 50 µl of chloroform/methanol (1:2, v/v) and was spotted on a Silica Gel 60 
(Merck) thin layer chromatography plate. Plates were developed with 
chloroform/methanol/acetic acid (65:15:5, v/v) and subjected to radioautography. The 
radioactive spot corresponding to AGP 18:1 was scraped into a scintillation vial. 
Counting was carried out in an LS-6500 Beckman scintillation counter. The radioligand 
bound to the PPAR" LBD fusion protein was precipitated using 36% (w/v) polyethylene 
glycol 8000 (Fisher Scientific) in the presence of 3.3% (w/v) "-globulin (Sigma-Aldrich), 
collected on DEAE-81 filter disks (Whatman), and quantified by liquid scintillation 
counting. Nonspecific binding was determined in the presence of nonradioactive 10 %M 
AGP. For competition binding assays, 1 µg of His6-PPAR" LBD protein was incubated at 
18°C for 1 h in 200 µl of binding buffer in the presence of 5 nM [3H]ROSI or 5 nM 
[32P]AGP with or without 2.5 %M cold compounds. The radioactive ligand-bound 
His6-PPAR" LBD was collected on DEAE-81 filter disks. The disks were washed three 
times with wash buffer (50 mM HEPES, pH 6.8, 100 mM NaCl, 5 mM DTT), and bound 
radioactivity was quantified by scintillation counting. An example of LPA and CPA 
competition with [3H]ROSI binding is shown in Figure 4-4B. 
 
 
4.2.3 Corepressor Mammalian Cell Two-Hybrid Assay 
 
This assay was performed to test the effect of CPA on SMRT corepressor binding 
to PPAR" (Figure 4-5A). CV-1 cells (African green monkey kidney cell line) were grown 
in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum 
(FBS) supplemented with 100 IU/ml penicillin G and 100 %g/ml streptomycin at 37°C in 
a humidified 5% CO2 atmosphere. The cells were plated onto 96-well plate at the density 
of 1.0 $ 104 cells per well in DMEM containing 10% FBS. The next day, the cells were 
transiently transfected with 71 ng UAS-Luc, 14.3 ng Gal4-SMRT, 14.3 ng 
pVP16-PPAR"2, and 10 ng pSV-!-galactosidase (Promega) using Lipofectamine LTX 
(Invitrogen) and Opti-MEM (Invitrogen) for 20 h. After 20 h transfection, the cells were 
pretreated with 10 nM, 100 nM, 1 %M, and 10 %M of CPA 18:1 or 
cyclic glycerophosphate (CGP, Figure 4-1; Avanti Polar Lipids), which is the alkyl ether 
analog of CPA 18:1, for 30 min, followed by treatment with 1 nM ROSI for 6 h. 
Luciferase and !-galactosidase activities were measured with the Steady-Glo luciferase 
assay system (Promega) and the Galacto-Light Plus system (Applied Biosystems), 
respectively. Samples were run in quintuplicate, and the mean ± SEM were calculated. 
The data shown in Figure 4-5B are representative of at least three independent 
transfections. As shown in Figure 4-5B, CPA 18:1 and its ether analog CGP 18:1 dose 
dependently stabilized the PPAR$-SMRT complex and prevented ROSI-induced 
dissociation of the complex (*p < 0.05; **p < 0.01). 
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Figure 4-5 CPA inhibits PPAR! activation and recruits PPAR! corepressor 
 
(A) Schematic diagram of two-hybrid assay using full length of SMRT and PPAR"2. (B) 
CPA 18:1 and CGP 18:1 dose-dependently inhibited SMRT release from PPAR" induced 
by ROSI. CV-1 cells were transfected with UAS-Luc, pECE-Gal4-SMRT, 
pVP16-PPAR"2, and pSV-#-gal. After transfection, the cells were treated with CPA 18:1 
or CGP 18:1 for 30 min, followed by 1 nM ROSI for 6 h, and luciferase activities were 
measured. Data are mean ± SEM; n = 4; *p < 0.05, **p < 0.01; representative of three 
transfections. 
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4.2.4 Non-Injury Infusion Model Using Rat Carotid Arteries to Elicit Neointima 
Formation 
 
To examine the regulatory role of CPA in PPAR$-dependent pathophysiological 
responses, a rat non-injury infusion model was used. The animal procedures were 
approved by the Institutional Animal Care and Use Committee of the University of 
Tennessee Health Science Center. Adult male Sprague-Dawley rats weighing 250-300 g 
were anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg). After anesthesia, 
the forelimbs and incisors were fixed to the surgical board with tape. The hair around the 
neck was shaved, and the skin was disinfected with povidone-iodine and 70% 
isopropyl alcohol. The surgery was carried out under a dissecting microscope. The right 
side of the carotid artery was surgically exposed through a midline incision. The proximal 
sides of the common carotid artery (CCA) and internal carotid artery (ICA) were ligated 
using vessel clips (85 gr. pressure, BRI). The distal end of the external carotid artery 
(ECA) was tied with 5.0 surgical suture (Harvard); subsequently, another 5.0 surgical 
suture was passed through the proximal end of the ECA and a loose loop was made. A 
PE-10 catheter (Becton Dickinson) was connected to a servo-controlled peristaltic pump 
(Model PS-200; Living Systems Instrumentation (ST.Albans, VT)) to maintain the 
intraarterial pressure at 100 mm Hg. The other end of the PE-10 catheter was inserted 
into the ECA through arteriotomy without mechanical injury to the CCA. The loose loop 
was tightened on the ECA to keep the catheter in place. The clip occluding the CCA was 
temporarily released, and the vessel was rinsed with a retrograde injection of 50 %l of 
phosphate-buffered saline (PBS) to remove residual blood. The CCA was clipped again, 
and a treatment solution either 0.1% DMSO (vehicle), 10 %M AGP, 10 %M ROSI, 10 %M 
PIO, 10 nM insulin, 750 nM FIPI, or the combination of these compounds was applied. 
The delivery pressure of the solutions was maintained at 100 mm Hg using the peristaltic 
pump. 
 
In some experiments, ROSI was applied outside the carotid artery in a pluronic 
gel. Pluronic F-127 (Sigma-Aldrich) was dissolved in PBS (25% w/v) and maintained at 
4°C until use. At the time of compound administration via the PE-10 catheter, 100 %l of 
the pluronic gel containing 100 %M ROSI and 0.1% DMSO was topically applied around 
the adventitia of the CCA for 1 h. The control group received the pluronic gel without 
ROSI. 
 
For cotreatment with FIPI, the inhibitor was applied for 30 min as a pretreatment 
and also included during the application of the PPAR" agonists. After a 60-min 
incubation, the ligation was loosened to withdraw the catheter and the loop was tied up 
again to ligate the ECA. The vessel clips on the CCA and ICA were released to restore 
blood flow. The wound was closed with 4.0 surgical suture. After the surgery, the rats 
were kept on a warming pad to avoid hypothermia during recovery and were 
administered Buprenex (0.05 mg/kg). Three weeks after the surgery, transcardial 
perfusion was performed with 4% buffered paraformaldehyde (pH 7.4), and the CCAs 
were dissected and postfixed in 4% buffered paraformaldehyde (pH 7.4). The dissected 
CCAs were embedded in paraffin; and 5-%m thick sections were cut, deparaffinized, and 
stained with Masson’s trichrome stain (Allan Scientific). Neointima formation was 
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observed under a light microscope. To evaluate neointima progression, the 
intima-to-media ratio was used. The intima (area between the endothelium and the 
internal elastic lamina) and media (area between the external and internal elastic lamina) 
were measured using ImageJ software (version 1.42), and intima-to-media ratios were 
calculated. 
 
As shown in Figure 4-6 (unpublished data), neointima formation induced by AGP 
was attenuated by insulin due to the production of CPA through PLD2 activation by 
insulin (Figure 4-6B, C, and E) (Tsukahara et al., 2010). This insulin effect was blocked 
by the PLD inhibitor FIPI because the CPA production was not sufficient due to the 
inhibition of PLD2 activity (Figure 4-6D and E). 
 
Pioglitazone induced arterial wall remodeling; the magnitude, however, was 
significantly less than that induced by ROSI (Figure 4-7 B, C, and E) (unpublished data). 
This might be one of the reasons that ROSI shows higher cardiovascular risks. ROSI 
applied to the outside of CCAs with pluronic gel also induced neointima formation 
(Figure 4-7D and E), suggesting that ROSI diffused toward the inside of the vessel and 
promoted arterial wall thickness. 
 
 
4.2.5 Immunohistochemical Staining 
 
It has been implicated that bone marrow-derived vascular progenitor cells (VPCs) 
can contribute to neointima formation (Saiura et al., 2001, Zernecke et al., 2005). To 
assess whether VPCs are recruited to form neointima in response to AGP or ROSI 
treatment in the non-injury model, immunohistochemical analysis was performed using 
antibodies to the VSMC marker !SMA and the VPC marker CD133. Five-%m thick cross 
sections of the rat CCAs were double-stained for !SMA and CD133 to identify VPCs in 
the neointimal regions. After deparaffinization and rehydration, heat-mediated antigen 
retrieval was carried out using citrate-based antigen unmasking solution (Vector 
Laboratories) for 10 min on formalin-fixed tissue slides. After three washes in PBS (pH 
7.4), the slides were blocked with blocking solution containing 5% normal goat serum 
(Vector Laboratories) and 5% normal horse serum (Vector Laboratories) in PBS for 1 h 
at room temperature. !SMA antibody (mouse monoclonal [clone 1A4], 1:400 dilution; 
Abcam) and CD133 (rabbit polyclonal [ab19898], 1:100 dilution; Abcam) diluted in 
blocking solution were applied to the slides and incubated overnight at 4°C. The slides 
were incubated with fluorescein-conjugated horse anti-mouse IgG (1:200 dilution; Vector 
Laboratories) secondary antibody or biotinylated goat anti-rabbit IgG (1:500 dilution; 
Vector Laboratories) secondary antibody dissolved in blocking solution for 30 min, 
followed by incubation with rhodamine-avidin D (1:1000; Vector Laboratories) for 30 
min at room temperature after washes with PBS. The slides were mounted with 
VECTASHIELD with DAPI (Vector Laboratories) and visualized with a Nikon Eclipse 
80i fluorescence microscope. 
 
DMSO-treated CCA showed no CD133-positive cells (Figure 4-8B); however, 
anti-CD133 staining showed positive cells in the neointimal region (Figure 4-8E), and  
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Figure 4-6 PLD inhibitor FIPI inhibits physiological insulin effect on vascular 
wall remodeling 
 
(A-D) Carotid arteries of anesthetized adult rats were treated with DMSO (vehicle) (A), 
10 %M AGP (B), 10 %M AGP and 10 nM insulin (C), or 10 %M AGP, 10 nM insulin, and 
750 nM FIPI(D) for 1h. Three weeks after the treatment, the CCAs were dissected and 
the sections were stained with Masson’s trichrome stain. Scale bars represent 200 %m. (E) 
Quantification of intima/media ratios. Data are mean ± SEM; n=5. 
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Figure 4-7 PIO induces less neointima and ROSI application from the outside 
also induces arterial wall thickness 
 
(A-D) Carotid arteries of anesthetized adult rats were transfused with vehicle (A), 10%M 
PIO (B), or 10 %M ROSI (C) for 1h. 100 %M ROSI was applied to the outside of vessel 
using 25% pluronic gel for 1h (D). The sections were stained with Masson’s trichrome 
stain. Scale bars represent 200 %m. (E) Quantification of intima/media ratios. Data are 
mean ± SEM; n=5. 
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Figure 4-8 Immunohistochemical staining for !SMA and CD133 in the 
neointima induced by AGP 
 
Rat carotid arteries treated with DMSO (A-C) and 10 %M AGP (D-F) were 
double-stained for !SMA (green; A and D) and CD133 (red; B and E). The cells were 
intensively stained with anti-!SMA in the media and neointima layers (A and D). 
Anti- CD133 stained cells were barely seen (B), however, CD133 positive cells were 
accumulated in neointima region (E). Double stained cells were seen in the merged image 
(F). Area between the white arrows is neointima (D-F). Scale bars: 200 %m.  
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CD133-positive cells were also expressed !SMA (Figure 4-8F). 
 
 
4.3    SUMMARY 
 
In this chapter, we have focused on the responses mediated by PPAR" modulated 
by lysophosphatidic acids, especially in the vasculature; and we have introduced some of 
the fundamental methods for examining the regulation of PPAR" by endogenous 
lysophosphatidic acids analogs. 
 
CPA is a high-affinity ligand and an endogenous negative regulator of PPAR", 
unlike unsaturated acyl species of LPA and AGP, which have agonist properties (Figure 
4-9).?CPA binds to a site within the LBD, which inhibits PPAR" activation (Figure 4-9). 
CPA binding to PPAR" facilitates conformational change that leads to recruitment of 
corepressor SMRT, resulting in stabilization of the SMRT-PPAR" complex. LPA and 
AGP induce neointima formation through the activation of PPAR", whereas, CPA 
inhibits PPAR"-mediated arterial wall remodeling in the non-injury model. In addition, 
the physiological stimulus of PLD2 is effective in PPAR"-dependent vascular 
remodeling, and this effect is blocked by the PLD inhibitor FIPI in vivo. When 
vehicle-treated CCAs were stained for CD133, no CD133-positive cells were observed; 
however, CD133-positive cells were seen in the neointimal region when the artery was 
treated with AGP. Moreover, the CD133-positive cells in the neointimal region also 
expressed !SMA, suggesting that VPCs are recruited to form neointima in response to 
AGP. There are some controversies about the contribution of VPCs (Daniel et al., 2010, 
Iwata et al., 2010); therefore, further studies are needed to elucidate the role of LPA 
GPCR and PPAR" in the regulation of VPCs. 
 
These observations detailed in this present chapter were intended to point to the 
intracellular signaling role of LPA and its analogs. Thus, LPAs fulfill dual roles as 
mediators through the activation of cell surface GPCRs and as second messenger 
intracellularly through the activation/inhibition of PPAR". Overall, our findings may 
provide a novel mechanism for the regulation of PPAR" and they open novel therapeutic 
opportunities. Further clarification of the PLD2-CPA axis could lead us to the possibility 
of synthesizing novel medicines acting on PPAR". 
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Figure 4-9 Schematic diagram of the PPAR! signaling 
 
LPA, AGP, and ROSI activate PPAR" and promote downstream signals, whereas CPA 
negatively regulates PPAR". CPA stabilizes PPAR"-SMRT corepressor complex and 
inhibits PPAR"-mediated post signal transduction. 
 
 
 
 
81 
LIST OF REFERENCES 
 
 
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, 
Glass CK, Brewer HB, Jr., Gonzalez FJ (2002) Conditional disruption of the 
peroxisome proliferator-activated receptor gamma gene in mice results in lowered 
expression of ABCA1, ABCG1, and apoE in macrophages and reduced 
cholesterol efflux. Mol Cell Biol 22:2607-2619. 
Alexander JS, Patton WF, Christman BW, Cuiper LL, Haselton FR (1998) 
Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro. 
Am J Physiol 274:H115-122. 
Angeli V, Llodra J, Rong JX, Satoh K, Ishii S, Shimizu T, Fisher EA, Randolph GJ 
(2004) Dyslipidemia associated with atherosclerotic disease systemically alters 
dendritic cell mobilization. Immunity 21:561-574. 
Anliker B, Chun J (2004) Cell surface receptors in lysophospholipid signaling. Semin 
Cell Dev Biol 15:457-465. 
Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, 
Taguchi R, Arai H (2002) Serum lysophosphatidic acid is produced through 
diverse phospholipase pathways. J Biol Chem 277:48737-48744. 
Asami-Miyagishi R, Iseki S, Usui M, Uchida K, Kubo H, Morita I (2004) Expression and 
function of PPARgamma in rat placental development. Biochem Biophys Res 
Commun 315:497-501. 
Asmis R, Begley JG, Jelk J, Everson WV (2005) Lipoprotein aggregation protects human 
monocyte-derived macrophages from oxLDL-induced cytotoxicity. J Lipid Res 
46:1124-1132. 
Baim D, Brady TJ, Casscells SW, Dunne M, Fayad Z, Fuster V, Gazelle S, Heldman A, 
Hatsukami T, Kinlay S, Lafont A, Lee R, Libby P, Meier B, Muller JE, Naghavi 
M, O'Donnell C, Perin E, Rekhter M, Rumberger J, Russell M, Schwartz R, 
Selwyn A, Strauss HW, Tearney G, Tomaru T, Tuzcu EM, Wasserman B (2002) 
Thoughts on the role of the healing professions and the events of September 11, 
2001. Circulation 105:1509-1510. 
Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ (2001) Direct quantitative 
analysis of lysophosphatidic acid molecular species by stable isotope dilution 
electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem 
292:287-295. 
 
 
 
82 
Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, Uchiyama A, 
Murakami-Murofushi K, Koh E, Bandle RW, Byun HS, Bittman R, Fan D, Murph 
M, Mills GB, Tigyi G (2006) Carba analogs of cyclic phosphatidic acid are 
selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol 
Chem 281:22786-22793. 
Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM, Bonfrer JM, 
Bais E, Moolenaar WH, Tigyi G (2002) Plasma lysophosphatidic acid 
concentration and ovarian cancer. JAMA 287:3081-3082. 
Baker PR, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C, Sweeney S, 
Long MH, Iles KE, Baker LM, Branchaud BP, Chen YE, Freeman BA (2005) 
Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated 
fatty acid derivatives exist in human blood and urine and serve as endogenous 
peroxisome proliferator-activated receptor ligands. J Biol Chem 280:42464-
42475. 
Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K (2000) Lysophosphatidic acid 
(LPA) receptors of the EDG family are differentially activated by LPA species. 
Structure-activity relationship of cloned LPA receptors. FEBS Lett 478:159-165. 
Banno Y, Takuwa Y, Akao Y, Okamoto H, Osawa Y, Naganawa T, Nakashima S, Suh 
PG, Nozawa Y (2001) Involvement of phospholipase D in 
sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and 
Akt in Chinese hamster ovary cells overexpressing EDG3. J Biol Chem 
276:35622-35628. 
Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can 
J Biochem Physiol 37:911-917. 
Bolen AL, Naren AP, Yarlagadda S, Beranova-Giorgianni S, Chen L, Norman D, Baker 
DL, Rowland MM, Best MD, Sano T, Tsukahara T, Liliom K, Igarashi Y, Tigyi 
G (2011) The phospholipase A1 activity of lysophospholipase A-I links platelet 
activation to LPA production during blood coagulation. J Lipid Res 52:958-970. 
Boullier A, Gillotte KL, Horkko S, Green SR, Friedman P, Dennis EA, Witztum JL, 
Steinberg D, Quehenberger O (2000) The binding of oxidized low density 
lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are 
associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 
275:9163-9169. 
Breen DM, Chan KK, Dhaliwall JK, Ward MR, Al Koudsi N, Lam L, De Souza M, 
Ghanim H, Dandona P, Stewart DJ, Bendeck MP, Giacca A (2009) Insulin 
increases reendothelialization and inhibits cell migration and neointimal growth 
after arterial injury. Arterioscler Thromb Vasc Biol 29:1060-1066. 
 
 
83 
Brown FD, Thompson N, Saqib KM, Clark JM, Powner D, Thompson NT, Solari R, 
Wakelam MJ (1998) Phospholipase D1 localises to secretory granules and 
lysosomes and is plasma-membrane translocated on cellular stimulation. Curr 
Biol 8:835-838. 
Camp HS, Ren D, Leff T (2002) Adipogenesis and fat-cell function in obesity and 
diabetes. Trends Mol Med 8:442-447. 
Carrigan SO, Pink DB, Stadnyk AW (2007) Neutrophil transepithelial migration in 
response to the chemoattractant fMLP but not C5a is phospholipase D-dependent 
and related to the use of CD11b/CD18. J Leukoc Biol 82:1575-1584. 
Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF 
(2009) Identification of a physiologically relevant endogenous ligand for 
PPARalpha in liver. Cell 138:476-488. 
Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear 
hormone receptors. Nature 377:454-457. 
Chen X, Yang XY, Wang ND, Ding C, Yang YJ, You ZJ, Su Q, Chen JH (2003) Serum 
lysophosphatidic acid concentrations measured by dot immunogold filtration 
assay in patients with acute myocardial infarction. Scand J Clin Lab Invest 
63:497-503. 
Cheng Y, Makarova N, Tsukahara R, Guo H, E S, Farrar P, Balazs L, Zhang C, Tigyi G 
(2009) Lysophosphatidic acid-induced arterial wall remodeling: requirement of 
PPARgamma but not LPA1 or LPA2 GPCR. Cell Signal 21:1874-1884. 
Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, 
Mosley AN, Chun J (2010) LPA receptors: subtypes and biological actions. Annu 
Rev Pharmacol Toxicol 50:157-186. 
Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH (2010) International union of basic 
and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. 
Pharmacol Rev 62:579-587. 
Cockcroft S (1996) ARF-regulated phospholipase D: a potential role in membrane traffic. 
Chem Phys Lipids 80:59-80. 
Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y, Bar-Sagi D, Morris 
AJ, Frohman MA (1997) Phospholipase D2, a distinct phospholipase D isoform 
with novel regulatory properties that provokes cytoskeletal reorganization. Curr 
Biol 7:191-201. 
Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J (2000) Requirement for the 
LPA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl 
Acad Sci U S A 97:13384-13389. 
 
 
84 
Contos JJ, Ishii I, Fukushima N, Kingsbury MA, Ye X, Kawamura S, Brown JH, Chun J 
(2002) Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) 
lysophosphatidic acid receptor knockout mice: signaling deficits without obvious 
phenotypic abnormality attributable to lpa(2). Mol Cell Biol 22:6921-6929. 
Cremers B, Flesch M, Kostenis E, Maack C, Niedernberg A, Stoff A, Sudkamp M, 
Wendler O, Bohm M (2003) Modulation of myocardial contractility by 
lysophosphatidic acid (LPA). J Mol Cell Cardiol 35:71-80. 
Cui MZ, Laag E, Sun L, Tan M, Zhao G, Xu X (2006) Lysophosphatidic acid induces 
early growth response gene 1 expression in vascular smooth muscle cells: CRE 
and SRE mediate the transcription. Arterioscler Thromb Vasc Biol 26:1029-1035. 
Daniel JM, Bielenberg W, Stieger P, Weinert S, Tillmanns H, Sedding DG (2010) Time-
course analysis on the differentiation of bone marrow-derived progenitor cells 
into smooth muscle cells during neointima formation. Arterioscler Thromb Vasc 
Biol 30:1890-1896. 
Davies SS, Pontsler AV, Marathe GK, Harrison KA, Murphy RC, Hinshaw JC, Prestwich 
GD, Hilaire AS, Prescott SM, Zimmerman GA, McIntyre TM (2001) Oxidized 
alkyl phospholipids are specific, high affinity peroxisome proliferator-activated 
receptor gamma ligands and agonists. J Biol Chem 276:16015-16023. 
Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, 
Staels B (1999) Peroxisome proliferator-activated receptor activators inhibit 
thrombin-induced endothelin-1 production in human vascular endothelial cells by 
inhibiting the activator protein-1 signaling pathway. Circ Res 85:394-402. 
Deng W, E S, Tsukahara R, Valentine WJ, Durgam G, Gududuru V, Balazs L, Manickam 
V, Arsura M, VanMiddlesworth L, Johnson LR, Parrill AL, Miller DD, Tigyi G 
(2007) The lysophosphatidic acid type 2 receptor is required for protection against 
radiation-induced intestinal injury. Gastroenterology 132:1834-1851. 
Diep QN, Schiffrin EL (2001) Increased expression of peroxisome proliferator-activated 
receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats. 
Hypertension 38:249-254. 
Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M (1999) Identification 
of nuclear receptor corepressor as a peroxisome proliferator-activated receptor 
alpha interacting protein. J Biol Chem 274:15901-15907. 
Du G, Huang P, Liang BT, Frohman MA (2004) Phospholipase D2 localizes to the 
plasma membrane and regulates angiotensin II receptor endocytosis. Mol Biol 
Cell 15:1024-1030. 
Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B (2002) The role of PPARs in 
atherosclerosis. Trends Mol Med 8:422-430. 
 
 
85 
E S, Lai YJ, Tsukahara R, Chen CS, Fujiwara Y, Yue J, Yu JH, Guo H, Kihara A, Tigyi 
G, Lin FT (2009) Lysophosphatidic acid 2 receptor-mediated supramolecular 
complex formation regulates its antiapoptotic effect. J Biol Chem 284:14558-
14571. 
Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH (1993) The bioactive phospholipid 
lysophosphatidic acid is released from activated platelets. Biochem J 291 
(Pt 3):677-680. 
Eisen SF, Brown HA (2002) Selective estrogen receptor (ER) modulators differentially 
regulate phospholipase D catalytic activity in ER-negative breast cancer cells. 
Mol Pharmacol 62:911-920. 
Evans RM (2005) The nuclear receptor superfamily: a rosetta stone for physiology. Mol 
Endocrinol 19:1429-1438. 
Exton JH (2002) Regulation of phospholipase D. FEBS Lett 531:58-61. 
Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville 
M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, 
Auwerx J (1997) The organization, promoter analysis, and expression of the 
human PPARgamma gene. J Biol Chem 272:18779-18789. 
Fischer DJ, Liliom K, Guo Z, Nusser N, Virag T, Murakami-Murofushi K, Kobayashi S, 
Erickson JR, Sun G, Miller DD, Tigyi G (1998) Naturally occurring analogs of 
lysophosphatidic acid elicit different cellular responses through selective 
activation of multiple receptor subtypes. Mol Pharmacol 54:979-988. 
Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, Baker DL, Bautista D, Parrill AL, 
Tigyi G (2001) Short-chain phosphatidates are subtype-selective antagonists of 
lysophosphatidic acid receptors. Mol Pharmacol 60:776-784. 
Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte 
determination factor PPAR gamma. Cell 83:803-812. 
Friedman P, Haimovitz R, Markman O, Roberts MF, Shinitzky M (1996) Conversion of 
lysophospholipids to cyclic lysophosphatidic acid by phospholipase D. J Biol 
Chem 271:953-957. 
Froberg K, Andersen LB (2005) Mini review: physical activity and fitness and its 
relations to cardiovascular disease risk factors in children. Int J Obes (Lond) 29 
Suppl 2:S34-39. 
Frohman MA, Sung TC, Morris AJ (1999) Mammalian phospholipase D structure and 
regulation. Biochim Biophys Acta 1439:175-186. 
 
 
86 
Fueller M, Wang DA, Tigyi G, Siess W (2003) Activation of human monocytic cells by 
lysophosphatidic acid and sphingosine-1-phosphate. Cell Signal 15:367-375. 
Fujiwara Y, Sardar V, Tokumura A, Baker D, Murakami-Murofushi K, Parrill A, Tigyi G 
(2005) Identification of residues responsible for ligand recognition and 
regioisomeric selectivity of lysophosphatidic acid receptors expressed in 
mammalian cells. J Biol Chem 280:35038-35050. 
Fujiwara Y, Sebok A, Meakin S, Kobayashi T, Murakami-Murofushi K, Tigyi G (2003) 
Cyclic phosphatidic acid elicits neurotrophin-like actions in embryonic 
hippocampal neurons. J Neurochem 87:1272-1283. 
Fukushima N, Kimura Y, Chun J (1998) A single receptor encoded by vzg-1/lpa1/edg-2 
couples to G proteins and mediates multiple cellular responses to 
lysophosphatidic acid. Proc Natl Acad Sci U S A 95:6151-6156. 
Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan 
MA, Perez AT, Jacober SJ (2005) A comparison of lipid and glycemic effects of 
pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. 
Diabetes Care 28:1547-1554. 
Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, Tonnel AB, Trottein 
F (2001) Peroxisome proliferator-activated receptor gamma activators affect the 
maturation of human monocyte-derived dendritic cells. Eur J Immunol 31:2857-
2865. 
Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, 
Breyer MD (2005) Thiazolidinediones expand body fluid volume through 
PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 
11:861-866. 
Gueguen G, Gaige B, Grevy JM, Rogalle P, Bellan J, Wilson M, Klaebe A, Pont F, 
Simon MF, Chap H (1999) Structure-activity analysis of the effects of 
lysophosphatidic acid on platelet aggregation. Biochemistry 38:8440-8450. 
Gugger M, White R, Song S, Waser B, Cescato R, Riviere P, Reubi JC (2008) GPR87 is 
an overexpressed G-protein coupled receptor in squamous cell carcinoma of the 
lung. Dis Markers 24:41-50. 
Guo H, Makarova N, Cheng Y, E S, Ji RR, Zhang C, Farrar P, Tigyi G (2008) The early 
and late stages in phenotypic modulation of vascular smooth muscle cells: 
differential roles for lysophosphatidic acid. Biochim Biophys Acta 1781:571-581. 
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect 
of rosiglitazone treatment on nontraditional markers of cardiovascular disease in 
patients with type 2 diabetes mellitus. Circulation 106:679-684. 
 
 
87 
Haseruck N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, Siess W 
(2004) The plaque lipid lysophosphatidic acid stimulates platelet activation and 
platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and 
P2Y12 receptors. Blood 103:2585-2592. 
Hausmann J, Kamtekar S, Christodoulou E, Day JE, Wu T, Fulkerson Z, Albers HM, van 
Meeteren LA, Houben AJ, van Zeijl L, Jansen S, Andries M, Hall T, Pegg LE, 
Benson TE, Kasiem M, Harlos K, Kooi CW, Smyth SS, Ovaa H, Bollen M, 
Morris AJ, Moolenaar WH, Perrakis A (2011) Structural basis of substrate 
discrimination and integrin binding by autotaxin. Nat Struct Mol Biol 18:198-204. 
Hayashi K, Takahashi M, Nishida W, Yoshida K, Ohkawa Y, Kitabatake A, Aoki J, Arai 
H, Sobue K (2001) Phenotypic modulation of vascular smooth muscle cells 
induced by unsaturated lysophosphatidic acids. Circ Res 89:251-258. 
Hodgkinson CP, Ye S (2003) Microarray analysis of peroxisome proliferator-activated 
receptor-gamma induced changes in gene expression in macrophages. Biochem 
Biophys Res Commun 308:505-510. 
Huang P, Frohman MA (2007) The potential for phospholipase D as a new therapeutic 
target. Expert Opin Ther Targets 11:707-716. 
Ishihara R, Tatsuta M, Iishi H, Baba M, Uedo N, Higashino K, Mukai M, Ishiguro S, 
Kobayashi S, Murakami-Murofushi K (2004) Attenuation by cyclic phosphatidic 
acid of peritoneal metastasis of azoxymethane-induced intestinal cancers in 
Wistar rats. Int J Cancer 110:188-193. 
Ishii I, Contos JJ, Fukushima N, Chun J (2000) Functional comparisons of the 
lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and 
LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol 
Pharmacol 58:895-902. 
Ishii I, Fukushima N, Ye X, Chun J (2004) Lysophospholipid receptors: signaling and 
biology. Annu Rev Biochem 73:321-354. 
Ishii S, Noguchi K, Yanagida K (2009) Non-Edg family lysophosphatidic acid (LPA) 
receptors. Prostaglandins Other Lipid Mediat 89:57-65. 
Iwata H, Manabe I, Fujiu K, Yamamoto T, Takeda N, Eguchi K, Furuya A, Kuro-o M, 
Sata M, Nagai R (2010) Bone marrow-derived cells contribute to vascular 
inflammation but do not differentiate into smooth muscle cell lineages. 
Circulation 122:2048-2057. 
Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, Shiota M, Kesterson 
RA, Kahn BB, Magnuson MA (2005) Deletion of PPARgamma in adipose tissues 
of mice protects against high fat diet-induced obesity and insulin resistance. Proc 
Natl Acad Sci U S A 102:6207-6212. 
 
 
88 
Jones JR, Shelton KD, Guan Y, Breyer MD, Magnuson MA (2002) Generation and 
functional confirmation of a conditional null PPARgamma allele in mice. Genesis 
32:134-137. 
Kaneyuki U, Ueda S, Yamagishi S, Kato S, Fujimura T, Shibata R, Hayashida A, 
Yoshimura J, Kojiro M, Oshima K, Okuda S (2007) Pitavastatin inhibits 
lysophosphatidic acid-induced proliferation and monocyte chemoattractant 
protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated 
reactive oxygen species generation. Vascul Pharmacol 46:286-292. 
Kiec-Wilk B, Dembinska-Kiec A, Olszanecka A, Bodzioch M, Kawecka-Jaszcz K (2005) 
The selected pathophysiological aspects of PPARs activation. J Physiol 
Pharmacol 56:149-162. 
Kim J, Keys JR, Eckhart AD (2006) Vascular smooth muscle migration and proliferation 
in response to lysophosphatidic acid (LPA) is mediated by LPA receptors 
coupling to Gq. Cell Signal 18:1695-1701. 
Kim JH, Lee BD, Kim Y, Lee SD, Suh PG, Ryu SH (1999) Cytosolic phospholipase A2-
mediated regulation of phospholipase D2 in leukocyte cell lines. J Immunol 
163:5462-5470. 
Kobayashi T, Tanaka-Ishii R, Taguchi R, Ikezawa H, Murakami-Murofushi K (1999) 
Existence of a bioactive lipid, cyclic phosphatidic acid, bound to human serum 
albumin. Life Sci 65:2185-2191. 
Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, Owman C, 
Sillard R, Leeb-Lundberg LM, Olde B (2006) Lysophosphatidic acid binds to and 
activates GPR92, a G protein-coupled receptor highly expressed in 
gastrointestinal lymphocytes. J Pharmacol Exp Ther 318:619-628. 
Kou R, Igarashi J, Michel T (2002) Lysophosphatidic acid and receptor-mediated 
activation of endothelial nitric-oxide synthase. Biochemistry 41:4982-4988. 
Lala DS, Mukherjee R, Schulman IG, Koch SS, Dardashti LJ, Nadzan AM, Croston GE, 
Evans RM, Heyman RA (1996) Activation of specific RXR heterodimers by an 
antagonist of RXR homodimers. Nature 383:450-453. 
Lautamaki R, Airaksinen KE, Seppanen M, Toikka J, Luotolahti M, Ball E, Borra R, 
Harkonen R, Iozzo P, Stewart M, Knuuti J, Nuutila P (2005) Rosiglitazone 
improves myocardial glucose uptake in patients with type 2 diabetes and coronary 
artery disease: a 16-week randomized, double-blind, placebo-controlled study. 
Diabetes 54:2787-2794. 
Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, 
Hsueh WA (2000) Expression and function of PPARgamma in rat and human 
vascular smooth muscle cells. Circulation 101:1311-1318. 
 
 
89 
Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J, Park KW, Cho HJ, Kang HJ, 
Park YB, Kim HS (2009) New mechanism of rosiglitazone to reduce neointimal 
hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition 
of MMP-9. Arterioscler Thromb Vasc Biol 29:472-479. 
Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006) GPR92 as a new G12/13- and 
Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol 
Chem 281:23589-23597. 
Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen CK, Fang 
X (2008) Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol 
Biol Cell 19:5435-5445. 
Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, 
Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, 
Therapontos C, Willson TM, Blanchard SG (2002) Functional consequences of 
cysteine modification in the ligand binding sites of peroxisome proliferator 
activated receptors by GW9662. Biochemistry 41:6640-6650. 
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 
(1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome 
proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-
12956. 
Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123:993-999. 
Leslie DS, Dascher CC, Cembrola K, Townes MA, Hava DL, Hugendubler LC, Mueller 
E, Fox L, Roura-Mir C, Moody DB, Vincent MS, Gumperz JE, Illarionov PA, 
Besra GS, Reynolds CG, Brenner MB (2008) Serum lipids regulate dendritic cell 
CD1 expression and function. Immunology 125:289-301. 
Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, 
Purushothaman KR, Fuster V, Moreno PR (2007) Haptoglobin genotype is a 
determinant of iron, lipid peroxidation, and macrophage accumulation in the 
atherosclerotic plaque. Arterioscler Thromb Vasc Biol 27:134-140. 
Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000) Peroxisome 
proliferator-activated receptor gamma ligands inhibit development of 
atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531. 
Li AC, Glass CK (2002) The macrophage foam cell as a target for therapeutic 
intervention. Nat Med 8:1235-1242. 
Li Y, Zhang J, Schopfer FJ, Martynowski D, Garcia-Barrio MT, Kovach A, Suino-Powell 
K, Baker PR, Freeman BA, Chen YE, Xu HE (2008) Molecular recognition of 
nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol 15:865-867. 
 
 
90 
Lim S, Jin CJ, Kim M, Chung SS, Park HS, Lee IK, Lee CT, Cho YM, Lee HK, Park KS 
(2006) PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth 
muscle cell proliferation, and reduces neointima formation after balloon injury in 
rats. Arterioscler Thromb Vasc Biol 26:808-813. 
Lin CI, Chen CN, Chen JH, Lee H (2006) Lysophospholipids increase IL-8 and MCP-1 
expressions in human umbilical cord vein endothelial cells through an IL-1-
dependent mechanism. J Cell Biochem 99:1216-1232. 
Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H (2008) 
Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube 
formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB 
activation- and EGFR transactivation-dependent mechanisms. Cell Signal 
20:1804-1814. 
Lin CI, Chen CN, Lin PW, Chang KJ, Hsieh FJ, Lee H (2007) Lysophosphatidic acid 
regulates inflammation-related genes in human endothelial cells through LPA1 
and LPA3. Biochem Biophys Res Commun 363:1001-1008. 
Lin DA, Boyce JA (2005) IL-4 regulates MEK expression required for lysophosphatidic 
acid-mediated chemokine generation by human mast cells. J Immunol 175:5430-
5438. 
Liscovitch M (1996) Phospholipase D: role in signal transduction and membrane traffic. J 
Lipid Mediat Cell Signal 14:215-221. 
Liscovitch M, Czarny M, Fiucci G, Tang X (2000) Phospholipase D: molecular and cell 
biology of a novel gene family. Biochem J 345 (Pt 3):401-415. 
Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ (2004) Emigration of 
monocyte-derived cells from atherosclerotic lesions characterizes regressive, but 
not progressive, plaques. Proc Natl Acad Sci U S A 101:11779-11784. 
Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J (1998) Peroxisome proliferator-
activated receptor gamma activators inhibit gene expression and migration in 
human vascular smooth muscle cells. Circ Res 83:1097-1103. 
McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, 
Hama K, Aoki J, Arai H, Prestwich GD (2003) Identification of an intracellular 
receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma 
agonist. Proc Natl Acad Sci U S A 100:131-136. 
 
 
 
 
 
91 
Medina-Gomez G, Virtue S, Lelliott C, Boiani R, Campbell M, Christodoulides C, Perrin 
C, Jimenez-Linan M, Blount M, Dixon J, Zahn D, Thresher RR, Aparicio S, 
Carlton M, Colledge WH, Kettunen MI, Seppanen-Laakso T, Sethi JK, O'Rahilly 
S, Brindle K, Cinti S, Oresic M, Burcelin R, Vidal-Puig A (2005) The link 
between nutritional status and insulin sensitivity is dependent on the adipocyte-
specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes 
54:1706-1716. 
Meredith D, Panchatcharam M, Miriyala S, Tsai YS, Morris AJ, Maeda N, Stouffer GA, 
Smyth SS (2009) Dominant-negative loss of PPARgamma function enhances 
smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler 
Thromb Vasc Biol 29:465-471. 
Meydani M (2001) Vitamin E and atherosclerosis: beyond prevention of LDL oxidation. 
J Nutr 131:366S-368S. 
Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory 
effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin 
Endocrinol Metab 83:1818-1820. 
Monovich L, Mugrage B, Quadros E, Toscano K, Tommasi R, LaVoie S, Liu E, Du Z, 
LaSala D, Boyar W, Steed P (2007) Optimization of halopemide for 
phospholipase D2 inhibition. Bioorg Med Chem Lett 17:2310-2311. 
Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone 
DS, Mortensen RM, Spiegelman BM, Freeman MW (2001) The role of PPAR-
gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47. 
Muehlich S, Schneider N, Hinkmann F, Garlichs CD, Goppelt-Struebe M (2004) 
Induction of connective tissue growth factor (CTGF) in human endothelial cells 
by lysophosphatidic acid, sphingosine-1-phosphate, and platelets. Atherosclerosis 
175:261-268. 
Mukai M, Imamura F, Ayaki M, Shinkai K, Iwasaki T, Murakami-Murofushi K, 
Murofushi H, Kobayashi S, Yamamoto T, Nakamura H, Akedo H (1999) 
Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid 
(cyclic LPA). Int J Cancer 81:918-922. 
Munnik T, Arisz SA, De Vrije T, Musgrave A (1995) G protein activation stimulates 
phospholipase D signaling in plants. The Plant Cell 7:2197-2210. 
Murakami M, Shiraishi A, Tabata K, Fujita N (2008) Identification of the orphan GPCR, 
P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid 
receptor. Biochem Biophys Res Commun 371:707-712. 
Murakami-Murofushi K, Mukai M, Kobayashi S, Kobayashi T, Tigyi G, Murofushi H 
(2000) A novel lipid mediator, cyclic phosphatidic acid (cPA), and its biological 
functions. Ann N Y Acad Sci 905:319-321. 
 
 
92 
Murakami-Murofushi K, Uchiyama A, Fujiwara Y, Kobayashi T, Kobayashi S, Mukai 
M, Murofushi H, Tigyi G (2002) Biological functions of a novel lipid mediator, 
cyclic phosphatidic acid. Biochim Biophys Acta 1582:1-7. 
Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates 
macrophage gene expression through ligand activation of PPARgamma. Cell 
93:229-240. 
Nakane S, Tokumura A, Waku K, Sugiura T (2001) Hen egg yolk and white contain high 
amounts of lysophosphatidic acids, growth factor-like lipids: distinct molecular 
species compositions. Lipids 36:413-419. 
Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H (2005) Rosiglitazone effects on 
blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes 
Res Clin Pract 70:20-25. 
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction 
and death from cardiovascular causes. N Engl J Med 356:2457-2471. 
Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for 
myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191-
1201. 
Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, 
Willson TM, Glass CK, Milburn MV (1998) Ligand binding and co-activator 
assembly of the peroxisome proliferator-activated receptor-gamma. Nature 
395:137-143. 
Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, Panchatcharam M, Fulkerson 
Z, Berdyshev E, Natarajan V, Fang X, van Meeteren LA, Moolenaar WH, Mills 
GB, Morris AJ, Smyth SS (2009) Autotaxin/lysopholipase D and 
lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem 
284:7385-7394. 
Panchatcharam M, Miriyala S, Yang F, Rojas M, End C, Vallant C, Dong A, Lynch K, 
Chun J, Morris AJ, Smyth SS (2008) Lysophosphatidic acid receptors 1 and 2 
play roles in regulation of vascular injury responses but not blood pressure. Circ 
Res 103:662-670. 
Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, 
Greaves DR (2008) Galectin-3 is an amplifier of inflammation in atherosclerotic 
plaque progression through macrophage activation and monocyte 
chemoattraction. Arterioscler Thromb Vasc Biol 28:433-440. 
Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K, Hillmer 
AM, Molderings GJ, Franz T, Ramirez A, Nurnberg P, Nothen MM, Betz RC 
(2008) G protein-coupled receptor P2Y5 and its ligand LPA are involved in 
maintenance of human hair growth. Nat Genet 40:329-334. 
 
 
93 
Plevin R, Cook SJ, Palmer S, Wakelam MJ (1991) Multiple sources of sn-1,2-
diacylglycerol in platelet-derived-growth-factor-stimulated Swiss 3T3 fibroblasts. 
Evidence for activation of phosphoinositidase C and phosphatidylcholine-specific 
phospholipase D. Biochem J 279 (Pt 2):559-565. 
Rangwala SM, Lazar MA (2004) Peroxisome proliferator-activated receptor gamma in 
diabetes and metabolism. Trends Pharmacol Sci 25:331-336. 
Ricote M, Glass CK (2007) PPARs and molecular mechanisms of transrepression. 
Biochim Biophys Acta 1771:926-935. 
Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, 
Glass CK (1998) Expression of the peroxisome proliferator-activated receptor 
gamma (PPARgamma) in human atherosclerosis and regulation in macrophages 
by colony stimulating factors and oxidized low density lipoprotein. Proc Natl 
Acad Sci U S A 95:7614-7619. 
Riebeling C, Morris AJ, Shields D (2009) Phospholipase D in the Golgi apparatus. 
Biochim Biophys Acta 1791:876-880. 
Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, Lee H, Tigyi G, Berliner 
JA (1999) Lysophosphatidic acid as a regulator of endothelial/leukocyte 
interaction. Lab Invest 79:1227-1235. 
Rosen ED, MacDougald OA (2006) Adipocyte differentiation from the inside out. Nat 
Rev Mol Cell Biol 7:885-896. 
Ross R (1999) Atherosclerosis is an inflammatory disease. Am Heart J 138:S419-420. 
Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G, Siess W (2003) Subtype-
selective antagonists of lysophosphatidic acid receptors inhibit platelet activation 
triggered by the lipid core of atherosclerotic plaques. Circulation 108:741-747. 
Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M (2001) Circulating smooth muscle 
progenitor cells contribute to atherosclerosis. Nat Med 7:382-383. 
Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G (2002) 
Multiple mechanisms linked to platelet activation result in lysophosphatidic acid 
and sphingosine 1-phosphate generation in blood. J Biol Chem 277:21197-21206. 
Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas 
PC, Kazakos KA, Yovos JG, Tourkantonis AA (2005) The effect of rosiglitazone 
on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and 
hypertension. An open-label observational study. Metabolism 54:1236-1242. 
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, 
Singer S, Fletcher C, Spiegelman BM (1998) Differentiation and reversal of 
malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052. 
 
 
94 
Schneider A, Zhang Y, Guan Y, Davis LS, Breyer MD (2003) Differential, inducible 
gene targeting in renal epithelia, vascular endothelium, and viscera of Mx1Cre 
mice. Am J Physiol Renal Physiol 284:F411-417. 
Schulze C, Smales C, Rubin LL, Staddon JM (1997) Lysophosphatidic acid increases 
tight junction permeability in cultured brain endothelial cells. J Neurochem 
68:991-1000. 
Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, Kuriakose G, Tall AR, Tabas 
IA (2009) Macrophage deficiency of p38alpha MAPK promotes apoptosis and 
plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest 
119:886-898. 
Shimada H, Rajagopalan LE (2010) Rho-kinase mediates lysophosphatidic acid-induced 
IL-8 and MCP-1 production via p38 and JNK pathways in human endothelial 
cells. FEBS Lett 584:2827-2832. 
Shinkuma S, Akiyama M, Inoue A, Aoki J, Natsuga K, Nomura T, Arita K, Abe R, Ito K, 
Nakamura H, Ujiie H, Shibaki A, Suga H, Tsunemi Y, Nishie W, Shimizu H 
(2010) Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability 
of PA-PLA1alpha in autosomal recessive hypotrichosis. Hum Mutat 31:602-610. 
Siess W (2002) Athero- and thrombogenic actions of lysophosphatidic acid and 
sphingosine-1-phosphate. Biochim Biophys Acta 1582:204-215. 
Siess W (2006) Platelet interaction with bioactive lipids formed by mild oxidation of 
low-density lipoprotein. Pathophysiol Haemost Thromb 35:292-304. 
Siess W, Tigyi G (2004) Thrombogenic and atherogenic activities of lysophosphatidic 
acid. J Cell Biochem 92:1086-1094. 
Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, 
Aepfelbacher M (1999) Lysophosphatidic acid mediates the rapid activation of 
platelets and endothelial cells by mildly oxidized low density lipoprotein and 
accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A 96:6931-
6936. 
Slaaby R, Du G, Altshuller YM, Frohman MA, Seedorf K (2000) Insulin-induced 
phospholipase D1 and phospholipase D2 activity in human embryonic kidney-293 
cells mediated by the phospholipase C gamma and protein kinase C alpha 
signalling cascade. Biochem J 351 (Pt 3):613-619. 
Spector AA (2003) Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation 
108:641-643. 
 
 
 
95 
Stapleton CM, Mashek DG, Wang S, Nagle CA, Cline GW, Thuillier P, Leesnitzer LM, 
Li LO, Stimmel JB, Shulman GI, Coleman RA (2011) Lysophosphatidic acid 
activates peroxisome proliferator activated receptor-gamma in CHO cells that 
over-express glycerol 3-phosphate acyltransferase-1. PloS one 6:e18932. 
Stocker R, Keaney JF, Jr. (2004) Role of oxidative modifications in atherosclerosis. 
Physiol Rev 84:1381-1478. 
Su W, Yeku O, Olepu S, Genna A, Park JS, Ren H, Du G, Gelb MH, Morris AJ, 
Frohman MA (2009) 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a 
phospholipase D pharmacological inhibitor that alters cell spreading and inhibits 
chemotaxis. Mol Pharmacol 75:437-446. 
Subramanian P, Karshovska E, Reinhard P, Megens RT, Zhou Z, Akhtar S, Schumann U, 
Li X, van Zandvoort M, Ludin C, Weber C, Schober A (2010) Lysophosphatidic 
acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle 
progenitor cell recruitment in neointima formation. Circ Res 107:96-105. 
Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A, Hanahan DJ 
(1999) Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in 
rat brain and comparison of their biological activities toward cultured neural cells. 
Biochim Biophys Acta 1440:194-204. 
Sumida H, Noguchi K, Kihara Y, Abe M, Yanagida K, Hamano F, Sato S, Tamaki K, 
Morishita Y, Kano MR, Iwata C, Miyazono K, Sakimura K, Shimizu T, Ishii S 
(2010) LPA4 regulates blood and lymphatic vessel formation during mouse 
embryogenesis. Blood 116:5060-5070. 
Szatmari I, Gogolak P, Im JS, Dezso B, Rajnavolgyi E, Nagy L (2004) Activation of 
PPARgamma specifies a dendritic cell subtype capable of enhanced induction of 
iNKT cell expansion. Immunity 21:95-106. 
Tabata K, Baba K, Shiraishi A, Ito M, Fujita N (2007) The orphan GPCR GPR87 was 
deorphanized and shown to be a lysophosphatidic acid receptor. Biochem 
Biophys Res Commun 363:861-866. 
Tai TA, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown 
HR, Lehmann JM, Kliewer SA, Morris DC, Graves RA (1996) Activation of the 
nuclear receptor peroxisome proliferator-activated receptor gamma promotes 
brown adipocyte differentiation. J Biol Chem 271:29909-29914. 
Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, 
Arai H (2006) Autotaxin stabilizes blood vessels and is required for embryonic 
vasculature by producing lysophosphatidic acid. J Biol Chem 281:25822-25830. 
Tigyi G (2010) Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 
161:241-270. 
 
 
96 
Tigyi G, Miledi R (1992) Lysophosphatidates bound to serum albumin activate 
membrane currents in Xenopus oocytes and neurite retraction in PC12 
pheochromocytoma cells. J Biol Chem 267:21360-21367. 
Tigyi G, Parrill AL (2003) Molecular mechanisms of lysophosphatidic acid action. Prog 
Lipid Res 42:498-526. 
Tokumura A, Fukuzawa K, Akamatsu Y, Yamada S, Suzuki T, Tsukatani H (1978a) 
Identification of vasopressor phospholipid in crude soybean lecithin. Lipids 
13:468-472. 
Tokumura A, Fukuzawa K, Tsukatani H (1978b) Effects of synthetic and natural 
lysophosphatidic acids on the arterial blood pressure of different animal species. 
Lipids 13:572-574. 
Tokumura A, Harada K, Fukuzawa K, Tsukatani H (1983) Biphasic action of platelet-
activating factor on isolated guinea-pig ileum. Lipids 18:848-850. 
Tokumura A, Iimori M, Nishioka Y, Kitahara M, Sakashita M, Tanaka S (1994) 
Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle 
cells from rat aorta. Am J Physiol 267:C204-210. 
Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K 
(2002) Identification of human plasma lysophospholipase D, a lysophosphatidic 
acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol 
Chem 277:39436-39442. 
Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARgamma 
promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 
93:241-252. 
Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of 
PPARgamma. Annu Rev Biochem 77:289-312. 
Tsuda S, Okudaira S, Moriya-Ito K, Shimamoto C, Tanaka M, Aoki J, Arai H, 
Murakami-Murofushi K, Kobayashi T (2006) Cyclic phosphatidic acid is 
produced by autotaxin in blood. J Biol Chem 281:26081-26088. 
Tsukahara R, Tsukahahara T, Tigyi G (2011) Regulation of the nuclear hormone receptor 
PPARgamma by endogenous lysophosphatidic acids. In: Lysophospholipid 
receptors: Signaling and biochemistry, in press. NJ: Wiley. 
Tsukahara T, Tsukahara R, Fujiwara Y, Yue J, Cheng Y, Guo H, Bolen A, Zhang C, 
Balazs L, Re F, Du G, Frohman MA, Baker DL, Parrill AL, Uchiyama A, 
Kobayashi T, Murakami-Murofushi K, Tigyi G (2010) Phospholipase D2-
dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic 
phosphatidic acid. Mol Cell 39:421-432. 
 
 
97 
Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P, Yuan H, 
Baker DL, Li Z, Bittman R, Parrill A, Tigyi G (2006) Different residues mediate 
recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand 
binding domain of peroxisome proliferator-activated receptor gamma. J Biol 
Chem 281:3398-3407. 
Tzameli I, Fang H, Ollero M, Shi H, Hamm JK, Kievit P, Hollenberg AN, Flier JS (2004) 
Regulated production of a peroxisome proliferator-activated receptor-gamma 
ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J 
Biol Chem 279:36093-36102. 
Uchiyama A, Mukai M, Fujiwara Y, Kobayashi S, Kawai N, Murofushi H, Inoue M, 
Enoki S, Tanaka Y, Niki T, Kobayashi T, Tigyi G, Murakami-Murofushi K 
(2007) Inhibition of transcellular tumor cell migration and metastasis by novel 
carba-derivatives of cyclic phosphatidic acid. Biochim Biophys Acta 1771:103-
112. 
Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, 
Inoue K, Aoki J, Arai H (2002) Autotaxin has lysophospholipase D activity 
leading to tumor cell growth and motility by lysophosphatidic acid production. J 
Cell Biol 158:227-233. 
van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, Pettit 
TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J 
(2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel 
formation during development. Mol Cell Biol 26:5015-5022. 
van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW (2000) Role of RhoA and 
Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. 
Arterioscler Thromb Vasc Biol 20:E127-133. 
Vancura A, Carroll MA, Haldar D (1991) A lysophosphatidic acid-binding cytosolic 
protein stimulates mitochondrial glycerophosphate acyltransferase. Biochem 
Biophys Res Commu 175:339-343. 
Weatherman RV, Fletterick RJ, Scanlan TS (1999) Nuclear-receptor ligands and ligand-
binding domains. Annu Rev Biochem 68:559-581. 
Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, Parrill AL, Tigyi G, 
Fujiwara Y (2009) Unique ligand selectivity of the GPR92/LPA5 
lysophosphatidate receptor indicates role in human platelet activation. J Biol 
Chem 284:17304-17319. 
Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, Xu Y (2001) 
Electrospray ionization mass spectrometry analysis of lysophospholipids in 
human ascitic fluids: comparison of the lysophospholipid contents in malignant vs 
nonmalignant ascitic fluids. Anal Biochem 290:302-313. 
 
 
98 
Xu J, Kochanek DK, Murphy LS, Tejada-Vera B (2010) Deaths: Final Data for 2007. 
Natl Vital Stat Rep 58:1-136. 
Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, Taguchi R, 
Shimizu T, Ishii S (2009) Identification and characterization of a novel 
lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 284:17731-17741. 
Yang AH, Ishii I, Chun J (2002) In vivo roles of lysophospholipid receptors revealed by 
gene targeting studies in mice. Biochim Biophys Acta 1582:197-203. 
Yang JS, Gad H, Lee SY, Mironov A, Zhang L, Beznoussenko GV, Valente C, Turacchio 
G, Bonsra AN, Du G, Baldanzi G, Graziani A, Bourgoin S, Frohman MA, Luini 
A, Hsu VW (2008) A role for phosphatidic acid in COPI vesicle fission yields 
insights into Golgi maintenance. Nat Cell Biol 10:1146-1153. 
Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, 
Kennedy G, Arai H, Aoki J, Chun J (2005) LPA3-mediated lysophosphatidic acid 
signalling in embryo implantation and spacing. Nature 435:104-108. 
Ye X, Skinner MK, Kennedy G, Chun J (2008) Age-dependent loss of sperm production 
in mice via impaired lysophosphatidic acid signaling. Biol Reprod 79:328-336. 
Yokoyama K, Baker DL, Virag T, Liliom K, Byun H, Tigyi G, Bittman R (2002) 
Stereochemical properties of lysophosphatidic acid receptor activation and 
metabolism. Biochim Biophys Acta 1582:295-308. 
Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J, Arai H, Sobue K 
(2003) Vascular remodeling induced by naturally occurring unsaturated 
lysophosphatidic acid in vivo. Circulation 108:1746-1752. 
Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN (2005) The nuclear 
receptor corepressors NCoR and SMRT decrease peroxisome proliferator-
activated receptor gamma transcriptional activity and repress 3T3-L1 
adipogenesis. J Biol Chem 280:13600-13605. 
Yu S, Reddy JK (2007) Transcription coactivators for peroxisome proliferator-activated 
receptors. Biochim Biophys Acta 1771:936-951. 
Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, 
Gierschik P, Biessen EA, Weber C (2005) SDF-1alpha/CXCR4 axis is 
instrumental in neointimal hyperplasia and recruitment of smooth muscle 
progenitor cells. Circ Res 96:784-791. 
Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, Marathe GK, 
McIntyre TM, Xu Y, Prestwich GD, Byun HS, Bittman R, Tigyi G (2004) 
Lysophosphatidic acid induces neointima formation through PPARgamma 
activation. J Exp Med 199:763-774. 
 
 
99 
Zheng Y, Rodrik V, Toschi A, Shi M, Hui L, Shen Y, Foster DA (2006) Phospholipase D 
couples survival and migration signals in stress response of human cancer cells. J 
Biol Chem 281:15862-15868. 
Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, 
Heyll K, Chun J, Saulnier-Blache JS, Reinholz M, van Zandvoort M, Weber C, 
Schober A (2011) Lipoprotein-derived lysophosphatidic acid promotes 
atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 13:592-
600. 
 
 
 
 
 
100 
APPENDIX.    SUPPLEMENTAL INFORMATION FOR CHAPTER 3 
 
 
A.1    MATERIALS AND METHODS 
 
 
A.1.1 Materials 
 
Oleoyl cyclic phosphatidic acid (CPA 18:1) and 1-O-
octadecenyl cyclic glycerophosphate (CGP 18:1), oleoyl lysophosphatidic acid (LPA 
18:1), 1-O-octadecenyl glycerophosphate (AGP 18:1), monooleoyl glycerol (MG), and 
1-O-octadecenyl glycerol (AG) were purchased from Avanti Polar Lipids. CPA 18:1 was 
repurified by thin layer chromatography (TLC) using 
chloroform-methanol-ammonium hydroxide (3:6:1) on fluorescent indicator-free Silica 
Gel 60 TLC plates (Whatman), and its purity was determined using negative ion liquid 
chromatography- mass spectrometry (data not shown).  
2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoyl)-1-
hexadecanoyl-sn-glycero-3-phosphocholine (!-BODIPY FL C12-HPC) was obtained from 
Invitrogen Japan. Rhizopus delemer lipase and phospholipase D from Actinomadura sp. 
No. 362 were purchased from Seikagaku Co. (Tokyo, Japan). [32P]-AGP 18:1 was 
synthesized from AG using purified recombinant 1,2-diacylglycerol kinase (Calbiochem). 
Oleic acid (OA), 4#-phorbol 12-myristate 13-acetate (PMA), WY-14643, and L-165041 
were purchased from Sigma. [3H]-ROSI (50 Ci/mmol) was purchased from American 
Radiolabeled Chemicals, and cold ROSI, TRO and PIO from ALEXIS Biochemicals, Inc. 
[32P]-Orthophosphoric acid (314-337 TBq/mmol) was purchased from PerkinElmer. 
Mastoparan was from Bachem. Polyclonal anti-rabbit PPAR" antibody (H-100) was 
purchased from Santa Cruz Biotechnology Inc. Polyclonal anti-rabbit FABP4 was 
purchased from Cell Signaling Technology. 
 
 
A.1.2 Plasmids and Vectors 
 
SV40-!-galactosidase (Promega), pET15b (Novagen) and pcDNA3.1 (Invitrogen) 
vectors were purchased. WT pcDNA3.1-PPAR"1 (amino acids 1-475) and 
pET15b-PPAR"1-LBD (amino acids 173-475) were used as templates for mutagenesis as 
described (Tsukahara et al., 2006). MH-100-PPRE-TK-Luciferase and 
pCMX-PPAR"-Gal4 vectors were a gift from Dr. Peter Tontonoz (HHMI, UCLA, CA). 
The construction and application of the pGL3b-PPRE-Luc, pGL3b-PPRE-cd36 plasmids, 
the PPAR! and !/" reporter gene assays and PLD2 and CI-PLD2 bacmid vectors have 
been previously described (Colley et al., 1997; Liliom et al., 2006). UAS-Luc, 
pECE-Gal4-SMRT, and pVP16-PPAR"2 plasmids were a gift from Dr. Ron Cohen (U. 
Chicago, IL). 
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A.1.3 Synthesis Cellular Uptake and Visualization of BODIPY-CPA 
 
N-((6-(2,4-dinitrophenyl) amino)hexanoyl)-2-(4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine 
(BODIPY-PC) was deacylated by Rhizopus delemer lipase to prepare 2-BODIPY-labeled 
LPC. 1-BODIPY-labeled LPC was generated through spontaneous acyl migration by 
incubation at 37ºC for 3 h in 0.1 M TRIS-HCl buffer (pH 9.0). The 1-BODIPY-labeled 
LPC was converted to BODIPY-CPA by transphosphatidylation using Actinomadura 
phospholipase D as described previously (Tsuda et al., 2006). BODIPY-CPA was added 
to a final concentration of 3 nmol/well to RAW264.7 cells (1.6?106) and cells were 
incubated for 0.5 to 60 min at 37°C. Cells were centrifuged and washed with ice-cold 
PBS. The lipids from the cells and medium were separately extracted by the method of 
Bligh and Dyer, and separated by TLC using 
chloroform-methanol-acetic acid-1% sodium disulfite (100:40:12:5). Fluorescence 
images of TLC plates were obtained and quantified with the FOTODYNE Image 
Analysis system using the Analyst P 5.0 software (FOTODYNE Inc.). For microscopic 
examination, RAW 264.7 cells were treated with 10 µM BODIPY-CPA and incubated at 
37°C for 30 min. Cells were briefly rinsed with PBS and viewed with a NIKON Eclipse 
80i fluorescence microscope. 
 
 
A.1.4 Quantitative Determination of CPA by MS 
 
MDA-MB-231 (3$107), 3T3-L1 or RAW 264.7 (3$106) cells per sample were 
used in these experiments. Following serum starvation, cells were treated with 100 nM 
PMA, 100 nM insulin (Sigma), or vehicle control (1% DMSO) for 30 min at 37°C and 
washed with PBS and collected by centrifugation (Eppendorf centrifuge, 1,000 rpm, 2 
min). Cellular phospholipids were spiked with 100 pmol of CPA 17:0 as internal standard 
and extracted using chloroform/methanol (200/400 µl), and citrate-phosphate buffer, pH 
4.0 (160 µl). Samples were extracted and analyzed by LC-MS as previously described 
(Baker et al., 2001) with a Thermo-Finnigan LCQ Advantage mass spectrometer. 
Quantification of the CPA species was done by ratioing the [M- H]- signal intensity for 
CPA 16:0 and 18:1 to that of the signal intensity of CPA 17:0 internal standard.  
 
LC-MS quantification of CPA in 3T3-L1 or RAW 264.7 cells (3.0$106) 
expressing scrambled shRNA, PLD2 shRNA and WT were pretreated with 30 nM insulin 
or 100 nM PMA for 30 min. Total lipid was extracted using Bligh & Dyer method with 
100 pmol CPA 17:0 (m/z: 405.0) as internal standard and dissolved in 0.1 ml of 
methanol/ chloroform/ 28% NH4OH (90:10:0.1) and were immediately analyzed by 
electrospray ionization LC-MS. LC-MS was performed on an LCMS-2010A mass 
spectrometer (Shimadzu, Japan) equipped with an Econosphere 3 µm 50 $ 4.6 mm silica 
column (Alltech Associates, IL). The sample was maintained at 250°C with drying gas 
flow of 1.5 L/min, and data were collected in the negative ion mode from 100 to 1000 
m/z. The amount of CPA 18:1(m/z: 417.0) produced was estimated by the calibration 
curve of CPA16:0 (m/z: 391.0) /17:0 (picomoles versus peak area). The final values are 
shown with the standard errors for the three sets of experiments.  
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Human PBMC were isolated from Leukopacks by Ficoll-Hystopaque density 
gradient centrifugation. Monocytes were purified from human PBMC using MACS 
CD14 microbeads (Miltenyi Biotech). Purity was checked by staining with a FITC 
conjugated anti-CD14 antibody (Sigma) and FACScan analysis, and routinely found to be 
higher than 94%. The cells (107) were pretreated with or without 750nM FIPI for 30 min 
followed by treated with 1µg/ml lipoporysaccharide, 100nM PMA, 100nM insulin, or 
1mM hydrogen peroxide for 30 min at 37°C. After the treatment the cells were washed 
with PBS and collected by centrifugation. Total lipids were extracted as described above. 
The samples were dissolved in 20 µl of chloroform/water/isopropanol/acetonitrile 
(1:1:1:1) and CPA production was measured by LC- MS/MS. All LC-MS/MS analysis 
was done with an Applied Biosystems Sciex (Foster City, CA) ABI 4000 QTRAP tandem 
mass spectrometer equipped with a TurbolonsprayTM interface, a Shimadazu 
LC-10ADvp pump (Columbia, MD) with a Leap HTS PAL autosampler (Carrboro, NC). 
Ten microliters of each sample was injected to Tosoh TSK-ODS-100Z column (150mm 
$ 2 mm; silica with 5-µm particle size) with methanol/water (95:5), 5mM ammonium 
formate solvent with an isocratic flow rate of 0.22ml/min. The data was processed by 
Analyst software, version 1.5. Various species of CPA were analyzed by multiple 
reaction monitoring (MRM) in negative ion mode with Q3 (product ion) set at m/z 255.1 
for CPA16:1, 281.1 for CPA 18:1, and 269.0 for CPA 17:0 (glycerophosphate moiety) 
(Shan et al., 2008). Q1 was set for the deprotonated molecular ion for all 
lysophospholipids. Quantification of CPA16:0 and CPA18:1 was done by taking the ratio 
of peak area to that of CPA 17:0 internal standard. 
 
 
A.1.5 PLD2 Knockdown 
 
The lentiviral vector pLKO1(clone ID#: TRCN0000076937) containing the 
validated PLD2 shRNA sequence CCGGGCAGTGTTTCCGAGTCTACTTCTCGAGA 
AGTAGACTCGGAAACACTGCTTTTTG was purchased from OpenBiosystems 
(Huntsville, AL.USA). The scrambled shRNA plasmid (#1864) was obtained from 
Addgene (Cambridge, MA, USA), in which a nonsilencing sequence CCGGCCTAAGGT 
TAAGTCGCCCTCGCTCTAGCGAGGGCGACTTAACCTTAGGTTTTTG was 
inserted into lentiviral vector pLKO1. The lentiviruses with scrambled and PLD2 shRNA 
were produced in UTHSC Viral Vector Core Laboratory (Memphis, TN, USA). Briefly, 
the shRNAs in pLKO1 were co-transfected into 293FT cells with the packaging plasmids 
pCMV-VSVG and psPAX2. The supernatant was collected 60 h after transfection and 
virus particles were collected by ultra-centrifugation. 3T3-L1 and RAW 264.7 cells were 
transduced by the viruses at 10 MOI. 3T3-L1 and RAW 264.7 stably expressing 
lenti-mediated shRNA for PLD2 were grown in DMEM containing 10% FBS and 
puromycin (Sigma) (2.0 µg/ml for 3T3-L1, 3.0 µg/ml for RAW 264.7). The knockdown 
of PLD2 shRNA was examined by immunoblotting using an antibody specific to PLD2 
(gift from Dr. Yoshiko Banno, Gifu University, Japan). RAW264.7 or NIH3T3 cells 
expressing scrambled shRNA (SC-shRNA) or PLD2 shRNA (PLD2-shRNA) were lysed, 
the lysates were separated by SDS-PAGE and transferred to a PVDF membrane. The blot 
was probed with the anti-rabbit anti-PLD2 antibody (1:2000), and incubated with 
anti-rabbit secondary antibody conjugated to horseradish peroxidase (Promega, Madison, 
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WI; 1:10000) and visualized using SuperSignal ELISA Pico substrate (Thermo Fisher 
Scientific Inc., Rockford, IL). 
 
 
A.1.6 Purification of Recombinant PLD2 
 
Sf-9 insect cells were transduced with recombinant baculoviruses encoding PLD2 
or CI-PLD2 at MOI of 10. The cells were grown for 48 h and washed with PBS, lysed on 
ice by the addition of 3 ml lysis buffer [20 mM TRIS-HCl, pH7.4, 100 mM NaCl, 0.5% 
Triton X-100, 1 mM PMSF and protease inhibitor cocktail (Sigma)]. After 15 min on ice, 
the cells were collected by scraping and the lysate was centrifuged at 13,000$g for 30 
min at 4°C. The supernatant was mixed with 0.1 ml TALON His-tag Affinity Resin (BD 
Biosciences) and kept at 4°C with constant agitation for 1 h. PLD2 was eluted after the 
resin was washed three times with 1 ml of lysis buffer. The purity of the PLD2 
preparation was tested by western blotting with a mouse anti-polyhistidine antibody 
(Sigma) or a rabbit anti-actin (Sigma) primary antibodies, and an anti-mouse or 
anti-rabbit IgG horseradish peroxidase conjugated secondary antibody (Promega), 
visualized using the Super Signal kit (Pierce). 
 
 
A.1.7 In Vitro Assay of PLD Activity  
 
Purified PLD2 was incubated with 50 µM [14C]-LPC 16:0 (2.1 GBq/mmol) at 
40°C for 1 h in the presence of 10 mM TRIS-HCl, (pH7.2). The reaction was terminated 
by 30 µl 1-BuOH. The mixture was centrifuged at 12,000$g for 1 min and the upper 
phase was spotted on Silica Gel 60 TLC plates (Whatman). The plates were developed 
with chloroform/methanol/acetic acid/1% aqueous sodium metabisulfite (100:40:12:5). 
Radioactivity was detected using a Cyclone phosphorimager. PLD activity in cell lysates 
was determined using the Amplex Red PLD kit from Molecular Probes (Eugene, OR). 
 
 
A.1.8 Oil Red O Stain 
 
RAW 264.7 cells were seeded in Lab-Tek slide-chambers in DMEM at 104 cells 
per well for 24 h. Acetylated LDL (25 µg/ml) was added. After 24 h, the cells were 
washed twice with PBS and fixed with 10% formaldehyde in PBS for 10 min. ORO 
(0.5%) in isopropanol was diluted with 1.5 volumes of distilled water, filtered, and added 
to the fixed cells for 1 h. Cells were viewed using a Nikon Eclipse 80i microscope. 
3T3-L1-derived adipocytes were washed three times with PBS and fixed for 2 min with 
10% formaldehyde in PBS. Cells were then washed three-times with wash solution 
(Chemicon International) and stained with ORO. For the quantification of ORO uptake, 
cells were extracted using dye extraction solution (Chemicon International), and 
absorbance was measured at 520 nm in a Shimadzu UV-1700 spectrophotometer. 
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A.1.9 Induction of Adipocytic Differentiation in 3T3-L1 Cells 
 
 Cells were cultured in DMEM supplemented with 10% FBS to reach confluence. 
1 µM CPA or vehicle (1% DMSO) was added 24 h prior to induction with 100 nM ROSI 
with 0.1 - 10 nM insulin. The medium with ligand(s) was replenished every other day. 
Cytoplasmic lipid droplets were visible by day 5. The cells were cultured following the 
standard differentiation induction protocol for 14 days. Adipogenesis was determined by 
staining of lipids with ORO and by RT-PCR and western blotting for the expression of 
adipocyte marker FABP4. 
 
 
A.1.10 Animal Experiments 
 
 The procedure used in these experiments was approved by the IACUC of the 
University of Tennessee Health Science Center. The surgical procedure for exposing and 
cannulating the external and common carotid arteries has been described previously 
(Zhang et al., 2004). Briefly, 5 µM ROSI or AGP with and without 5 µM CPA or 3 nM 
insulin were injected into a ligated carotid artery previously rinsed free of blood; the 
cannula was left in the vessel for 1 h. The cannula was then withdrawn and the external 
carotid was ligated. The clips isolating the distal and proximal common carotid were 
released, and blood flow was restored. All animals (groups of 5 for each treatment) 
received adequate analgesia and preventive antibiotics during recovery. Three weeks post 
surgery the animals were euthanized, and the carotid arteries were dissected en-block, 
fixed, and processed for paraffin embedding. Sections 5 µm thick were cut and stained 
using Masson’s trichrome stain (Richard-Allan Scientific Inc.). Intima-to-media ratios 
were measured using the NIH Image (version 1.62) software. 
 
 
A.1.11 RNA Extraction and Real-Time Quantitative RT-PCR 
 
 C57BL/6 mouse peritoneal macrophages were pretreated with 5 µM CPA or 1µM 
GW9662 for 15 min and cultured for 12 h in the presence of 5 µM ROSI. 3T3-L1 and 
RAW 264.7 cells were treated with 30nM insulin or 10µM mastoparan for 30 min 
followed by treated with vehicle or 10µM ROSI for 24h. RNA was isolated by using 
TRIzol-LS (Invitrogen) and quantitative real-time RT-PCR analysis was performed using 
7300 Fast Real-time PCR system, (Applied Biosystems). Transcript levels were 
normalized to !-actin or GAPDH for 3T3-L1 and RAW 264.7 cells. Experiments were 
done using four different pools of macrophages collected from 10 mice. RNA from 
3T3-L1 cells was isolated using RNAspin Mini kit (GE Healthcare). Assays of reverse 
transcription were conducted with specific primer for PPAR", FABP4 and !-actin and 1 
µg of total RNA in 25 µl reaction volume. Reverse transcription was performed at 50 °C 
for 60 min and the PCR conditions were as follows: 94 °C for 30 s, 50 °C for 60 s, and 72 
°C for 60 s with initial activation of enzyme at 94 °C for 1 min for a total of 35 cycles.  
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A.1.12 PCR Primers Used 
 
qPCR; cd36; forward GCCTCCTTTCCACCTTTTGT, reverse TCTGTACACGG 
GGATTCCTT, cyp27a1; forward GGCACCTTTCCTGAGCTG, reverse CACCAGTCA 
CTTCCTTGTGC, hadh; forward GACATCCTGGCAAAATCCAA reverse GCTCAGG 
GTCTTCTCCACAA, capn3; forward TACGCAGGGATCTTCCACTT, reverse GAAC 
TCATTGCGGTGGTTG, csf1; forward GAGTCTGTCTTCCACCTGCTG, reverse ACT 
GGCAGTTCCACCTGTCT, ppar$; forward AGGGCGATCTTGACAGGAA, reverse C 
ACCTCTTTGCTCTGCTCCT, #-actin; forward TTCTACAATGAGCTGCGTGTG 
reverse GGGGTGTTGAAGGTCTCAAA, pld1; forvard AGTGCTTCAGACTTGTCCT 
GGTT, reverse ATGGTAGCGTTTCGAGCTGCTGT, pld2; forward TTGCGGAAGCA 
CTGTTTCAGTGTG, reverse TTGTTCTCCGCTGTTTCTTGCCAC. 
 
RT- PCR; #-actin; forward GACAACGGCTCCGGCATGTG reverse GGCTGG 
GGTGTTGAAGGTCTCAA, fabp4; forward AATGTGTGATGCCTTTGTGGG reverse 
TGGCTCATGCCCTTTCA. 
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A.2    SUPPORTING FIGURES 
 
 
 
 
 
Figure A-1 Inhibition of Pioglitazone (PIO) and Troglitazone (TRO)-induced 
reporter gene activation by CPA (related to Figure 3-1) 
 
(A and B) CPA dose-dependently suppresses PIO or TRO-induced PPAR"-dependent 
PPRE-TK- Luc reporter gene activation in B103 cells. The cells were treated for 20 h 
with ligands and/or different concentrations of CPA as indicated (n=4). Data are 
representative of two independent transfections. (C-F) CPA does not activate PPAR# and 
PPAR!/&. CPA did not activate PPAR# and !/& reporter gene expression over a 
wide-range of concentrations in B103 cells exposed to WY-14643 (C, PPAR#-specific 
agonist) or L-165041 (E, PPAR!/&-selective agonist) or CPA 18:1 for 20 h. No reporter 
gene activation was found after treatment with up to 10 µM of CPA, the highest 
concentration tested, whereas nanomolar concentrations of the synthetic agonists elicited 
robust expression of the reporter genes. CPA did not inhibit specific agonist induced 
PPAR# or PPAR!/& activation (D and F). 
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Figure A-2 PLD2 induces CPA production (related to Figure 3-4) 
 
(A) PMA-induced CPA generation in CHO cells transfected with tet-regulated PLD1 and 
PLD2 constructs without doxycycline induction. 106 Cells biosynthetically labeled with 
[32P]-orthophosphate were treated with 100 nM PMA for 30 min, and CPA was isolated 
and separated using 2DTLC and quantified by liquid scintillation counting (n=3). (B) 
Enzymatic properties of PLD2 using LPC as substrate. Affinity-purified recombinant 
PLD2 and CI-PLD2 were reacted [14C]-LPC (2.05 GBq/mmol) in vitro, and generation of 
[14C]-CPA was quantified using a [14C]-sensitive phosphorimager screen. The Vmax and 
Km values were derived from double-reciprocal plots of the data (insets) yielding 
Vmax=190 pmol/min/mg protein, Km =20 µM for LPC, Data represent the mean ± SEM 
of values from three experiments. (C-E) Mass spectrometry of CPA production in 
MDA-MB-231 cells. Cells (3$107) were treated with DMSO (vehicle), PMA (100 nM), 
or insulin (100 nM) for 30 min, spiked with 100 pmol of CPA 17:0 (m/z 405), and CPA 
was extracted. In vehicle-treated cells (C) CPA was below the detection limit (>10 
pmol/3$107 cells). In contrast, significant amounts of CPA 16:0 (m/z 391) and CPA 18:1 
(m/z 417) were readily detected in PMA- (D) and insulin-treated cells (E). LC- MS/MS 
quantification of CPA species in unstimulated (F), and insulin (100 nM, G), or PMA (100 
nM, I) stimulated human peripheral blood monocytes. The cells were treated for 30 min 
with the activators and in some cases also pretreated with 750 nM of the PLD2 inhibitor 
FIPI (H). CPA were analyzed by MRM in negative ion mode monitoring the 
glycerophosphate moiety at m/z 255.1 for CPA16:1, 281.1 for CPA 18:1, and 269.0 for 
CPA 17:0 (internal standard). CPA was below the detection limit in unstimulated cells 
but became detectable after insulin or PMA stimulation. FIPI reduced CPA production.    
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Figure A-3 Insulin induced CPA production and PLD2 knock down by shRNA 
(related to Figure 3-5) 
 
(A-C) Stimulus coupled CPA production in CV-1 cells. Cells (3$106) were labeled with 
[32P]-orthophosphate for 6 h, subsequently exposed to 100 nM insulin or 1% DMSO 
solvent for 30 min at 37°C, and lipids were extracted and analyzed by 2DTLC and 
phosphorimaging. (A) [32P]-labeled phospholipids in DMSO treated cells. (B) Primulin 
staining of the plate shown in panel A spiked with authentic LPA and CPA standards (10 
nmols each; A-C designate unidentified phospholipids). (C) [32P]-labeled phospholipids 
in cells treated with 100 nM insulin. Arrows point to spots co-migrating with the CPA 
and LPA standard. Note that there in no increase in LPA upon insulin stimulation and as 
a metabolite of phospholipids synthesis LPA shows a constitutive turnover indicated by 
the incorporation of the label. In contrast, CPA shows a robust increase upon insulin 
stimulation. (D and E) shRNA knockdown of PLD2 in RAW 264.7 (D) and 3T3-L1 cells 
(E). Quantitative RT- PCR showed a selective decrease in pld2 transcripts without 
significant change in pld1 transcript abundance. (F) Western blotting of PLD2 protein 
shows diminished levels in the PLD2-shRNA transduced cells compared to WT or 
scramble shRNA transduced cells. 
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Figure A-4 CPA and insulin prevent ROSI-induced carotid wall remodeling 
(related to Figure 3-7) 
 
CPA and insulin inhibit neointima formation induced by ROSI in rat carotid arteries. 
(A-D) Carotid arteries of anesthetized adult female rats were cannulated and filled with 5 
µM ROSI either with or without 5 µM CPA for 1 h; after this treatment, the circulation 
was restored. Animals were sacrificed 3 weeks later, and the carotid tissue was processed 
for Masson trichrome staining. (A) In carotids arteries treated with 3% DMSO PBS 
vehicle no changes in vascular wall morphology were noted. The PPAR" agonist 
ROSI-induced neointima formation (B) in the common carotid arteries was blocked by 
co-application of CPA (C, bar, 200 µm). Intima-to-media ratios were determined in the 
carotids using quantitative image analysis (D). CPA completely abolished ROSI-induced 
neointima formation. Data represent the mean intima- to-media ratio ± SD of carotid 
arteries from groups of 5 rats. (E-G) Insulin (3 nM, E) was co-applied with 10 µM ROSI 
(F) lumenally for 1 h using the described experimental paradigm. Insulin treatment alone 
induced no vascular remodeling, but it significantly reduced the neointima formation 
elicited by ROSI. Bar; 200 µm. (G) Data represent the mean intima-to-media ratio ± SD 
for groups of 5 carotid arteries. 
 
 
 
112 
 
 
 
????????????
????????????????
??????????????
????????????????????????
!"
?
# $
%
????????????????????
&
'"
'(')"
'('*"
'('+"
'(',"
'(-"
'(-)"
'(-*"
????
!!"
!!"./'('-"
"?
""
??"0
"?
?
?
"0
""
??"?
"1
?
?
"
2
"0
"3
??"4
"?
??
#
"
?
?
"5
""
6"
????
????" ????? ????? ????????
'('7"
'(-"
'(-7"
'()"
'()7"
'"
!!"./'('-"
?????
6"
"?
""
??"0
"?
?
?
"0
""
??"?
"1
?
?
"
2
"0
"3
??"4
"?
??
#
"
?
?
"5
""
!!"
!!"
????????
 
 
113 
VITA 
 
 
 Ryoko Tsukahara was born in 1974 in Kushiro, Japan. She obtained her bachelor 
degree in Pharmaceutical Sciences from Hokkaido University in Sapporo, Japan in March 
1999. She joined the Integrated Program in Biomedical Sciences at the University of 
Tennessee Health Science Center (UTHSC) in August 2007. She received the J. Paul. 
Quigley Memorial Scholarship for 2009 and the Dorothy K. and Daniel L. Gerwin 
Graduate Scholarship for 2010 from the Department of Physiology at UTHSC. She will 
receive her Doctor of Philosophy degree in December 2011. 
 
 
 
